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The aim of this research was to investigate the role of genetic and nutritional 
variation within the folate-mediated one-carbon network in relation to cardiovascular 
disease risk.  The enzymes serine hydroxymethyltransferase 1 (gene name SHMT1) 
and methylenetetrahydrofolate reductase (gene name MTHFR) regulate key reactions 
in folate-mediated one-carbon metabolism.  We investigated the effect of the SHMT1 
rs1979277 SNP and the SHMT1 rs1979277 – MTHFR rs1801133 interaction in two 
epidemiologic cohorts.  In the Nurses’ Health Study, the MTHFR rs1801133 variant 
genotypes were associated with an increased CVD risk, and there was an interaction 
between SHMT1 and MTHFR such that the association of MTHFR rs1801133 CT 
genotype (vs. CC; the TT genotype could not be evaluated) was stronger in the 
presence of the SHMT1 rs1979277 TT genotype.  In the Health Professionals Follow-
Up Study, the MTHFR rs1801133 genotype was not associated with CVD risk nor was 
there an interaction with SHMT1 rs1979277.  Next, using data from the Normative 
Aging Study, 330 SNPs in 52 genes were studied in relation to cardiovascular disease 
biomarkers.  Using a nominal significance threshold of P≤0.005, 20 SNPs were 
associated with homocysteine, 8 with Alu methylation, and 1 with LINE-1 
methylation.  Using a more stringent false discovery rate threshold, SNPs in FTCD, 
SLC19A1, and SLC19A3 genes were associated with plasma homocysteine, gene x 
vitamin B-6 interactions were identified for Alu and LINE-1 methylation, and epistatic 
  
interactions involving the MTHFR rs1801133 SNP were identified for the plasma 
homocysteine phenotype.  Finally, the SNPs were prospectively evaluated for their 
association with cardiovascular disease in a U.S. population studied prior to 
mandatory folate fortification.  Using a nominal significance threshold of P≤0.005, 8 
SNPs were associated with CVD risk.  Using a more stringent false discovery rate 
threshold, a polymorphism in the GGH gene was associated with reduced CVD risk.  
A gene x folate interaction was identified (MAT2B) and two gene x vitamin B-12 
interactions were identified (BHMT and SLC25A32).  Hypotheses related to SHMT1 
were explored and significant gene x gene interactions were identified.  Overall, 
genetic variation in folate-mediated one-carbon metabolism, other than the well-
known effects of the MTHFR 677 C→T rs1801133, is predictive of cardiovascular 
disease risk.  
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CHAPTER 1 
 
INTRODUCTION 
 
Cardiovascular Disease (CVD) 
 
CVD (primarily coronary heart disease and stroke) is America’s leading killer 
and was responsible for 36.3% of all U.S. deaths in 2004 (16, 86).  Many risk factors 
for CVD have been identified, ranging from modifiable factors such as high blood 
cholesterol and lack of physical activity to non-modifiable factors including heredity 
and male gender.  Like other chronic diseases, the origins of CVD are complex and 
likely comprise both the independent and interactive effects of genetic and 
environmental factors, including nutrition.   
 
Folate-mediated one-carbon metabolism and CVD risk 
 
Folate and other B vitamins play key roles in biologic processes important to 
health, including DNA synthesis and the generation of cellular methylation potential 
for a variety of methylation reactions.  Folate status is influenced by both dietary 
intake and variation in genes encoding folate-related enzymes, and altered folate status 
due to nutritional or genetic perturbations is associated with adverse outcomes, 
including birth defects, cardiovascular disease (CVD), and cancer (32) 
The reactions of one-carbon metabolism, through which folate carries out its 
biological functions, comprise an interconnected set of pathways with reactions 
occurring in both the cytoplasm and the mitochondria of the cell (96).  The purpose of 
one-carbon metabolism is to use tetrahydrofolate to chemically activate one-carbon 
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units for a number of important reduction or oxidation reactions (49, 97).  In the 
cytoplasm, the one-carbon units donated by folate are used for both nucleotide 
synthesis (5,10-methylenetetrahydrofolate is used as a coenzyme in the conversion of 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), 
contributing to thymidylate biosynthesis, and can also be oxidized to 10-
formyltetrahydrofolate for purine synthesis) and the generation of methylation 
potential (MTHFR catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-
methyltetrahyrofolate, which then donates a methyl group for the remethylation of 
homocysteine to methionine, or for the synthesis of S-adenosylmethionine (AdoMet)).  
AdoMet is considered the “universal methyl donor” because of its role as a cofactor in 
over 80 methylation reactions, including the methylation of DNA, RNA, proteins 
(including histones), and neurotransmitters (49, 97).  Even after AdoMet has donated 
its methyl group to these reactions and been converted to S-adenosylhomocysteine 
(AdoHcy), it still has the ability to regulate cellular methylation through its role as a 
potent inhibitor of most AdoMet-dependent methyltransferases (49).  One-carbon 
metabolism also occurs in the mitochondria, where formate (the source of most one-
carbon units) is synthesized (97).    
Individuals homozygous for a relatively common polymorphism, MTHFR 677 
C→T TT, which causes an alanine to valine amino acid change at residue 222, 
resulting in reduced enzyme activity, have 25% higher homocysteine concentrations 
when compared to individuals homozygous for the CC genotype (109).  Several 
publications have examined the role of the MTHFR 677 C→T polymorphism in 
relation to cardiovascular disease risk.  In 2002, two meta-analyses were published.  
The first, by Wald et al, involved case-control studies examining the prevalence of the 
MTHFR 677 C→T TT genotype (72 studies) and prospective studies of homocysteine 
and CVD events (20 studies) (108).  Wald and colleagues computed a summary odds 
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ratio of 1.21 (95% CI:1.06-1.39, p=0.006) for ischemic heart disease comparing the 
MTHFR 677 C→T TT vs. CC genotypes (48 studies); and a summary odds ratio of 
1.31 (95% CI: 0.66-4.13) for stroke, comparing MTHFR 677 C→T TT vs. CC (7 
studies) (108).  The authors concluded that lowering homocysteine levels 3 µmol/l 
would reduce the risk of ischemic heart disease by 16% and stroke by 24%.  The 
Homocysteine Studies Collaboration, published the same year, reported that a 25% 
lower usual homocysteine level (about 3 µmol/l) was associated with an 11% 
reduction in ischemic heart disease risk (OR 0.89; 95% CI: 0.83 – 0.96) and a 19% 
reduction in stroke risk (OR 0.81; 95% CI: 0.69 – 0.95), after adjustment for known 
CVD risk factors and regression dilution bias in prospective studies (1).  A third meta 
analysis, also published in 2002, authored by Klerk et al and the MTHFR Studies 
Collaboration, involved 40 case-control studies of the MTHFR 677C→T 
polymorphism and risk of CHD (52), and found that individuals with the MTHFR 677 
C→T TT genotype have a 16% higher odds of CHD compared to those with the CC 
genotype (OR 1.16; 95% CI: 1.05 – 1.28) (52).  In 2005, Lewis et al conducted a 
meta-analysis of a total of 80 case-control and prospective studies of the association 
between the MTHFR 677 C→T variant and myocardial infarction, coronary artery 
occlusion, or both, which found that the MTHFR 677 C→T TT genotype vs. the CC 
genotype was associated with an increase of 2.2 µmol/l homocysteine and a 14% 
higher risk of ischemic heart disease (OR 1.14, 95% CI:1.05-1.24) (58).  Although the 
interpretation of the findings in these publications differed (52, 58, 108), Wald et al in 
2006 concluded that the results of these meta-analyses were consistent with a 16% 
lower risk of ischemic heart disease for a 3 µmol/l decrease in homocysteine (109).  In 
addition, two meta-analyses focusing on ischemic stroke, a form of CVD, were 
published.  The first reviewed data from 120 case-control candidate gene association 
studies of ischemic stroke and found a statistically significant association between 
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MTHFR 677 C→T and ischemic stroke (OR 1.24, 95% CI: 1.08-1.42, p=0.002) 
comparing TT to CC/CT genotypes (15).  The second meta-analysis examined 31 
retrospective case-control or cross-sectional studies or prospective cohort studies of 
MTHFR 677 C→T polymorphism in relation to stroke risk (27).  This analysis found 
that the OR for stroke/transient ischemic attack (TIA) associated with the MTHFR TT 
vs. CC genotype was 1.37 (95% CI: 1.15-1.64, p<0.001).  A graded dose response 
relationship was observed for increasing numbers of T alleles (OR 1.17 for CT, 95% 
CI: 1.09-1.26, p<0.001) and when outcomes were restricted to those events confirmed 
by imaging, an almost identical relation was observed.   
However, a meta-analysis conducted in 2009 indicated that CVD risk 
associations involving other variants in the one carbon metabolic pathway have been 
far less well-studied (114).  An examination of the role of the genetic variants in the 
one-carbon pathway as a whole is of interest as it is not currently known how a more 
complete description of genetically-driven alterations in folate metabolism influences 
CVD risk, thus leaving an important gap in the evidence base. 
 
Folate-related CVD Biomarkers 
 
A sulfur-containing amino acid, homocysteine plays an important role in the 
metabolism of the amino acid methionine.  Homocysteine levels are governed by the 
reactions of the folate one-carbon metabolic network, an interconnected series of 
reactions that serve to transfer one-carbon units for the purpose of amino acid or 
nucleotide metabolism (96), and are also influenced by B vitamin status, particularly 
folate and to some extent, vitamin B-12 (45).   Methylenetetrahydrofolate reductase 
(MTHFR) is an enzyme which plays a key role in the methionine cycle of the one 
carbon metabolic pathway, and converts 5,10-methylenetetrahydrofolate to 5-
 5 
methyltetrahydrofolate, which then serves as a cofactor for the remethylation of 
homocysteine to methionine, a reaction catalyzed by the B-12 dependent enzyme, 
methionine synthase (MTR), which produces tetrahydrofolate and methionine (96).  
As previously described, the MTHFR 677 C→T rs1801133 genetic variant, which 
results in an enzyme with reduced activity, has been associated with increased 
homocysteine levels in several meta-analyses (52, 58, 108). 
Elevated plasma homocysteine, a sulfur-containing amino acid byproduct of 
folate metabolism, is a marker of disturbed folate-mediated one-carbon metabolism, 
and is associated with an increased risk of CVD, based on evidence from prospective 
studies, meta-analyses, and genetic studies (58, 87, 100, 108).  In the past ten years, 
homocysteine has sparked interest as a modifiable CVD risk factor because blood 
homocysteine concentrations are amenable to change by alterations in dietary B-
vitamin intake, a simple intervention.  
Thus, supplementation with key nutrients from the folate-mediated one-carbon 
pathway, such as folate and B-12, leads to lower circulating homocysteine 
concentrations (45), and is hypothesized to lead ultimately to reductions in CVD risk. 
The observational studies described above led to the conduct of randomized clinical 
trials to test the hypothesis in an experimental design. Whether homocysteine 
represents an independent risk factor for CVD, or is simply a marker of CVD risk, has 
been vigorously debated in the literature, stimulated in part by results from three 
recently published randomized trials of B-vitamin supplementation and the occurrence 
or recurrence of CVD  (the Heart Outcomes Prevention Evaluation (HOPE) 2 trial 
(65), the Norwegian Vitamin (NORVIT) trial (14), and the Vitamin Intervention for 
Stroke Prevention (VISP) trial (101)). The trials published to date have failed to show 
that supplementation led to a reduced risk of CVD despite achieved reductions in 
homocysteine levels.  Wald et al suggest that these randomized trials lack the 
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statistical power needed to detect the expected modest reductions in CVD resulting 
from B-vitamin supplementation and that the relatively short follow-up (from 2 – 5 
years) may be insufficient, given that the Kaplan-Meier estimates published in the 
HOPE 2 paper begin to show modest risk reduction only in the 3rd and 4th years of 
follow-up (65).  The consistency in the cohort studies and the genetic studies, as well 
as the fact that among the genetic polymorphism studies, those with the greatest 
difference in homocysteine had the greatest difference in CVD risk (109) continue to 
support a causal role for homocysteine in the development of CVD.   Gillies and Krul 
note that there are many examples of discordant results between epidemiologic studies 
and clinical trials, perhaps because the simplification of complex biological systems in 
order to generate testable clinical hypotheses may exceed the ability of these 
hypotheses to inform us about the biological systems from which they arose (39); this 
may indeed be the case for the homocysteine trials.    
The association of homocysteine with CVD is hypothesized to be mediated, in 
part, by changes in DNA methylation status (48).  DNA methylation is an epigenetic 
modification that involves the addition of methyl groups to cytosine to form 5-
methylcytosine.  Folate-mediated one-carbon metabolism is linked to DNA 
methylation status through regulation of AdoMet, the universal methyl donor, as well 
as through the activity of enzymes involved in methylation reactions, such as the DNA 
methyltransferases (82, 105).  Changes in methylation influence gene expression, 
cellular differentiation and development, preservation of chromosomal integrity, and 
X chromosome inactivation, and methylation status is associated with the risk of CVD 
and some cancers (7, 48, 82, 104).  
Comprising about 27% of the human genome, LINE-1 and Alu elements are 
common, highly methylated transposable elements that correlate with genome-wide 
DNA methylation in some studies (25, 120).  LINE-1 promoters contain CpG islands 
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that are typically highly methylated, and Alu elements contain about one-third of all 
human CpG methylation sites (25).  Changes in LINE-1 and Alu element methylation 
are hypothesized to have functional consequences on the expression of nearby genes 
(25).  Atherosclerosis is characterized by DNA hypomethylation and transposable 
element methylation levels are associated with heart disease, stroke, and total 
mortality (5, 82); these findings contribute to interest in global genomic DNA 
methylation as a potential biomarker of cardiovascular disease risk.    
Most previous work investigating variation in genes playing a role folate-
mediated one-carbon metabolism in relation to homocysteine and genomic 
methylation focused on a small number of candidate genes. Given the 
interconnectedness of the one-carbon pathway, less proximal enzymes and genes may 
be important, yet few studies have attempted to evaluate a more comprehensive gene 
set.  An investigation of genetic variation within the network of genes representing 
folate-mediated one-carbon metabolism in relation to CVD, homocysteine, and key 
methylation phenotypes is needed.   
 
Nutritional Genomics 
 
The literature contains many examples of diseases that are associated with 
genetic polymorphisms that may affect nutrition requirements, including CVD, neural 
tube defects, Down syndrome, colon cancer, hemochromatosis, and asthma (98).  The 
MTHFR 677 C→T change decreases the affinity of the MTHFR enzyme for its 
cofactor riboflavin (vitamin B-2), rendering the protein less enzymatically active.  
Carriers of the alternate allele have an increased risk for neural tube defects and CVD, 
but a decreased risk for colon cancer.  To ameliorate these effects, carriers must 
increase their consumption of dietary folate (6).  However, disentangling the 
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relationships between genotype and diet in order to formulate appropriate nutrition 
recommendations is not always straightforward.  Derivation of specific dietary 
recommendations for chronic disease prevention and management must account for 
underlying genetic variation while maintaining disease-specificity and balancing 
competing interests both within and among individuals (39, 98).   
Previous work has identified several pairs of SNPs in genes encoding folate-
regulating enzymes that catalyze linked steps in the one-carbon metabolic pathway, 
which have an interactive effect on CVD risk.  Lim et al demonstrated an interaction 
between the MTHFR 677C→T and SHMT1 1420 C→T polymorphisms that resulted 
in a significantly increased CVD risk in Normative Aging Study participants.  SHMT1 
reversibly converts serine and THF to glycine and 5,10-methylene THF.  MTHFR 
then converts 5,10-methylene THF to 5-methylTHF, which is required for the 
remethylation of homocysteine to methionine (40).  Specifically, among men with 
SHMT1 1420 C→T TT genotype, the odds ratio for CVD for MTHFR 677 C→T CT 
and TT genotypes (compared to MTHFR CC genotype, no loss of function) was 3.6 
and 10.6, respectively (62).  Additionally, using the same Normative Aging Study 
data, Raiszadeh et al observed a gene-gene interaction between MTHFD1 and 
MTHFR, which also catalyze linked steps in the one carbon pathway, such that the 
increased risk associated with the MTHFR 677C→T CT and TT polymorphism 
(compared to MTHFR CC genotype, no loss of function) was observed only among 
men with the MTHFD1 GA/AA genotype (odds ratios 1.2 and 1.6, respectively), but 
the MTHFR SNP had little or no association with CVD risk in persons with the 
MTHFD1 GG genotype.  In fact, MTHFR 677 CT genotype was associated with a 
protective effect in those with the MTHFD1 GG genotype (odds ratio 0.8) (83).  The 
MTHFD1 enzyme uses the one carbon units produced by the mitochondria (as 
formate) to convert THF to 10-formylTHF, which then enters the cytoplasmic one-
 9 
carbon folate pool (97).  The MTHFD1 enzyme also converts 5,10-methenylTHF to 
5,10-methyleneTHF which serves as a substrate for SHMT1 as described above (96).  
These examples of gene-gene interactions observed within linked steps in the one-
carbon network suggest that the framework of a metabolic pathway provides an 
important context for studying genetic variation. 
We therefore propose to use the tools of genome wide association studies, 
informed by the underlying biology of one carbon metabolism, to describe the 
relations among a full set of genetic variants in members of the one-carbon metabolic 
pathway and the ways in which these variants influence CVD risk, in terms of both 
individual and interactive effects. In essence, the proposed study pursues a candidate 
network approach, including an evaluation of gene-gene and gene-nutrient interactions 
within the network. 
 
Conclusion 
 
Determining the role of genetic and nutritional factors in mediating CVD risk 
is of central importance in understanding not only the pathogenesis of CVD, but in 
developing appropriate and effective intervention strategies for CVD prevention.  
There is a promising body of evidence to support the significance of variation in the 
folate metabolic network, based on prospective cohort studies as well as genetic 
studies examining subsets of the folate network.  There are, however, no studies to 
date that evaluate the role of genetic and nutritional variation in the folate network in 
its entirety.  Such strategies are important for informing future dietary 
recommendations aimed at improving public health and preventing disease, as the risk 
of disease may be elevated in specific population subsets defined by genetic and 
nutritional characteristics.  The lack of a complete understanding of the contribution of 
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genetic and nutritional variation within the folate-mediated one-carbon network to 
CVD risk represents an important gap in the literature and one that will be directly 
addressed by studies proposed herein.  
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CHAPTER 2 
 
POLYMORPHISMS IN SERINE HYDROXYMETHYLTRANSFERASE 1 AND 
METHYLENETETRAHYDROFOLATE REDUCTASE INTERACT TO INCREASE 
CARDIOVASCULAR DISEASE RISK IN HUMANS1 
 
2.1 Abstract  
 
The enzymes serine hydroxymethyltransferase 1 (gene name SHMT1) and 
methylenetetrahydrofolate reductase (gene name MTHFR) regulate key reactions in 
folate-mediated one-carbon metabolism.  Common genetic variants with the potential 
to influence disease risk exist in both genes.  A prior report from the Normative Aging 
Study indicated no association of the SHMT1 rs1979277 SNP with CVD, but a strong 
gene-gene interaction was detected with MTHFR rs1801133. We investigated the 
effect of the SHMT1 rs1979277 SNP and the SHMT1 rs1979277 – MTHFR rs1801133 
interaction in two epidemiologic cohort studies.  In the Nurses’ Health Study, the 
MTHFR rs1801133 variant genotypes were associated with an increased CVD risk, 
and there was an interaction between SHMT1 and MTHFR such that the association of 
MTHFR rs1801133 CT genotype (vs. CC; the TT genotype could not be evaluated) 
was stronger in the presence of the SHMT1 rs1979277 TT genotype (OR 4.34, 95% CI 
1.2, 16.2, P=0.049).  In the Health Professionals Follow-Up Study, the MTHFR 
rs1801133 genotype was not associated with CVD risk nor was there an interaction 
with SHMT1 rs1979277.  The association of genetic variation in the SHMT1 gene, 
alone and in interaction with MTHFR, in relation to CVD risk is relatively  
___________________________________________________________________ 
1 Reproduced with permission from the Journal of Nutrition, accepted for publication October, 2010. 
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understudied at the population level, and results in the Nurses’ Health Study 
confirmed a past report of gene-gene interaction, which is consistent with mechanisms 
suggested by basic science studies.  
 
2.2 Introduction 
 
Folate, a B vitamin fortified in the U.S. food supply since 1998, is involved in 
many cellular processes that influence disease risk.  As tetrahydrofolate 
polyglutamates, folate coenzymes carry and activate one-carbon units for use in 
metabolic pathways including generation of methylation potential and synthesis of 
purine and pyrimidine nucleotides (32). Evidence from basic science studies suggests 
genetic variants that alter the function of folate coenzymes have the potential to impact 
disease risk.  The SHMT1 enzyme plays a key role in the folate metabolic pathway by 
catalyzing the interconversion of serine and tetrahydrofolate to glycine and 5,10-
methylenetetrahydrofolate (5,10-methyleneTHF) (40).  The negligible concentration 
of free intracellular folate implies competition for the product of this reaction, 5,10-
methyleneTHF, thus, SHMT1 is poised to mediate the flow of one-carbon units 
through thymidylate synthesis and the methionine cycle; both pathways are highly 
sensitive to folate status (8, 42).  The MTHFR enzyme, which catalyzes a metabolic 
step linked to SHMT1, functions to convert 5,10 methyleneTHF to 5-methylTHF, 
thereby committing one-carbon units to methylation reactions at the expense of 
thymidylate synthesis (21, 32).  A common genetic variant in the SHMT1 gene, 
rs1979277 (1420 C→T), results in a modified protein (L474F).  While this mutation 
does not affect catalytic activity, it impairs SHMT1 nuclear transport and subsequent 
thymidylate synthesis, and results in accumulation of the altered SHMT1 protein in 
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the cytoplasm, where it may inhibit cellular methylation reactions by sequestering 5-
methyl-THF (2, 42, 116). A common genetic variant in the MTHFR gene, rs1801133 
(677 C→T) results in an altered protein (A222V) with impaired ability to partition one 
carbon units to the remethylation pathway (21, 35).  Because the MTHFR and SHMT1 
enzymes catalyze linked metabolic steps, the accumulation of the variant SHMT1 
L474F protein in the cytoplasm and sequestration of 5-methylTHF, coupled with the 
impaired 5-methylTHF synthetic activity of the MTHFR A222V protein suggests the 
potential for an interaction between the SHMT1 rs1979277 and MTHFR rs1801133 
genotypes.  Such an interaction could have important metabolic consequences on 
cellular remethylation reactions and/or nucleotide synthesis, and ultimately on disease 
risk.  
The association of the MTHFR rs1801133 variant with CVD risk has been 
well-studied (52, 58, 108); the increased risk of heart disease associated with the 
MTHFR rs1801133 TT vs. CC genotype is most pronounced in unfortified populations 
(52). Few studies have examined genetic variation in SHMT1 in relation to CVD risk 
and the majority of publications investigating genetic variation in SHMT1 focus on 
cancer  
(28 of 31 studies published prior to 8/2009).  One of 3 studies of the SHMT1—CVD 
association (4, 41, 62) investigated the SHMT1-MTHFR gene-gene interaction in 
relation to CVD risk (62), and the risk associated with the MTHFR rs1801133 CT and 
TT genotypes (vs. CC) was stronger in the subgroup of men with the SHMT1 
rs1979277 TT genotype.   
Given the key role of the SHMT1 and MTHFR enzymes in the generation of 
cellular methylation potential and nucleotide biosynthesis, further studies examining 
the MTHFR-SHMT1 interaction in relation to CVD risk are needed.  Thus, a candidate 
gene association study was conducted to investigate the hypothesis that the SHMT1 
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rs1979277 and MTHFR rs1801133 genotypes interact to increase heart disease risk in 
the Health Professionals Follow-Up Study (HPFS) and the Nurses’ Health Study 
(NHS).  Since the association between these genotypes and CVD risk may be 
mediated by homocysteine and/or modified by B vitamins, these questions were also 
investigated.   
 
2.3 Methods 
 
To compute expected SHMT1 genotype frequencies in European-ancestry 
populations, a literature search was conducted in 8/2009, using standardized methods. 
Genetic association studies reporting the association of SHMT1 variants and chronic 
disease were identified on the PubMed search engine at the National Center for 
Biotechnology Information (74).  Studies reporting original research on humans 
published in English were included if they reported the frequency of the SHMT1 
rs1979277 TT genotype and studied any of the following outcomes: CVD, coronary 
artery disease, coronary heart disease (CHD), and cancers (including the pre-
cancerous condition, colorectal adenoma).  18 case-control studies conducted in 
European-ancestry populations were identified (11, 20, 29, 41, 53, 57, 61-64, 73, 75, 
78, 93, 94, 106, 118, 121), and using data from controls only (total n=12,883), 
genotype counts were extracted and used to compute expected SHMT1 genotype 
frequencies in European-ancestry populations. 
Data from two cohort studies comprised the study population.  The HPFS 
enrolled 51,529 male health professionals aged 40 y to 75 y in 1986, and the nested 
case-control study of CHD has been previously described (81).  Cases comprised 266 
men with incident non-fatal myocardial infarction or fatal CHD; case events occurred 
between the date of blood draw (about 1994 for all participants providing blood 
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samples) and the return of the year 2000 questionnaire (81).  Using risk-set sampling, 
532 controls matched for age, smoking status and date of blood sampling, were 
randomly selected from the subgroup of participants free of CVD at the time of cases’ 
diagnosis.  Only case-control sets in which all men had successful genotyping on both 
SHMT1 rs1979277 and MTHFR rs1801133 were included (245 cases, 474 controls 
comprising 229 triads (1 case: 2 controls) and 16 pairs).  Blood samples were analyzed 
for total cholesterol (81) and red blood cell folate (90) as described elsewhere.  
The NHS enrolled 121,700 female registered nurses aged 30 y to 55 y in 1976, 
and a nested case-control study comprising 227 incident cases of nonfatal myocardial 
infarction (MI) and fatal CHD occurring between 1990 and 1998 was conducted (77).  
All women provided a blood sample prior to the case accrual period, thus in the pre-
folate fortification era; controls were matched to each case on age, smoking, month of 
blood draw, fasting status, and reported problems with blood drawing, and were 
randomly selected using risk-set sampling from participants with the matching criteria 
and free of CHD at the time of case diagnosis (77).  Only case-control sets in which all 
women had successful genotyping on both SHMT1 rs1979277 and MTHFR rs1801133 
were included (227 cases, 425 controls comprising 198 triads (1 case: 2 controls) and  
29 pairs).  Blood samples were analyzed for total cholesterol (77), red blood cell 
folate, plasma folate, vitamin B-6, vitamin B-12 and homocysteine, as previously 
described (90).   
Genotyping for the studied polymorphisms in both cohorts, SHMT1 rs1979277 
(1420 C→T) and MTHFR rs1801133 (677 C→T), was conducted as part of a larger 
genotyping effort (53). Laboratory personnel were unaware of case-control status and 
genotyping was repeated to exclude errors when genotype distributions were found to 
be out of Hardy-Weinberg equilibrium (HWE). The median genotyping success rate 
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across all polymorphisms assayed was 95%, and concordance between the 10% 
quality control samples and genotyped variants was 100%.   
SAS software (SAS Institute Inc., Cary, NC) was used for all statistical 
analyses.  Genotype frequencies in controls were compared with those expected in 
HWE and Monte Carlo estimates of the exact P-values for the disequilibrium tests 
were computed (10,000 permutations).  Conditional logistic regression analysis was 
used; adjusted regression models considered known risk factors for CHD.  To test for 
the SHMT1 rs1979277 – MTHFR rs1801133 gene-gene interaction, and to test for 
gene-nutrient and gene-gene-nutrient interactions, product terms involving the relevant 
genes and/or nutrients were included in regression models.  The SHMT1 rs1979277 
SNP was coded as recessive, and the MTHFR rs1801133 SNP was coded using 
dummy variables to allow for non-linear associations.  Nutrients and metabolites 
related to folate metabolism (red blood cell folate, plasma folate, plasma vitamins B-6, 
B-12, and homocysteine) were considered as mediators and/or effect modifiers.  An 
alpha level of 0.05 was used for main effects and HWE tests, an alpha level of 0.15 
was used for interactions, and point estimates and 95% confidence intervals are 
shown. The study was approved by the Cornell University Committee on Human 
Subjects. 
 
2.4 Results 
 
In the Health Professionals Follow-Up Study, the frequency of the MTHFR 
rs1801133 TT genotype was higher in controls (13.3%) than cases, and the 
prevalence in controls was greater than the expected frequency of 10.7% based on a 
past meta-analysis (52).  In the NHS cohort, the frequency of the MTHFR rs1801133 
TT genotype was similar between cases and controls, and in the range expected. The 
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expected SHMT1 rs1979277 genotype frequencies were computed using data on 
controls from 18 studies conducted in European-ancestry populations, as follows: 
48.9% CC (95% CI 48.1, 49.8), 41.0% CT (95% CI 40.2, 41.9), and 10.0% TT (95% 
CI 9.5, 10.5).  In comparison, the prevalence of the SHMT1 rs1979277 TT genotype 
in HPFS controls (12.0%) was high, while the NHS genotype prevalence was closer 
to expected (Table 2.1).  In the NHS, cross-classification of the two genotypes 
revealed an absence of the double variant homozygote genotype (rs1979277 TT and 
rs1801133 TT) in the cases. Genotype distributions for SHMT1 rs1979277 and 
MTHFR rs1801133 did not differ significantly from HWE expectations in either 
cohort. 
Genotype—Outcome Associations 
Based on the biological hypothesis that the SHMT1 rs1979277 TT genotype 
leads to increased cytoplasmic protein levels and therefore less remethylation of 
homocysteine to methionine, the first analysis goal was to establish an MTHFR—heart 
outcomes association given well-known effects of common variants in MTHFR on 
homocysteine accumulation.  Paradoxically, the MTHFR rs1801133 T allele was 
associated with a lower risk of CHD in the HPFS, and estimates of association were 
similar in simple models adjusting for demographics only, and in models fully 
adjusting for multiple cardiovascular risk factors. In the NHS, the MTHFR rs1801133 
T allele was associated with an increased risk of CHD, although there was no gradient 
in risk per MTHFR allele. Thus, women with the MTHFR CT genotype had a 30% 
increased risk of CHD (vs. CC genotype: OR 1.30, 95% CI 0.9, 1.8), and women with 
the MTHFR TT genotype had a 22% increased risk (vs. CC genotype: OR 1.22, 95% 
CI 0.7, 2.1).  
Following the hypothesis, the next analysis tested for a genotype-genotype 
interaction between MTHFR rs1801133 and SHMT1 rs1979277.  In the HPFS, where 
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Table 2.1.  Genotype frequencies for SHMT1 rs1979277 (1420 C→T) and MTHFR rs1801133 (677 
C→T) in the Health Professionals Follow-Up Study, 1994-2000 (n=719), and the Nurses’ Health 
Study, 1990-1998 (n=652)1 
  SHMT1 rs1979277 (1420 C→T)  MTHFR rs1801133 (677 C→T) 
 Genotype: CC   CT   TT  CC CT  TT 
   %   %  
NHS Cases (n=227) 46.3 46.7 7.1 43.2 46.7 10.1 
 Controls (n=425) 48.5 43.1 8.5 48.9 41.2 9.9 
HPFS Cases (n=245) 49.0 44.9 6.1 42.0 48.2 9.8 
 Controls (n=474) 45.6 42.4 12.0 39.0 47.7 13.3 
1Values are percentages for cases and controls, respectively, and are presented separately for each study. 
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Table 2.2.  The relation of MTHFR rs1801133 677 C→T genotype with CVD 
risk stratified by SHMT1 rs1979277 1420 C→T genotype in the Health 
Professionals Follow-Up Study (HPFS) and the Nurses’ Health Study (NHS)1 
Cohort: NHS2 HPFS3 
SHMT1 genotype:
CC/CT TT CC/CT TT 
MTHFR genotype: 
     MTHFR 677 C→T CT vs. CC 
1.18  
0.8, 1.7 
4.34 
1.2, 16.2 
1.0   
0.7, 1.4 
0.46 
0.1, 1.7 
     MTHFR 677 C→T TT vs. CC 
1.25 
0.7, 2.2 
N/A 
0.68 
0.4, 1.2 
0.69 
0.2, 3.1 
1Values are odds ratios,95% confidence intervals, and P values computed from conditional 
logistic regression models. 
2n=227 cases.  Unadjusted.  No double homozygous variants among the cases.   
3 n=245 cases. Unadjusted.   
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no main effects of the MTHFR rs1801133 genotype were evident, the risk associated 
with the MTHFR rs1801133 genotype did not differ by SHMT1 rs1979277 genotype 
(P=0.47 for interaction, liklihood ratio test statistic = 1.5, 2 df; Table 2.2 and Table 
A2.1). However, in the NHS the risk associated with the MTHFR rs1801133 CT 
genotype varied by SHMT1 rs1979277 genotype (P=0.049 for interaction, liklihood 
ratio test statistic = 3.9, 1 df; Table 2 and Table A1.1).  In women with the SHMT1 
rs1979277 TT genotype, the risk of CHD in the MTHFR rs1801133 CT genotype 
group was ~4 times the risk in the MTHFR rs1801133 CC genotype group (OR 4.34, 
95% CI 1.2, 16.2).  In contrast, in women with the SHMT1 rs1979277 CC/CT 
genotype, there was little or no association of the MTHFR rs1801133 CT (vs. CC) 
genotype with CHD (OR 1.18, 95% CI 0.8, 1.7).  Risk associated with the MTHFR 
rs1801133 TT genotype in women with the SHMT1 rs1979277 TT genotype could not 
be estimated because there were no cases with the double homozygote genotype.  In 
both the Health Professionals Follow-Up Study and the Nurses’ Health Study, 
minimally and fully adjusted models yielded very similar estimates of association for 
genotype.  
Potential mediation of the gene-disease association by homocysteine was 
evaluated only in the NHS where homocysteine data were available. Only the SHMT1 
1420 C→T TT genotype was associated with homocysteine in the NHS, and this 
association was not diminished after adjusting for the association of the MTHFR 
variant and the SHMT1-MTHFR interaction (β=2.35, P<0.04).  Similarly, there was 
little or no difference in regression coefficients for genotype associations estimated in 
models further adjusted for homocysteine.   
Given that folate intake may modify associations with CVD risk for at least 
one of the polymorphisms under study, the role of folate was explored.  In the HPFS, 
there was little or no difference in RBC folate between cases and controls (no other 
 21 
 
folate-related biomarker data were available).  In regression models, RBC folate was 
not predictive of CHD, and including RBC folate in regression models did not change 
either the coefficient for the SNP or the coefficient for the gene—gene interaction. 
The occurrence of cases in the HPFS spanned January, 1998 when mandatory folate 
fortification of the U.S. food supply took effect; about half of the outcomes occurred 
prior to January, 1998. Stratifying regression models by date of case event did not 
meaningfully change model coefficients.  No statistically significant two-way 
interactions (gene-nutrient) were observed between RBC folate and the SHMT1 
rs1979277 or MTHFR rs1801133 genotypes, and there were no significant 3-way 
interaction terms (gene-gene-nutrient; data not shown).   
 In the NHS, in addition to RBC folate, plasma concentrations of vitamin B-6, 
vitamin B-12, folate, and homocysteine were measured.  Case accrual for NHS events 
ended in 1998, thus, all cases occurred prior to mandatory folate fortification in the 
U.S.  There was little or no difference in folate-related biomarkers between cases and 
controls, with the exception of vitamin B-6 (the mean in controls was higher, P=0.08).  
RBC folate, plasma folate, and plasma vitamin B-6 were not associated with CHD in 
models with or without adjusting for homocysteine, and adding biomarkers to 
regression models had little or no effect on coefficients for the SNP or the interaction.  
No two-way gene-nutrient interactions involving any of the polymorphisms or 
biomarkers were identified, and there were no significant 3-way interactions (gene-
gene-nutrient; data not shown).   
 
2.5 Discussion 
 
The published literature investigating the role of the SHMT1 rs1979277 1420 
C→T genotype in chronic disease risk focuses mainly on cancer risk, and evidence for 
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genotype associations with cardiovascular disease (CVD) is limited to 3 studies, 
underscoring the need for further population-level studies of SHMT1 and CVD.  While 
no prior studies reported a direct association of the SHMT1 rs1979277 SNP with 
CVD, a strong interaction between the SHMT1 rs1979277 and MTHFR rs1801133 
genotypes was identified, which is consistent with emerging findings in basic science 
studies of functional effects of the SNP.  Thus, the association of the MTHFR 
rs1801133 CT and TT genotypes (vs. CC) with CVD risk are stronger in people with 
the SHMT1 rs1979277 TT genotype (62).     
Using data from nested case-control studies in the population-based, 
prospective NHS and HPFS cohorts, the gene-gene interaction hypothesis was tested.  
The NHS findings were consistent with associations previously reported in the 
Normative Aging Study (NAS): risk associated with the MTHFR rs1801133 T allele 
was stronger in women with the SHMT1 rs1979277 TT genotype.  The absence of 
double homozygote cases in the NHS precluded estimating the association of MTHFR 
rs1801133 TT genotype with CHD risk in women with the SHMT1 rs1979277 TT 
genotype.  The lack of double homozygote cases may indicate the selective loss of 
such individuals from the cohort, but this scenario is highly unlikely given observed 
association sizes.  An alternative and more likely explanation is that observed 
genotype frequencies are a chance phenomenon.  While the fraction of all NHS cohort 
members who provided blood samples, and the fraction who developed CHD and were 
included in this study, should be random with respect to genotype, it is possible that a 
chance event led to the absence of the MTHFR rs1801133 TT / SHMT1 rs1979277 TT 
double homozygote genotype class.  Indeed, given the prevalence of the genotypes for 
each SNP in European-ancestry populations (expect 10.0% SHMT1 TT and expect 
10.7% MTHFR TT in European-Ancestry populations), only 3 double homozygous 
individuals are expected in the 249 incident NHS cases under the null hypothesis of no 
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association with CHD. The three cells that can be estimated from the NHS data are 
each consistent with past findings (62). 
The findings in the HPFS are inconsistent with summary estimates from prior 
meta-analyses regarding the association of the MTHFR rs1801133 genotype on CVD 
risk. In the HPFS, the MTHFR rs1801133 T allele was associated with a decreased risk 
of CVD, thus opposite in direction to findings from prior meta-analyses (52, 58, 108). 
The HPFS findings are also inconsistent with the past report (62) and the NHS 
findings reported herein with regard to the gene-gene interaction between MTHFR 
rs1801133 and SHMT1 rs1979277. It is unlikely that gender influences the findings 
given that the past report of the interaction was in the Normative Aging Study, an all-
male cohort.  It is also unlikely that genotyping errors led to the paradoxical findings 
in the HPFS: an independent genotyping effort involving a larger sample from the 
NHS and HPFS case-control studies confirmed the same associations with CHD risk 
reported herein, based on imputed genotypes for MTHFR rs1801133 and SHMT1 
rs1979277; in this expanded subset, the imputed MTHFR rs1801133 TT genotype 
frequency was also 13.3% (data not shown).  The differences in findings in the HPFS 
are also not likely to be due to differences in average folate or homocysteine levels.  
The mean folate and homocysteine levels in the cohorts are virtually identical, 
differing by less than 10% in all comparisons (data not shown).  A possible 
explanation for the unexpected findings is random error. 
A recent Institute of Medicine report on Nutrigenomics states, “There is, today, 
an unprecedented opportunity to use foods and food components to aid in achieving 
the genetic potential of humans, improve the overall performance of humans, and 
reduce the risk for chronic disease” (72). Given that the evidence base needed to make 
nutrition recommendations tailored to individual genotype is far from complete, this 
study investigated the interaction of nutritional status with the genetic variants studied, 
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and carefully considered the gene x nutrient and gene x gene x nutrient interactions.  
No gene–nutrient or gene-gene-nutrient interactions involving SHMT1 rs1979277 
and/or MTHFR rs1801133 were evident in either the NHS or the HPFS.  In the HPFS, 
blood markers of folate status were collected prior to the introduction of mandatory 
folate fortification, although approximately half of the case events occurred after 
fortification.  In both the HPFS and the NHS, nutritional status was not assessed at a 
uniform time relative to disease occurrence in cases.  Future work should carefully 
consider the timing of nutrient measurements, and the role of folate fortification in the 
interpretation of findings.   
While prior studies of the association of MTHFR rs1801133 677 C→T 
estimate the TT genotype (vs. CC) is associated with a 14-21% excess risk of CVD in 
the 10% of the population who have the TT genotype (52, 58, 108), our findings 
suggest that the risk associated with MTHFR rs1801133 677 C→T T allele is limited 
to the subgroup with the SHMT1 rs1979277 1420 C→T TT genotype, comprising 
about 4.5% of the population studied. Similarly, in a prior report (62), risk associated 
with the MTHFR rs1801133 677 C→T CT (vs. CC) genotype was limited to the 
subgroup with the SHMT1 rs1979277 1420 C→T TT genotype, comprising about 5% 
of the population studied. Furthermore, CHD risk in men with the MTHFR rs1801133 
677 C→T TT genotype was 10 times the risk of men with the rs1801133 CC genotype 
in the 1% of men who were also SHMT1 rs1979277 1420 C→T TT genotype (62). A 
prior report from the NHS found only moderate increases in CHD risk associated with 
MTHFR 677 C→T (rs1801133) variant genotypes (90), but the authors did not 
consider the MTHFR rs1801133 – SHMT1 rs1979277 interaction investigated herein.  
Given that specific genotype and nutrition combinations may be required to confer 
risk, future studies wishing to further clarify the role of folate-related genes in chronic 
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disease will need to consider the possibility that risk may be stronger in population 
subgroups. 
 The effect of the SHMT1 rs1979277 and MTHFR rs1801133 polymorphisms 
on protein structure and function supports the population-level interaction observed in 
the NAS and the NHS cohorts.  Woeller et al established that the SHMT1 rs1979277 
polymorphism, which results in an L474F amino acid change, weakens the interaction 
between ubiquitin conjugating enzyme 9 (UBC9) and SHMT1 and prevents the 
addition of small ubiquitin-like modifiers (SUMOylation) in vitro (116), inhibiting 
nuclear transport (2), and thereby resulting in the accumulation of the variant SHMT1 
protein in the cytoplasm.  An increase in cytoplasmic levels of the SHMT1 protein 
impairs homocysteine remethylation and binds the same substrate as MTHFR, 5-
methylTHF (42); therefore, an accumulation of SHMT1 in the cytoplasm is 
hypothesized to exacerbate the reduced enzyme activity of the variant A222V MTHFR 
protein (116).  This proposed biological mechanism for the gene-gene interaction 
observed in the NAS and NHS suggests a pathogenic effect of the polymorphisms 
mediated by direct effects of homocysteine and/or effects on cellular methylation 
potential. Neither study demonstrated that the gene-gene interaction was mediated by 
homocysteine, but homocysteine may be an incomplete marker of cellular methylation 
potential or a single homocysteine measurement may not be an adequate reflection of 
either long-term homocysteine, homocysteine at the time of the event, or rate of 
change in homocysteine, depending on which aspect is most informative of risk.  
Additional biomarker data, including longitudinal measurements of homocysteine 
beginning prior to the event (84), and/or measures of other remethylation pathway 
biomarkers, such as S-adenosylhomocysteine (107), may be more informative.  
While cells contain a second serine hydroxymethyltransferase, encoded by the 
SHMT2 gene, which exhibits functional redundancy with the SHMT1 enzyme under 
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investigation here (2), evidence suggests the functional redundancy is incomplete.  
The SHMT2 gene encodes two transcripts – an SHMT2 protein that localizes only to 
the mitochondria, and an SHMT2α protein that, lacking a mitochondrial targeting 
sequence, localizes to the cytoplasm and nucleus (2).  While the SHMT2α protein 
provides some functional redundancy to the SHMT1 protein, studies of SHMT1 -/- 
mice confirm persistent aberrations in folate-related metabolism (2, 66), arguing 
against complete compensation for loss of SHMT1 function. Thus, there is some 
justification for the penetrance of the SHMT1 rs1979277 SNP despite expression of 
SHMT2 protein. 
This study directly addresses an important gap in the literature by investigating 
the relation of the SHMT1 rs1979277 TT genotype to heart disease and takes 
advantage of existing data from two nested case-control studies conducted in large 
epidemiologic prospective cohort studies. A weakness was the inability to test the 
MTHFR TT / SHMT1 TT strata of the gene-gene interaction in the NHS cohort because 
of the complete absence of double homozygote cases.  However, the MTHFR—
SHMT1 interaction that was detected agreed in direction and magnitude with a 
previous report (62). The study reported herein had a well-defined hypothesis linked to 
findings in basic science, and focused on only two genetic variants, the associated 
gene-gene and gene-nutrient interactions and mediation by a folate-related biomarker. 
 In summary, in the Nurses’ Health Study, the association of the MTHFR 
rs1801133 genotype was modified by SHMT1 rs1979277 genotype and associations 
were consistent in magnitude and direction with previously published findings. The 
biological plausibility for an interaction between MTHFR rs1801133 and SHMT1 
rs1979277 is strong, yet a review of published literature identified only one prior 
publication investigating the association of the MTHFR rs1801133 / SHMT1 
rs1979277 interaction in relation to CVD.  Further studies are warranted, but future 
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work must consider folate fortification and the range of folate nutrition in the 
population, as well as the timing and collection of data on dietary intake, nutrition 
status, and folate pathway biomarkers, and include a more complete evaluation of 
genetic variation across the network of folate-related genes.     
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APPENDIX 
 
TABLE A2.1 
 
CONDITIONAL LOGISTIC REGRESSION MODELS OF THE RELATION OF 
SHMT1 rs1979277 (1420 C→T) AND MTHFR rs1801133 (677 C→T) GENOTYPES 
TO CORONARY HEART DISEASE RISK, NURSES’ HEALTH STUDY (NHS), 
1990-1998, AND HEALTH PROFESSIONALS FOLLOW-UP STUDY  
(HPFS), 1994-2000 
 
 
 NHS2,3 HPFS4 
Variables β SE P β SE P 
SHMT1 1420 C→T (TT vs. CC/CT) 
MTHFR 677 C→T (CT vs. CC) 
MTHFR 677 C→T (TT vs. CC) 
Interaction between SHMT1 TT and MTHFR CT 
Interaction between SHMT1 TT and MTHFR TT 
-0.98 
0.17 
0.22 
1.30 
N/A 
0.56 
0.18 
0.29 
0.69 
N/A 
0.08 
0.35 
0.44 
0.06 
N/A 
-0.40 
0.005 
-0.39 
-0.77 
0.014 
0.47 
0.17 
0.30 
0.69 
0.83 
0.39 
0.98 
0.19 
0.26 
0.99 
1Values from conditional logistic regression models are β, beta-coefficient; SE, standard error; 
and P, P value. 
2n=652 cases and controls, unadjusted model. 
3Due to lack of double homozygous variants in cases, the second interaction term could not be 
estimated. 
4n=719 cases and controls, unadjusted model.
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CHAPTER 3 
 
FOLATE NETWORK GENETIC VARIATION, PLASMA HOMOCYSTEINE, AND 
GLOBAL GENOMIC METHYLATION CONTENT 
 
3.1 Abstract  
 
Sequence variants in genes functioning in folate-mediated one-carbon 
metabolism are hypothesized to lead to changes in levels of homocysteine and DNA 
methylation, which, in turn, are associated with risk of cardiovascular disease. 330 
SNPs in 52 genes were studied in relation to plasma homocysteine and global genomic 
methylation.  SNPs were selected based on functional effects and to achieve gene 
coverage, and assayed on the Illumina Goldengate platform. Age-, smoking-, and 
nutrient-adjusted genotype—phenotype associations were estimated in regression 
models.  Using a nominal P≤0.005 threshold for statistical significance, 20 SNPs were 
associated with homocysteine, 8 were associated with Alu methylation, and 1 was 
associated with LINE-1 methylation.  Using a more stringent false discovery rate 
threshold, SNPs in FTCD, SLC19A1, and SLC19A3 genes were associated with 
plasma homocysteine, gene x vitamin B-6 interactions were identified for both Alu 
and LINE-1 methylation, and epistatic interactions involving the MTHFR rs1801133 
SNP were identified for the plasma homocysteine phenotype.  Pleiotropy involving the 
MTHFD1L and SARDH genes for both plasma homocysteine and Alu methylation 
phenotypes was identified.  No single gene was associated with all three phenotypes, 
and the set of most statistically significant SNPs predictive of homocysteine or Alu or 
LINE-1 methylation was unique to each phenotype. Genetic variation in folate-
 30 
mediated one-carbon metabolism, other than the well-known effects of the MTHFR 
677 C→T rs1801133, is predictive of cardiovascular disease biomarkers.   
 
3.2 Introduction 
  
 Folate and other B vitamins play key roles in biologic processes important to 
health, including DNA synthesis and the generation of cellular methylation potential 
for a variety of methylation reactions.  Folate status is influenced by both dietary 
intake and variation in genes encoding folate-related enzymes, and altered folate status 
due to nutritional or genetic perturbations is associated with adverse outcomes, 
including birth defects, cardiovascular disease (CVD), and cancer (32).   
 Elevated plasma homocysteine, a sulfur-containing amino acid by-product of 
folate metabolism, is a marker of disturbed folate-mediated one-carbon metabolism, 
and is associated with an increased risk of CVD in prospective, meta-analysis, and 
genetic studies (58, 87, 100, 108).  Homocysteine levels are modulated by nutrition, 
particularly folate and vitamin B-12 (45), and by genetic variants, including a well-
studied SNP in the methylenetetrahydrofolate reductase gene (MTHFR 677 C→T; 
rs1801133) (52).   
 The association of homocysteine with CVD is hypothesized to be mediated, in 
part, by changes in DNA methylation (48).  Folate-mediated one-carbon metabolism is 
linked to DNA methylation status through regulation of S-adenosylmethionine, the 
universal methyl donor, as well as through the activity of enzymes involved in 
methylation reactions, such as the DNA methyltransferases (82, 105).  Changes in 
DNA methylation influence gene expression, cellular differentiation and development,  
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preservation of chromosomal integrity, and X chromosome inactivation, and 
methylation status is associated with the risk of CVD and some cancers (7, 48, 82, 
104).   
 LINE-1 and Alu elements are abundant, transposable elements whose 
methylation status has been shown to be highly correlated with genome-wide DNA 
methylation in some studies (25) (120).  LINE-1 promoters contain CpG dinucleotides 
that are typically highly methylated, and Alu elements contain about one-third of all 
human CpG methylation sites (25).  Changes in LINE-1 and Alu element methylation 
are hypothesized to have functional consequences on the expression of nearby genes.  
Atherosclerosis is characterized by global DNA hypomethylation and transposable 
element methylation levels are associated with heart disease, stroke, and total 
mortality; in fact, we recently showed that reduced LINE-1 methylation was 
associated with increased incidence of ischemic heart disease and stroke within the 
Normative Aging Study (5, 82). These findings contribute to interest in LINE-1, Alu, 
or global genomic DNA methylation as potential biomarkers of cardiovascular disease 
risk.    
 Most previous work investigating variation in genes contributing to folate-
mediated one-carbon metabolism in relation to homocysteine and genomic 
methylation phenotypes focused on a small number of candidate genes. Given the 
interconnectedness of the one-carbon pathway, less proximal enzymes and genes may 
be important, yet few studies have attempted to evaluate a comprehensive set of 
folate-related genes. 
 To investigate the genetic and nutritional predictors of homocysteine and 
methylation phenotypes, this candidate gene study examined variation across the 
network of genes representing folate-mediated one-carbon metabolism in relation to 
homocysteine and key methylation phenotypes. 330 single nucleotide polymorphisms 
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(SNPs) in 52 genes with a role in folate-mediated one-carbon metabolism were 
studied. The selection of the set of genes, the SNP markers, and the nutrients that were 
examined in this study was designed to represent the full functional variation of the 
folate-mediated one carbon metabolic pathway.  
 
3.3 Methods 
 
Study Population 
 The Normative Aging Study (NAS) was established by the Veterans’ 
Administration (VA) in 1961, and 2,280 men aged 21-81 years (mean age of 42 y at 
study entry) were enrolled in the study on the basis of health criteria; details have been 
described elsewhere (9, 28). The rate of continued participation of NAS men over the 
follow-up period from 1961 through 1998 was excellent, with <1% attrition for all 
causes.  As of June 1998, just prior to the homocysteine phenotype measurements, 543 
participants (24%) were deceased and ~1600 men (70%) were actively participating in 
follow-up visits (mean age of 70 y).  Men in the NAS were primarily non-Hispanic 
White males (>98% of the total NAS population) and the small number of participants 
in other racial/ethnic groups precluded separate analyses.  The analyses described 
herein focus on non-Hispanic white males using data from the subset of men (~ 700) 
with measurements of homocysteine and global genomic DNA methylation (Alu and 
LINE-1).   
 This study was approved by the following: Brigham and Women’s Hospital 
Human Subjects committee, Veterans’ Administration R&D committee, Harvard 
School of Public Health, and the Cornell University Committee on Human Subjects.  
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DNA Extraction 
 Genomic DNA was extracted from stored frozen buffy coat of 7 ml whole 
blood using the QIAamp DNA Blood Kit (QIAGEN, Valencia, CA).  The REPLI-g 
whole genome amplification kit (QIAGEN) was used to amplify genomic DNA when 
quantity was insufficient for genotyping.  Whole-genome amplified samples were 
quality checked using Taqman genotyping (119) and poor-performing samples were 
excluded.  Of 1,304 participant samples submitted for genotyping, 54.4% were 
genomic, 45.5% were whole-genome amplified.   
SNP Selection 
 52 genes that contribute to folate-mediated one-carbon metabolism were 
identified (Table A3.1).  SNP selection encompassed 2 kb on either side of the gene to 
include promoter and/or regulatory region variants.  Four databases were used for SNP 
selection: the National Center for Biotechnology Information (NCBI) dbSNP and 
PubMed databases, (http://www.ncbi.nlm.nih.gov/), the Applied Biosystems 
Incorporated (ABI) SNPBrowser website (http://www.allsnps.com), and the Illumina 
Assay Design Tool (www.illumina.com ).  SNPs identified from literature searches 
and functional variants (non-synonymous coding region SNPs and 
promoter/regulatory region SNPs) were selected preferentially.  Next, gene coverage 
considerations assessed linkage disequilibrium (LD) across the gene and physical 
coverage of the gene.  Adjacent SNPs were selected such that the decay of maximum 
linkage disequilibrium between the 2 was no more than 33% (≤0.9 LDU between 
adjacent SNPs, where 1 LDU represents the decay of LD between two SNPs by about 
37% of its maximum value when fitted to the Malecot model (67)) whenever possible 
to ensure sufficient SNP density to  adequately represent the LD characteristics of the 
gene.  GoldenGate SNP validation status was considered at each step, and SNPs with a 
minor allele frequency (MAF) ≥5% in European-ancestry populations were selected 
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where possible although exceptions were made for SNPs with prior evidence of 
putative function or when no SNPs with MAF ≥5% were available.  A total of 384 
SNPs were selected, including SNPs that were intentionally redundant to provide 
coverage in the event that key SNPs of interest failed in the genotyping assay.  To 
simultaneously evaluate genetic variation within the network as a whole in a single 
model, a subset of 52 non-redundant SNPs was selected to represent the most likely 
functional variant with the highest MAF that could be selected for each of the 52 
genes.   
SNP Genotyping 
 384 SNPs were submitted to the Center for Inherited Disease Research at the 
Johns Hopkins University for genotyping via an Illumina GoldenGate custom 
genotyping panel.  Genotype frequencies in controls were compared with those 
expected in Hardy-Weinberg equilibrium (HWE) and tested with Monte Carlo 
permutation estimates of exact P-values for HWE using 10,000 permutations.  Of the 
384 SNPs originally submitted, 54 were ultimately excluded for assay failure (46), 
monomorphic genotype data (4), minor allele frequencies less than 1% (3), and 
genotype frequencies out of HWE (1), leaving 330 SNPs available for analysis (Table 
A3.2).  Both blind duplicates and HapMap Centre d'Etude du Polymorphisme Humain 
(CEPH) control samples with known genotypes were included, and reproducibility 
rates were excellent (99.99% for blind duplicates, 99.83% for HapMap CEPH 
controls).  
Covariates 
 Extensive previously collected data on study participants includes physical 
measurements, lifestyle factors, and blood assays.  Since the time of enrollment 
participants have had clinical examinations at 3- to 5-year intervals, with a response 
rate > 90% for mailed questionnaires.  Fasting plasma samples were drawn at the VA 
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field site and stored at -80 °C.  Plasma samples were transferred to the Jean Mayer 
USDA Human Nutrition Research Center on Aging, where they were analyzed; the 
time between blood draw and analysis averaged 1.7 ± 1.2 y as previously described 
(102).  Plasma nutrient biomarkers were assayed in an unselected subset of stored 
blood samples.  Plasma folate, vitamin B-6 (as pyridoxal-5'-phosphate; PLP) and 
vitamin B-12 were assayed, and the methods for these measurements have been 
previously described; coefficients of variation (CV) were uniformly excellent, as 
follows: 4.3% for folate, 5.0% for vitamin B-6, and 4.7% for vitamin B-12 (102).      
Phenotype Assessment 
 Plasma total homocysteine was assayed in the same unselected subset of stored 
blood samples as plasma folate, vitamin B-6, and vitamin B-12.  Methods for the 
determination of plasma total homocysteine were published, and the CV for the assay 
was 4.0% (102).  The analysis of transposon DNA methylation has been reported in 
prior publications (Baccarelli, 2009) (13).  Briefly, Alu and LINE-1 transposons were 
assayed in bisulfite-treated blood leukocyte genomic DNA using highly quantitative 
polymerase chain reaction –pyrosequencing technology. The degree of methylation 
was expressed for both Alu and LINE-1 as the percentage of methylated cytosines 
over the sum of methylated and unmethylated cytosines (%  5-meC).  Each marker 
was tested in three replicates, and the average was used in statistical analyses. 
Statistical Analyses  
 Restricted maximum likelihood and ordinary least squares regression models 
evaluated the relation between SNPs and the plasma homocysteine and global DNA 
methylation phenotypes.  In a first step, additive, dominant, recessive, and 
overdominant genetic models of inheritance were tested for each SNP, and the model 
yielding the most statistically significant result in the unadjusted single SNP analysis 
was chosen as the best model going forward.  An exception was made for the MTHFR 
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rs1801133 SNP, where prior evidence supported model-free dummy variable coding.  
Previous work in this cohort demonstrated no population substructure (115), thus no 
adjustments were made.  All regression models were adjusted for age, smoking status, 
and nutrient residuals (portion of variation in nutrient not directly predicted by SNP), 
and an extended model also adjusted for the MTHFR 677 C→T (rs1801133) variant. 
Further models tested the interaction of each genotype with the rs1801133 SNP in 
relation to the homocysteine outcome, and later with nutrients in relation to all 
outcomes.  Where specific genetic models of inheritance led to sparse data for main 
effects analyses, additive coding was used as the default.  A small number of SNPs 
could not be evaluated in an interaction with MTHFR rs1801133, due to extensive data 
sparsity. 
 Regression coefficients with a nominal P≤0.005 were flagged to obtain a 
liberal set of associations for comparison with other studies and consideration for 
further follow up.  Subsequent analyses used the False Discovery Rate (FDR) multiple 
testing correction of Benjamini and Hochberg (10) to adjust P-values, with a q-value 
significance threshold of 0.05, indicating that we expect less than 5% of tests flagged 
by this criterion to be false positives.  For interactions, a nominal significance 
threshold of P≤0.02 was used, with an FDR q value significance threshold of 0.2, 
unless otherwise specified. 
 To investigate the joint role of nutrition and genetic variation, analyses of the 
SNP—phenotype association considered the possibility that nutrient biomarkers may 
affect this association by: 1) contributing to variation (“noise”) in the phenotype due to 
causal pathways that do not involve the SNP under consideration, 2) mediating the 
association of the SNP with the phenotype, and 3) modifying the SNP—phenotype 
association.  Because the set of genes under consideration encode enzymes that 
function as an interconnected network, it was important to account for variation in the 
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phenotype due to causes other than the SNP under consideration; for example, 
homocysteine is well-known to respond to folate levels, which may be influenced by a 
variety of factors including diet and several genetic variants.  Nutrient residuals were 
calculated and used in models to account for variation in the nutrient biomarker that 
was not directly associated with the SNP of interest.  Second, nutrient biomarkers may 
mediate the SNP-phenotype association and comparing models adjusting for the full 
variation in a nutrient to unadjusted models assessed the extent of mediation. Finally, 
nutrients may modify the SNP—phenotype association (for example, the association 
of MTHFR 677 C→T rs1801133 with homocysteine is modified by blood folate levels 
(47)). To assess effect modification, product terms between the SNP and the nutrient 
biomarker residual were included in models.  Interactions were captured in a single 
model term, therefore, significance of the interaction was assessed by the P value for 
the interaction term (except for MTHFR rs1801133, which was dummy-coded; thus, 
the interaction was assessed through the Likelihood Ratio Test P value).  To facilitate 
description of the genotype—nutrient interaction, a standardized approach was used, 
as follows: significant SNP—nutrient interactions were evaluated at 3 levels of the 
centered, log transformed nutrients: the 10th percentile (“low nutrient levels”), the 50th 
percentile (“median nutrient levels”), and the 90th percentile (“high nutrient levels”).   
 All statistical analyses were conducted with SAS v. 9.2 (SAS, Cary, NC).   
 
3.4 Results 
 
 Measurements of the homocysteine phenotype, the Alu element methylation 
phenotype, and the LINE-1 methylation phenotype were available for 760, 628 and 
621 participants, respectively. All participants had genotype data, and a subset of 533 
men had data on all three phenotypes.  Rather than limit data analysis to the subset of 
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533 men, each analysis included the maximum number possible. The three phenotype 
groups had similar genotype frequencies for the MTHFR 677 C→T rs1801133 TT 
genotype, but differed by age and hence differed slightly on age-related variables 
(Table 3.1).  The MTHFR 677 C→T rs1801133 TT genotype prevalence in the largest 
phenotype group, the plasma homocysteine group, was 12.2%, calculated on data from 
over 1500 chromosomes; this  
prevalence is higher than a sample of 120 chromosomes from the HapMap CEPH 
population with a TT frequency of 6.7%, but closely matches the TT frequency in a 
sample of 5064 chromosomes from North American ‘control’ participants  (from case-
control studies of heart outcomes) (52).  In exploratory regression models, prior to 
assessing the genotype—phenotype associations, age and current smoking status were 
associated with homocysteine (P≤0.001), age was associated with Alu  (P≤0.005), and 
current smoking was associated with LINE-1 (P=0.055). Plasma folate, vitamin B-6, 
and vitamin B-12 were associated with homocysteine (P≤0.005), plasma vitamin B-6 
was associated with Alu methylation (P≤0.05), and the nutrition biomarkers had little 
or no association with LINE-1.    
 Models exploring the SNP—phenotype association were adjusted for age, 
smoking, and nutrient residuals.  Adjustment for age and smoking made little 
difference to the coefficients for each SNP.  The set of SNPs represented in the most 
significant associations was nearly identical with or without adjustment for nutrient 
residuals. When models were further adjusted for the MTHFR 677 C→T (rs1801133) 
variant, the SNP regression coefficients were about the same as in models without the 
rs1801133 term, thus this term was not included in final models.  The top SNP hits for 
the three phenotypes were  relatively common variants, and nearly all had MAF > 
13%, but the set of top SNP hits was unique to each phenotype (Tables 3.2-3.4 and  
 39 
 
 
 
 
Table 3.1.  Characteristics of Normative Aging Study participants, 1961-2001, 
with measurements on three phenotypes1 
 
Plasma 
homocysteine2 
Global 
genomic DNA 
methylation 
(Alu 
elements)3 
Global genomic 
DNA  
methylation 
(LINE-1 
elements)3 
 N=760 N=628 N=621 
Age at phenotype measurement 68.6 (7.3) 72.5 (6.8) 72.5 (6.8) 
Education – college graduate or higher (%) 26.8 28.6 28.7 
White (%) 100 100 100 
Baseline BMI (kg/m2) 25.9 (2.9) 25.9 (2.9) 25.9 (2.9) 
Cigarette smoking4    
Current (%) 6.7 5.4 5.5 
Former (%) 63.0 63.4 63.5 
Never (%) 30.3 31.2 31.1 
Alcohol intake (% consuming ≥2 drinks/day) 12.4 13.7 13.5 
Baseline diabetes diagnosis (%) 0.13 0.16 0.16 
Baseline systolic blood pressure (mm Hg) 122.1 (12.7) 121.7 (12.5) 121.6 (12.6) 
MTHFR 677 C→T (rs1801133) TT genotype (%) 12.2 12.3 12.6 
Plasma folate (ng/ml)5 10.4 (5.7) 17.2 (15.1) 17.0 (14.9) 
Plasma vitamin B-6 (pmol/ml) 84.9 (85.3) 104.6 (96.1) 104.8 (96.7) 
Plasma vitamin B-12 (pg/ml) 458.9 (190.6) 512.8 (371.2) 514.9 (373.8) 
Plasma total homocysteine (nmol/ml) 10.6 (3.7) 11.0 (4.2) 10.9 (4.2) 
Global DNA methylation in Alu elements (%)  26.3 (1.1)  
Global DNA methylation in LINE elements (%)   76.9 (1.9) 
    
 
 
1Mean (standard deviation) unless otherwise indicated 
2 N for homocysteine group ranges from 730 to 760 for variables in table 
3Men in the two global genomic methylation groups were very similar, and dates of  
marker collection were nearly identical.  N for Alu group ranges from 618 to 628, and N  
for LINE-1 group ranges from 611 to 621.  
4Smoking status was assessed using most recent data prior to phenotype measurement.  
5Plasma measures of folate, vitamin B-6, and vitamin B-12 were collected prior to the  
initiation of folate fortification for men included in the homocysteine group, and were  
collected after the initiation of folate fortification for men included in the two global  
genomic methylation groups.   
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 Table 3.2.  The most statistically significant associations (P≤0.005) between single nucleotide polymorphisms 
and the plasma homocysteine phenotype for men in the Normative Aging Study1,5 
 40 
Gene Name rs# Nominal P Effect3 Chr.
Coded 
allele 
Coded 
allele 
frequency 
Genetic 
Model SNP Type 
FTCD rs2277820 3.09E-042 7.22% 21 T 26% Overdominant Intronic 
SLC19A1 rs1051266 4.16E-042 5.04% 21 A 44% Additive Coding nonsynonymous 
SLC19A1 rs1131596 4.31E-042 5.03% 21 C 44% Additive 5' region 
SLC19A3 rs13007334 4.61E-042 6.89% 2 C 46% Overdominant Intronic 
SLC19A1 rs4819130 5.65E-042 4.94% 21 C 44% Additive Intronic 
MTHFD1L rs117546614 1.51E-03 49.98% 6 A 7% Recessive Intronic 
DNMT1 rs2228611 2.42E-03 -6.44% 19 G 49% Dominant Coding synonymous 
ALDH1L1 rs3772424 2.52E-03 6.14% 3 A 20% Dominant Intronic 
GGH rs4617146 2.55E-03 5.31% 8 T 19% Additive Intronic  
CELF1 rs4752843 2.74E-03 -5.72% 11 C 14% Additive Intronic 
SLC19A1 rs12482346 3.02E-03 4.08% 21 T 44% Additive Intronic 
SLC19A1 rs2297291 3.39E-03 6.07% 21 A 41% Dominant Intronic 
TCN2 rs4820886 3.41E-03 -17.30% 22 G 13% Recessive Intronic 
TCN2 rs9621049 3.41E-03 -17.30% 22 T 13% Recessive Coding nonsynonymous 
GLDC rs7848919 3.52E-03 5.70% 9 G 32% Dominant 3' region 
SARDH rs25027416 3.60E-03 6.60% 9 A 50% Dominant Intronic 
SLC19A1 rs1051298 3.68E-03 3.98% 21 T 44% Additive 3' region 
CBS rs6586282 4.06E-03 -5.80% 21 T 18% Overdominant Intronic 
FOLH1 rs202673 4.08E-03 -19.30% 11 G 14% Recessive Intronic 
MTHFD1 rs19509026 4.19E-03 -5.18% 14 T 16% Additive Coding nonsynonymous 
 1Model adjusted for age, smoking, residuals of plasma folate, vitamin B-6, and vitamin B-12; forward strand allele shown. 
2Adjusted P values reached False Discovery Rate significance threshold of 0.05. 
3Effect is shown as percent change in plasma homocysteine levels. 
4Sparse data (fewer than 5 individuals per category) for some genotype categories. 
5No SNPs map to more than one gene. 
6Lower quality SNP. 
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 Table 3.3.  The most statistically significant associations (P≤0.005) between single nucleotide polymorphisms 
and the global genomic DNA methylation phenotype (Alu elements) for men in the Normative Aging Study1,4,6 
 
Gene rs# Nominal P 
Effect 
(s.d.)3 Chr
Coded 
allele 
Coded 
allele 
frequency 
Genetic 
Model Type 
 GNMT rs10512185 2.14E-04 -0.57 6 T 3% Dominant 3' region 
 DNMT3B rs2424914 2.16E-03 0.30 20 G 45% Recessive Intronic 
 SLC25A32 rs31342975 2.20E-03 0.65 8 C 20% Recessive 5' region 
 DNMT3B rs2424922 2.21E-03 0.30 20 C 45% Recessive Coding synonymous 
 DNMT3B rs6058891 2.21E-03 0.30 20 C 45% Recessive Coding synonymous 
 MTHFD1L rs1738574 2.39E-03 0.24 6 T 45% Overdominant  Intronic 
 AHCYL2 rs1665105 3.87E-03 0.16 7 T 44% Additive 3' region 
 SARDH rs129886 3.92E-03 -0.60 9 T 19% Recessive 3' region 
 
 
     41  
1Model adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele 
shown; s.d.: standard deviation.   
2No adjusted P values reached False Discovery Rate significance threshold of 0.05.   
3Effect represents fold change in Alu element methylation standard deviation.   
4No sparse data (fewer than 5 individuals per category) for any genotype categories of these SNPs.   
5SNP maps to more than one gene (rs1051218 also maps to PEX6, rs3134297 also maps to WDSOF1/DCAF13).   
6No lower quality SNPs. 
 
  
 Table 3.4.  The most statistically significant association (P≤0.005) between single nucleotide polymorphisms 
and the global genomic DNA methylation phenotype (LINE-1 elements) for men in the Normative Aging 
Study1,2 
 
Gene rs# Nominal P 
Effect 
(s.d.)3 Chr
Coded 
allele 
Coded 
allele 
frequency 
Genetic 
Model Type 
 MTHFR rs12121543 4.29E-03 0.48 1 A 24% Recessive Intronic 
 1Model adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele 
shown; s.d.: standard deviation.   
2No adjusted P values reached False Discovery Rate significance threshold of 0.05.   
3Effect represents fold change in LINE-1 element methylation standard deviation.   
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Figure 3.1). A nominal significance threshold of P < 0.005 was chosen as the 
threshold that effectively separated the top hits.   
Total Plasma Homocysteine Phenotype 
 In analyses of the homocysteine phenotype, of the 20 SNPs with a nominal P 
≤0.005, five SNPs were also significant at the FDR threshold (FDR-adjusted P≤0.05) 
(Table 3.2).  These 5 SNPs comprise 3 genes: formiminotransferase  
cyclodeaminase (FTCD; 1 SNP, intronic), solute carrier family 19 (folate transporter), 
member 1 (SLC19A1, 3 hits, representing coding nonsynonymous, 5’ region, and 
intronic variants), and solute carrier family 19, member 3 (SLC19A3, 1 SNP, intronic).  
Genetic variation in all 5 SNPs was positively associated with plasma homocysteine 
levels, and effects were similar in direction and magnitude; variant genotypes were 
associated with a 4.9-7.2% higher plasma total homocysteine compared to the referent 
genotype.  In each case, the association of the genotype with homocysteine was 
mediated in part by nutrients; when plasma folate and vitamin B-6 or B-12 biomarkers 
were added to the models, the regression coefficients were reduced by 29% for FTCD 
rs2277820, by 43% for SLC19A1 rs1051266, rs1131596, and rs4819130, and by 34% 
for SLC19A3 rs13007334 (data not shown).  The model containing a nonredundant set 
of 3 of the top 5 FDR-significant SNPs (FTCD rs2277820, SLC19A3 rs13007334, 
SLC19A1 rs1051266) explained 3.6% of the variation in plasma homocysteine beyond 
the variation explained in the model containing age, smoking, and folate, B-6, and B-
12 residuals (data not shown), and the set of 3 SNPs made a statistically significant 
contribution (LRT for 3 SNPs = 17.6, p=0.0005, 3df); the coefficients for each SNP 
were similar to coefficients obtained in single SNP models. Genetic variation in the 
folate network as represented by a subset of 52 SNPs was significantly predictive of 
plasma homocysteine levels (likelihood ratio test for the model with vs. without set of 
52 SNPs= 114.4; P value 1.39E-06, 52 degrees of freedom); after simultaneous  
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Figure 3.1.  Manhattan plot: Folate-related SNPs as predictors of plasma total homocysteine and global 
genomic DNA methylation phenotypes.  Models adjusted for age, smoking status, and folate, vitamin B-6, 
and vitamin B-12 residuals.  Horizontal lines represent nominal P values of 0.05 (lower dashed line), 0.02 
(center solid line) and 0.005 (upper dashed line).  Boxes indicate SNPs that reached False Discovery Rate 
significance.   
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adjustment for the other 51 SNPs in the nonredundant set, the SLC19A1 rs1051266 
SNP was the top hit (nominal P= 0.0024).  The set of 52 nonredundant SNPs together 
explained 14.3% of the variation in homocysteine above and beyond that explained by 
age and smoking.  The genes represented in the most significant hits were similar 
between the single SNP models and the simultaneous model of 52 SNPs. The top 3 
nominally significant hits in the simultaneous model were SLC19A1 rs1051266, TCN2 
rs9621049, and MTHFR rs1801133.  There was little or no difference between the 
coefficients for these SNPs in the simultaneous compared to the single SNP models, 
although for all three SNPs, p values were lower in the single SNP models as 
expected.   
 In models investigating interactions between each SNP and MTHFR 677 C→T 
rs1801133, 18 interaction terms were FDR-significant (FDR-adjusted P≤0.1) for the 
total plasma homocysteine phenotype (Table A3.3).  Plasma folate and vitamins B-6 
and B-12 are cofactors for enzymes involved in the reactions of the one-carbon 
metabolic network, and these nutrients are predicted to modify the SNP—phenotype 
association.  In further analyses assessing SNP—nutrient interactions (folate, B-6, or 
B-12), no interaction coefficients reached FDR-significance levels (FDR-adjusted 
P≤0.2) (Table A3.4).   
Global Genomic DNA Methylation Phenotype: Alu elements  
 In analyses of the Alu element methylation phenotype, 8 SNPs were 
statistically significant with a nominal P≤0.005, however, none were statistically 
significant at the FDR threshold (FDR-adjusted P≤0.05) (Table 3.3).  There was little 
or no mediation of the association by nutrients or plasma total homocysteine levels 
(data not shown).  Genetic variation in the folate network as represented by a subset of 
52 SNPs together explained 8.4% of the variation in Alu element methylation above 
and beyond that explained by age and smoking; however, this model was not 
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significantly predictive of Alu methylation levels as assessed by the likelihood ratio 
test (test statistic for the model with vs. without 52 SNPs: 20.4; P value 0.99, 52 
degrees of freedom).  The genes represented in the most significant hits differed 
somewhat between the single SNP models and the simultaneous model of 52 SNPs; 
the top 3 nominally significant hits in the simultaneous model were FOLR2 rs514933, 
AHCYL2 rs1665105, and MTHFR rs1801133.  The regression coefficient for the top 
hit from the simultaneous model (FOLR2 rs514933) was increased 45% compared to 
the coefficient from the single SNP model, but there was little or no difference in the 
regression coefficients for AHCYL2 rs166105 and MTHFR rs1801133.  
 There were no SNP—nutrient interactions with folate or B-12 that reached 
FDR thresholds for statistical significance (FDR-adjusted P≤0.2) (Table A3.5).   
Three SNPs had a statistically significant interaction with plasma vitamin B-6 
(nominal P≤0.02) (Table A3.6); these interactions involved 3 intronic SNPs in 2 
genes: aminomethyltransferase (AMT, rs1464567 and rs1464566) and DNA (cytosine-
5-)-methyltransferase 3 beta (DNMT3B, rs1883729). Comparing men in the AMT 
rs1464567 CC/CG genotype group to the GG genotype, the mean Alu element 
methylation was 0.4 SD higher at low B-6, 0.1 SD higher at median B-6, and 0.4 SD 
lower at high B-6. Comparing men in the AMT rs1464566 GG/GA genotype group to 
the AA genotype, the mean Alu element methylation was 0.4 SD higher at low B-6, 0.1 
SD higher at median B-6, and 0.3 SD lower at high B-6. Comparing men in the 
DNMT3B rs1883729 AA genotype group to the AG/GG genotype, the mean Alu 
element methylation was 0.1 SD lower at low B-6, 0.3 SD higher at median B-6, and 
0.8 SD higher at high B-6.    
Global Genomic DNA methylation Phenotype: LINE-1 elements 
 In models considering the main effect of SNPs on the LINE-1 methylation 
phenotype, no associations reached the FDR-significance threshold (FDR-adjusted 
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P≤0.05; Table 3.4).  Genetic variation in the folate network as represented by a subset 
of 52 SNPs was significantly predictive of LINE-1 methylation levels (likelihood ratio 
for the model with vs. without 52 SNPs: 76.5; P value 0.015, 52 degrees of freedom) 
and the AMT rs8897 SNP had the lowest nominal P value (P=0.0024).  The set of 52 
nonredundant SNPs together explained 11.0% of the variation in LINE-1 element 
methylation above and beyond that explained by age and smoking.  The genes 
represented in the most statistically significant hits for LINE-1 were generally similar 
between the single SNP models and the simultaneous model of 52 SNPs; the top 3 
nominally significant hits in the  
simultaneous model were AMT rs8897, DNMT1 rs2228612, and CBS rs1788484.  The 
regression coefficient for the top hit in the simultaneous model (AMT rs8897) 
increased by 28% compared to the coefficient from the single SNP model, but there 
was little or no difference in the regression coefficients for DNMT1 rs2228612 and 
CBS rs1788484.   
 There were no SNP—nutrient interactions for folate or B-12 that reached FDR-
significance levels (FDR-adjusted P≤0.2) (Table A3.6).  An interaction of plasma B-6 
with 1 SNP was significant at the FDR threshold of P≤0.2 (rs17080689, an intronic 
SNP in methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like, 
MTHFD1L) (Table A3.7), suggesting that the relation of the SNP to LINE-1 
methylation varied according to plasma levels of vitamin B-6.  Thus, comparing 
participants with the MTHFD1L rs17080689 CA genotype to the CC/AA genotype 
group, mean LINE-1 element methylation was 0.6 SD higher at low B-6, 0.2 SD 
higher at median B-6, and 0.4 SD lower at high B-6. 
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3.5 Discussion 
  
 We investigated sequence variation in a network of candidate genes involved 
in one-carbon metabolism in relation to plasma total homocysteine and two measures 
of global genomic DNA methylation (Alu and LINE-1 elements). Genes, SNPs, and 
related nutrients were carefully chosen to represent the full functional variation of the 
folate-mediated one carbon metabolism pathway. The analysis considered all 330 
SNPs in tests for main effects, epistatic interactions between each SNP and the 
MTHFR rs1801133 SNP in relation to the plasma homocysteine outcome, and 
interactions between each SNP and plasma measures of folate, vitamins B-6 and B-12. 
FDR-significant main effects were identified for plasma total homocysteine and Alu 
element methylation phenotypes, FDR-significant interactions with MTHFR 
rs1801133 were identified for the homocysteine outcome, and FDR significant SNP—
B-6 interactions were identified for Alu and LINE-1 element methylation phenotypes. 
 Genes involved in absorption and transport had the most significant 
associations with the homocysteine phenotype; consistent with this finding, about 30-
40% of the association was mediated through plasma folate and vitamin B-6 and B-12 
levels.  Mitochondrial metabolism, methylation/ homocysteine pathways, cytoplasmic 
metabolism, nuclear metabolism, and B-12 metabolism were also represented in the 
top hits.  For the Alu-element methylation phenotype, the top hits were in genes 
playing a role in mitochondrial metabolism, nuclear metabolism, and 
methylation/homocysteine metabolism.  For the global genomic methylation LINE-1 
phenotype, the top SNP was in a gene in the methylation/homocysteine pathway of 
one-carbon metabolism.  There was no evidence that plasma folate or vitamins B-6 or 
B-12 mediated the association of SNPs with the methylation phenotypes. 
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 The set of genes represented in the top hits was unique to each phenotype, 
although pleiotropy was identified among the plasma homocysteine and Alu element 
methylation outcomes, in which both the MTHFD1L and sarcosine dehydrogenase, 
SARDH, genes were among the most significant associations.  When a subset of 
nonredundent SNPs (52 SNPs) was included in a single model, the genes identified as 
top hits for each phenotype were generally similar to genes identified in the single 
SNP models for each phenotypes, suggesting independent associations.  
Plasma total homocysteine phenotype 
 SLC19A1.  There were FDR-significant associations between 3 SNPs in the 
SLC19A1 gene and plasma total homocysteine levels, and each SNP had about the 
same direction and magnitude of association with homocysteine.  Thus, each copy of 
the coding nonsynonymous rs1051266 A allele was associated with a 5.0% increase in 
plasma homocysteine; similarly, each copy of the 5’region rs1131596 C allele was 
associated with a 5.0% increase in plasma homocysteine and, each copy of the intronic 
rs4819130 C allele was associated with a 4.9% increase in plasma homocysteine.  
HapMap LD plots indicate the linkage disequilibrium across the SLC19A1 gene is 
high, and the results for all three SLC19A1 SNPs are similar suggesting that SNP hits 
in this gene may represent a single effect.  The SLC19A1 gene encodes a ubiquitously 
expressed plasma membrane transporter responsible for the uptake of reduced folates, 
folate analogues (such as methotrexate), and phosphate esters of thiamine (37).  This 
enzyme has also been detected in some mitochondrial membranes and may play a role 
in intracellular folate distribution (37).  Consistent with the functions of the SLC19A1 
protein, about half (~43%) of the association of these three SLC19A1 SNPs with 
homocysteine was mediated by plasma folate and vitamins B-6/B-12; thus, the SNP is 
proposed to lead to changes in the nutrient levels that in turn leads to changes in 
homocysteine.  The SLC19A1 rs1051266 SNP (formerly known as rs61510559 or 
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c.80A→G) results in a histidine to arginine change at amino acid 27, and, in prior 
reports, the variant was associated with blood folate levels, although the direction of 
effect was not consistent (33, 95), and with increased risk of intracranial aneurysm 
(88), but not with homocysteine (33, 41) or abdominal aortic aneurysm (41).  
Expression of the transporter appears to be regulated by folate status (high folate 
levels, low transporter expression) (37).  The C allele of the 5’ region SLC19A1 
rs1131596 SNP was associated with reduced RBC folate levels in coronary artery 
disease patients and also with decreased SLC19A1 protein expression (17, 18).     
Together, these findings suggest that genetic variation in SLC19A1 influences levels of 
folate-related biomarkers mediated by changes in folate and B-6/B-12 levels.  
Although SLC19A1 is not known to directly transport vitamins B-6/B-12, there was 
additional mediation through these nutrients, above and beyond mediation by folate, 
which may reflect changes in folate network flux that allow B-6/B-12 to compensate 
for altered folate transport.    
 FTCD. The intronic rs2277820 SNP in the FTCD gene was associated with 
plasma total homocysteine. The CT genotype group was 7.2% higher on plasma total 
homocysteine compared to the CC/TT genotype group.  FTCD encodes a bifunctional 
Golgi-membrane associated enzyme involved in histidine and purine catabolism, 
resulting in the production of 5,10-methenyl-tetrahydrofolate (THF), which enters the 
cytoplasmic one-carbon pool (32).  Based on HapMap LD patterns across the FTCD 
gene, it is possible that the association with the intronic rs2277820 SNP is a proxy for 
variation elsewhere in the gene – mutations in portions of the FTCD gene important 
for folate-binding, dimerization, or cyclodeaminase activity have been associated with 
autosomal recessive disorders of folate metabolism, characterized by significantly 
reduced formiminotransferase activity, absent cyclodeaminase activity, mental and 
physical retardation and metabolic disturbances (43).  Consistent with the role of the 
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FTCD enzyme in production of 5,10-methenyl-THF, approximately one-third (29%) 
of the association between rs2277820 and homocysteine was mediated through plasma 
folate and vitamins B-6/B-12.  
 SLC19A3.   A single FDR-significant association was identified between the 
intronic rs13007334 SNP in SLC19A3 and plasma total homocysteine. The CT 
genotype group was 6.9% higher on plasma total homocysteine compared to the 
CC/TT genotype group. The SLC19A3 gene belongs to the folate transporter family 
and encodes a ubiquitously expressed thiamine transporter (37); indeed SLC19A1 is 
also capable of transporting thiamine or phosphate esters of thiamine (37).  Although 
SLC19A3 is not known to transport folate or vitamins B-6/B-12, about one-third 
(34%) of the association between the rs13007334 SNP and homocysteine was 
mediated by plasma folate and vitamins B-6/B-12.  No prior reports link SLC19A3 to 
biochemical or disease phenotypes, and a biological basis for the link to thiamine 
metabolism could not be identified.   
    Proportion of variability explained.  The variability in homocysteine explained 
by the model containing the set of the 3 most significant nonredundant SNP hits was 
3.6%, a small proportion of the estimated >50% heritability in homocysteine, based on 
twin studies (76, 92).  The proportion of variation in homocysteine explained by these 
3 SNPs is similar to the proportion explained by two other determinants of 
homocysteine, age and smoking (84), which together explained 3.5%.  Together, a set 
of 52 nonredundant SNPs explained 14.3% of the variation in plasma homocysteine 
above and beyond that explained by age and smoking and was significantly associated 
with the homocysteine phenotype based on the likelihood ratio test. 
 Interactions.  Previous meta-analyses have identified important determinants 
of homocysteine levels, including the MTHFR 677 C→T rs1801133 variant, intake of 
folate and vitamin B-12, and to a lesser extent vitamin B-6 (52) (45).  In this study, 
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there were 18 statistically significant interactions between studied SNPs and MTHFR 
677 C→T rs1801133 (Table A3.3), and the most highly significant of these involved 
DHFR rs12517451.  Within the strata of individuals with the rs12517451 AG 
genotype, men with 1 copy of the rs1801133 T allele had plasma homocysteine levels 
1.9% higher than the men with no copies, and men with 2 copies of the rs1801133 T 
allele had plasma homocysteine levels 4.2% higher than men with no copies.   
 In contrast to the epistatic interactions, there were no significant interactions 
between studied SNPs and plasma folate, vitamin B-6, or vitamin B-12 for the plasma 
homocysteine phenotype. The null results may be due to an overly conservative FDR 
significance threshold, network compensation for genetic and nutritional stresses, or 
inadequate power to evaluate interactions involving low MAF SNPs. An additional 
explanation for this finding may be that the folate status for men in the NAS, although 
measured prior to introduction of mandatory folate fortification, was high: the mean 
plasma folate was 10.4 ng/ml, significantly higher than the prefortification serum 
folate mean of 5.8 ng/ml in non-Hispanic Whites reported by NHANES III (1988-
1994), although not as high as the post-fortification mean of 14.8 ng/ml measured in 
1999-2000 (80).  SNP—nutrient interactions may be blunted in this range of folate 
status. For example, the MTHFR rs1801133 SNP, which is expected to interact with 
folate in predicting the homocysteine phenotype, had a nonsignificant interaction in 
these data (p= 0.16).  At low plasma folate (4.36 ng folate/ml), men with the 
rs1801133 TT genotype had a 16% higher plasma homocysteine compared to the CC 
genotype; at median plasma folate (9.53 ng folate/ml) the TT group had a 4.4% higher 
homocysteine, while at high plasma folate (17.23 ng folate/ml) the TT group had a 
3.6% lower homocysteine.  Although these findings are consistent with direction of 
the well-described MTHFR 677—folate interaction, the magnitude is slightly smaller 
than previously reported (47, 108). 
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 A cluster of SNP—vitamin B-6 interactions was noted for variants in the CBS 
gene, but the P values for these interaction terms were about 0.1 and did not reach 
thresholds set prior to the analysis. The smallest P value was 0.086 for the interaction 
of vitamin B-6 with a variant in the CBS gene (rs1788484) and 0.216 for an interaction 
of vitamin B-6 with a variant in the SHMT1 gene (rs643333).  These findings are 
consistent with previous work showing that the human SHMT1 and CBS proteins bind 
B-6 tightly (Kd 850 nM and 700 nM, respectively) and effects of increasing vitamin B-
6 availability on SHMT1 quantity and activity as well as cellular AdoMet levels were 
greatest under stringent B-6 deprivation conditions; thus, interactions between vitamin 
B-6 and genetic variants in the SHMT1 and CBS genes may only be evident with very 
low vitamin B-6 status (79, 99).  A systematic review of literature published prior to 
August, 2009 revealed 1 statistically significant interaction between genetic variation 
in SHMT1 (rs1979277) and B-6 (53). 
Global genomic DNA methylation phenotype (Alu elements) 
 There were no FDR-significant main effect associations observed for the Alu 
element methylation phenotype.   The set of 52 nonredundant SNPs explained 8.4% of 
the variation in Alu element methylation above and beyond that explained by age and 
smoking but this set was not significantly predictive of Alu methylation based on the 
likelihood ratio test.  None of the SNP—folate or SNP—vitamin B-12 interaction 
terms reached FDR significance in predicting Alu element methylation.  Because the 
Alu phenotype was measured after the introduction of mandatory folate fortification in 
the U.S. findings may be limited by this timing.  However, three FDR-significant 
SNP—vitamin B-6 interactions were identified, including two intronic SNPs in the 
AMT gene (rs1464567 and rs1464566) and one intronic SNP in the DNMT3B gene 
(rs1883729).  In men with the AMT rs1464567 CC/CG genotype (compared to the GG 
genotype), mean Alu element methylation was 0.4 SD higher at low B-6, 0.1 SD 
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higher at median B-6, and 0.4 SD lower at high B-6. Similarly, in men with the AMT 
rs1464566 GG/GA genotype (compared to the AA genotype), mean Alu element 
methylation was 0.4 SD higher at low B-6, 0.1 SD higher at median B-6, and 0.3 SD 
lower at high B-6. For men with the DNMT3B rs1883729 AA genotype (vs. AG/GG 
genotype), mean Alu element methylation was 0.1 SD lower at low B-6, 0.3 SD lower 
at median B-6, and 0.8 SD higher at high B-6.  The AMT gene encodes an enzyme that 
functions as an aminomethyltransferase (the so-called “T protein”) in the vitamin B-6-
dependent mitochondrial glycine cleavage system, which functions to catabolize 
glycine while at the same time synthesizing serine and 5,10-methyleneTHF, and is a 
major route for the provision of 1 carbon units to the cellular one-carbon pool as 
formate(56).  Although the AMT enzyme itself is not vitamin B-6-dependent, through 
the glycine cleavage system it interacts closely with the vitamin B-6-dependent 
glycine dehydrogenase (decarboxylating) enzyme, (the so-called “P protein,” which is 
encoded by the GLDC gene).  B-6 interactions involving SNPs in GLDC were among 
the top nominally-significant hits for the homocysteine and Alu methylation 
phenotypes, although these interaction terms did not reach FDR-significance.  The 
DNMT3B gene encodes a DNA methyltransferase enzyme that is localized to the 
nucleus and developmentally regulated.  In mice, Dnmt3b knockouts are embryonic 
lethal while in humans, DNMT3B mutations have been shown to cause 
immunodeficiency, chromosomal instabilities, and facial abnormalities (ICF) 
syndrome (110).  Further, DNMT3B expression is associated with cancer (85, 103, 
110).  A recent publication links the DNMT3B enzyme to histone ubiquitin ligase 
complexes, suggesting it may be important for repressive chromatin formation (91).  
DNMT3B functions to establish de novo methylation patterns, including the 
methylation of CpG dinucleotides within transposons located near chromosome 
centromeres (103, 110).  Although cell culture studies have not supported Alu 
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elements as DNMT3B targets (22, 110) there is evidence that B vitamins may interact 
with DNA methylation enzymes. In both in vitro and in vivo models, DNMT3b protein 
levels were down-regulated by B vitamin deficiency (deficiency of folate, B-6, and B-
12 together), and further, de novo methylation was suppressed both in vitro and in vivo 
under conditions of B vitamin deficiency (36).  Finally, cell culture work has 
demonstrated that cellular AdoMet levels were markedly decreased in response to 
lowered B-6 concentrations in culture medium (79), consistent with the direction of 
effect observed for the DNMT3B-B-6 interaction. 
Global genomic DNA methylation phenotype (LINE-1 elements) 
 There were no FDR-significant associations observed for the LINE-1 
methylation phenotype.  The set of 52 nonredundant SNPs explained 11% of the 
variation in LINE-1 element methylation above that explained by age and smoking 
and this set of SNPs was significantly predictive of LINE-1 element methylation based 
on the likelihood ratio test.  There were no FDR-significant interactions between SNPs 
and folate or vitamin B-12; however, the LINE-1 phenotype was measured after the 
introduction of mandatory folate fortification in the U.S. which may have limited 
findings.  A single SNP—vitamin B-6 interaction was significant at the FDR 
threshold: for the intronic rs17080689 in the MTHFD1L gene, comparing men with 
the CA genotype to the AA/CC genotype, mean LINE-1 element methylation was 0.6 
SD higher at low B-6, 0.2 SD higher at median B-6, and 0.4 SD lower at high B-6.  
While the MTHFD1L gene is not vitamin B-6-dependent, the gene encodes a 
monofunctional mitochondrial tetrahydrofolate synthase and functions as part of the 
cellular folate metabolic network, downstream from the vitamin B-6-dependent 
glycine cleavage system, contributing to production of THF and formate (23). Intronic 
variation in MTHFD1L was associated with CVD in a large-scale genome-wide 
association study (112). 
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3.6 Conclusion 
  
 Strengths of the present study include investigation of a large cohort with 
homocysteine data collected prior to the introduction of mandatory folate-fortification 
in the U.S.  Thus, the study population is well-suited to investigate the network of 
folate-related genes in relation to such quantitative phenotypes.  SNP selection for the 
genotyping assay reflected coverage of genes based on function, linkage, and physical 
coverage, which led to markers that captured functional variants in addition to tagging 
of variation elsewhere in the gene. In a systematic approach to the data analysis, we 
identified the best genetic models for each SNP, then tested single SNPs, a reduced set 
of non-redundant SNPs, the interaction of each SNP with MTHFR 677 rs1801133, and 
the interaction of each SNP with folate, vitamin B-6 and vitamin B-12.  Findings were 
corrected for multiple comparisons and findings based on the FDR threshold were 
discussed in more detail. Weaknesses of the study include the fact that methylation 
(but not homocysteine) measures were collected after the introduction of mandatory 
folate fortification in the U.S., which may have attenuated associations, particularly 
gene-nutrient interactions, which might have been present in a population with more 
variation in B-vitamin status.  Available nutrient measures included folate and 
vitamins B-6 and B-12; however, information on additional nutrients such as choline 
would have allowed a more complete evaluation of gene-nutrient interactions.  
Although AdoHcy and/or the AdoMet/AdoHcy ratio are likely to be more sensitive 
indicators of vascular disease risk than homocysteine (51, 107), these biomarkers were 
not measured in the NAS cohort study.  Finally, due to genotyping failure, some key 
variants could not be analyzed, ex., rs6922269 in MTHFD1L (112).     
 The most significant hits for the homocysteine and methylation outcomes 
reflected genes involved in the generation of one-carbon units, including SLC19A1 
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and FTCD. Because a unique set of genes was identified among the most significant 
hits for each outcome, and because the top hits could not be predicted on the basis of 
projected impact on cellular methylation potential, this work suggests that not all 
folate effects are mediated through AdoMet/AdoHcy and that beyond the well-
described MTHFR rs1801133 SNP, polymorphisms in other genes make important 
contributions to homocysteine and global genomic DNA methylation phenotypes.  
Furthermore, some associations are sensitive to nutritional status of B vitamins. Future 
work should continue to include a broad evaluation of one-carbon network genetic and 
nutritional variation in unfortified or pre-fortification populations and extend these 
findings for CVD biomarkers to investigate CVD phenotypes directly.    
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TABLE A3.1 
 
 
THE 52 GENES IN THE FOLATE-MEDIATED ONE-CARBON PATHWAY 
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Gene 
Symbol Gene Name 
Entrez 
GeneID 
AHCY Adenosylhomocysteinase 191 
AHCYL1 Adenosylhomocysteinase-like 1 10768 
AHCYL2 Adenosylhomocysteinase-like 2, KIAA0828 23382 
ALDH1L1 Aldehyde dehydrogenase 1 family, member L1 10840 
AMT Aminomethyltransferase 275 
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
471 
BHMT Betaine-homocysteine S-methyltransferase 635 
CBS Cystathionine-beta-synthase 875 
CTH Cystathionase (cystathionine gamma-lyase) 1491 
CELF1 CUGBP, Elav-like family member 1 10658 
DHFR Dihydrofolate reductase 1719 
DMGDH Dimethylglycine dehydrogenase 29958 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 1786 
DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha 1788 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 1789 
FOLH1 Folate hydrolase (prostate-specific membrane antigen) 1 2346 
FOLR1 Folate receptor 1 (adult) 2348 
FOLR2 Folate receptor 2 (fetal) 2350 
FOLR3 Folate receptor 3 (gamma) 2352 
FPGS Folylpolyglutamate synthase 2356 
FTCD Formiminotransferase cyclodeaminase 10841 
FTH1 Ferritin, heavy polypeptide 1 2495 
GART Phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
2618 
GCSH Glycine cleavage system protein H (aminomethyl carrier) 2653 
GGH Gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
8836 
GLDC Glycine dehydrogenase (decarboxylating) 2731 
GNMT Glycine N-methyltransferase 27232 
HSPA8 Heat shock 70kDa protein 8 3312 
MARS Methionyl-tRNA synthetase 4141 
MAT1A Methionine adenosyltransferase I, alpha 4143 
MAT2A Methionine adenosyltransferase II, alpha 4144 
MAT2B Methionine adenosyltransferase II, beta 27430 
MTHFD1 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 
1, methenyltetrahydrofolate cyclohydrolase, 
formyltetrahydrofolate synthetase 
4522 
MTHFD1L Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 
1-like 
25902 
MTHFD2 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 
2, methenyltetrahydrofolate cyclohydrolase 
10797 
MTHFR Methylenetetrahydrofolate reductase (NAD(P)H) 4524 
MTHFS 5,10-methenyltetrahydrofolate synthetase (5-
formyltetrahydrofolate cyclo-ligase) 
10588 
MTR 5-methyltetrahydrofolate-homocysteine methyltransferase 4548 
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TABLE A3.1 (Continued) 
Gene 
Symbol Gene Name 
Entrez 
GeneID 
   
MTRR 5-methyltetrahydrofolate-homocysteine methyltransferase 
reductase 
4552 
SARDH Sarcosine dehydrogenase 1757 
SHMT1 Serine hydroxymethyltransferase 1 (soluble) 6470 
SHMT2 Serine hydroxymethyltransferase 2 (mitochondrial) 6472 
SLC19A1  Solute carrier family 19 (folate transporter), member 1 6573 
SLC19A2 Solute carrier family 19 (thiamine transporter), member 2 10560 
SLC19A3 Solute carrier family 19, member 3 80704 
SLC25A32 Solute carrier family 25, member 32 81034 
SLC46A1 Solute carrier family 46 (folate transporter), member 1 113235 
TCN1 Transcobalamin I (vitamin B-12 binding protein, R binder family) 6947 
TCN2 Transcobalamin II 6948 
TYMS Thymidylate synthetase 7298 
UBE2I Ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) 7329 
UBE2N Ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast) 7334 
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TABLE A3.2 
 
330 FOLATE-RELATED SNPS ASSAYED IN MEN IN THE NORMATIVE 
AGING STUDY1-5 
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Gene SNP Name Gene SNP Name Gene SNP Name 
AHCY rs819133 BHMT rs558133 DMGDH rs1805073 
AHCY rs819159 BHMT rs585800 DMGDH rs532964 
AHCY rs819155 CBS rs706209 DMGDH rs2253262 
AHCY rs13043752 CBS rs2124458 DMGDH rs644191 
AHCY rs819148 CBS rs760124 DNMT1 rs8101626 
AHCY rs1205366 CBS rs6586281 DNMT1 rs11880388 
AHCY AHCYC34T CBS rs6586282 DNMT1 rs2228611 
AHCY rs819146 CBS rs11203172 DNMT1  rs22286121 
AHCYL1 rs333079 CBS rs234704 DNMT1 rs2162560 
AHCYL1 rs3768480 CBS rs1801181 DNMT3A rs11695471 
AHCYL1 rs2298116 CBS rs2014564 DNMT3A rs6546045 
AHCYL1 rs720917 CBS rs1789953 DNMT3A rs7578575 
AHCYL1 rs186724 CBS rs12329764 DNMT3A rs6733868 
AHCYL2 rs6467233 CBS rs234705 DNMT3A rs11678631 
AHCYL2 rs4731569 CBS rs234706 DNMT3A rs1550117 
AHCYL2 rs7788327 CBS rs234709 DNMT3B rs6058869 
AHCYL2 rs6467244 CBS rs234711 DNMT3B rs1883729 
AHCYL2 rs1665105 CBS rs11701048 DNMT3B rs2424914 
ALDH1L1 rs4646760 CBS rs1788484 DNMT3B rs6058891 
ALDH1L1 rs4646750 CTH rs648743 DNMT3B rs2424922 
ALDH1L1 rs4646745 CTH rs663465 DNMT3B rs6058896 
ALDH1L1 rs3772424 CTH rs681475 FOLH1 rs16906158 
ALDH1L1 rs3772414 CTH rs535112 FOLH1 rs202673 
ALDH1L1 rs2305230 CTH rs663649 FOLH1 rs664584 
ALDH1L1 rs11715574 CTH rs1021737 FOLH1 rs202676 
ALDH1L1 rs1868138 CUGBP1 rs7102372 FOLR1 rs2071010 
ALDH1L1 rs1823213 CUGBP1 rs2242081 FOLR1 rs9282688 
AMT rs11922013 CUGBP1 rs7933019 FOLR2 rs514933 
AMT rs1464567 CUGBP1 rs4752843 FOLR2 rs2298444 
AMT rs1464566 DHFR rs12517451 FOLR3 rs7926875 
AMT rs8897 DHFR rs1677666 FOLR3 rs11235449 
ATIC rs7585489 DHFR rs1650723 FPGS rs10106 
ATIC rs2372536 DHFR rs2560424 FPGS rs41319447 
ATIC rs3821353 DHFR rs1643659 FPGS rs4451422 
ATIC rs1997059 DHFR rs1643650 FTCD rs16978930 
ATIC rs4672768 DHFR rs836822 FTCD rs2277820 
BHMT rs16876512 DHFR rs1650697 FTH1 rs1800009 
BHMT rs7700970 DHFR rs380691 FTH1 rs17185413 
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TABLE A3.2 (Continued) 
Gene SNP Name Gene SNP Name Gene SNP Name 
BHMT rs506500 DHFR rs1382540 FTH1 rs1801621 
BHMT rs567754 DMGDH rs28326 FTH1 rs17156609 
BHMT rs10037045 DMGDH rs1805074 FTH1 rs2073588 
GART rs8971 MAT1A rs1819684 MTHFD1L rs538017 
GART rs1804385 MAT1A rs17677908 MTHFD1L rs9478162 
GART rs87882 MAT2A rs1446667 MTHFD1L rs9478908 
GART rs2027592 MAT2A rs2028900 MTHFD1L rs7770982 
GART rs4817580 MAT2A rs1078004 MTHFD1L rs17080689 
GCSH rs8177940 MAT2A rs2043675 MTHFD1L rs1076746 
GCSH rs8177876 MAT2B rs10515861 MTHFD1L rs509474 
GCSH rs4889233 MAT2B rs6882306 MTHFD1L rs7746991 
GCSH rs11866124 MAT2B rs4869087 MTHFD1L rs6910267 
GCSH rs1563072 MAT2B rs17061795 MTHFD1L rs17354394 
GGH rs11995525 MAT2B rs7733775 MTHFD1L rs1047665 
GGH rs11545078 MTHFD1 rs1076991 MTHFD2 rs7340453 
GGH rs4617146 MTHFD1 rs8003379 MTHFD2 rs1667627 
GGH rs3780126 MTHFD1 rs1950902 MTHFR rs1537516 
GGH rs12544045 MTHFD1 rs17751556 MTHFR rs4846049 
GLDC rs7848919 MTHFD1 rs3783728 MTHFR rs13306556 
GLDC rs3902970 MTHFD1 rs11627525 MTHFR        rs1801131 
GLDC rs1929933 MTHFD1 rs8003567 MTHFR rs12121543 
GLDC rs4237166 MTHFD1 rs8012229 MTHFR rs1994798 
GLDC rs10975681 MTHFD1 rs2281603 MTHFR rs6541003 
GLDC rs4629927 MTHFD1L rs7765521 MTHFR rs1801133 
GLDC rs7049056 MTHFD1L rs11754661 MTHFR rs17421462 
GLDC rs1821892 MTHFD1L rs4869953 MTHFR rs17367629 
GLDC rs2118653 MTHFD1L rs17349743 MTHFR rs3737965 
GLDC rs1755617 MTHFD1L rs803422 MTHFS rs8923 
GNMT rs11752813 MTHFD1L rs997429 MTHFS rs7177659 
GNMT rs2296805 MTHFD1L rs2295084 MTHFS rs6495450 
GNMT rs2296804 MTHFD1L rs803456 MTHFS rs2733106 
GNMT rs736158 MTHFD1L rs803455 MTHFS rs2586167 
GNMT rs1051218 MTHFD1L rs803454 MTR rs16834388 
HSPA8 rs4936770 MTHFD1L rs12201472 MTR rs3754255 
HSPA8 rs1461496 MTHFD1L rs4869954 MTR rs10925260 
HSPA8 rs11218941 MTHFD1L rs6902664 MTR rs1805087 
HSPA8 rs1136141 MTHFD1L rs1474787 MTR rs2275566 
MARS rs899653 MTHFD1L rs4869955 MTR  rs22292763 
MARS rs496245 MTHFD1L rs742832 MTR rs11314494 
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TABLE A3.2 (Continued) 
Gene SNP Name Gene SNP Name Gene SNP Name 
MARS rs1678537 MTHFD1L rs803447 MTR rs1050996 
MAT1A rs1985908 MTHFD1L rs803446 MTRR rs2966952 
MAT1A rs2993763 MTHFD1L rs803466 MTRR rs1801394 
MAT1A rs10788546 MTHFD1L rs1738574 MTRR rs7730643 
MAT1A rs1143694 MTHFD1L rs524732 MTRR rs161869 
MTRR rs1532268 SLC19A1 rs1051266 TCN2 rs5749132 
MTRR rs3776465 SLC19A1 rs11315965 TCN2 rs9606756 
MTRR rs162036 SLC19A1 rs4819130 TCN2 rs740233 
MTRR rs2303081 SLC19A2 rs6656822 TCN2 rs757874 
MTRR rs10380 SLC19A2 rs1983546 TCN2 rs4820021 
MTRR rs1802059 SLC19A2 rs17518769 TCN2 rs9621049 
MTRR rs8659 SLC19A2 rs2038024 TCN2 rs4820886 
SARDH rs129886 SLC19A3 rs13025803 TCN2 rs4820887 
SARDH rs129932 SLC19A3 rs11694828 TCN2 rs2301957 
SARDH rs129891 SLC19A3 rs13007334 TCN2 rs2301958 
SARDH rs756682 SLC19A3 rs17438244 TCN2 rs4820889 
SARDH rs2073817 SLC25A32 rs1061196 TCN2 rs10418 
SARDH rs2502741 SLC25A32 rs3098260 TYMS rs2853533 
SARDH rs4979632 SLC25A32 rs17803441 TYMS rs502396 
SARDH rs2073815 SLC25A32 rs3098243 TYMS rs2612095 
SHMT1 rs12952556 SLC25A32 rs3134297 TYMS rs2853543 
SHMT1 rs1979276 SLC46A1 rs2239908 TYMS rs16948305 
SHMT1 rs1979277 SLC46A1 rs2239907 TYMS rs699517 
SHMT1 rs2273028 SLC46A1 rs17719944 TYMS rs2790 
SHMT1 rs17806489 TCN1 rs17154234 UBE2I rs9926094 
SHMT1 rs4924750 TCN1 rs34324219 UBE2I rs909915 
SHMT1 rs2461838 TCN1 rs519221 UBE2I rs8052688 
SHMT1 rs643333 TCN1 rs557564 UBE2I rs11248868 
SHMT2 rs28365862 TCN1 rs2000613 UBE2N rs4020454 
SHMT2 rs7301155 TCN1 rs34528912 UBE2N rs7311222 
SLC19A1 rs1051298 TCN1 rs526934 UBE2N rs7309933 
SLC19A1 rs12482346 TCN2 rs5749131 UBE2N rs7300607 
SLC19A1 rs2297291 TCN2 rs5753231 UBE2N rs1483003 
1Formerly known as rs8111085;  2Formerly known as rs9984077; 3Formerly known as 
rs16834521; 4Formerly known as rs10737812; 5Formerly known as rs3177999. 
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TABLE A3.3 
 
INTERACTIONS WITH MTHFR 677 C→T (rs1801133) WITH THE MOST 
STATISTICALLY SIGNIFICANT ASSOCIATION (LIKELIHOOD RATIO TEST 
P≤0.025) WITH THE PLASMA HOMOCYSTEINE PHENOTYPE1,2
 66 
 
 
 66 
Gene rs# Genetic Model 
MTHFR 
genotype 
Beta 
coefficient LRT P Chr 
Coded 
allele
Coded allele 
frequency (%) Type 
DHFR rs12517451 Overdominant CT 0.0081 0.021 5 A 24.7% 3' 
   TT 0.018      
GGH rs11995525 Overdominant CT -0.012 0.021 8 A 26.9% Intronic 
   TT -0.022      
DHFR rs16506973,4 Overdominant CT 0.012 0.021 5 T 24.6% 5' 
   TT 0.016      
CBS rs2347063 Overdominant CT 0.018 0.021 21 A 35.0% Synonymous 
   TT 0.0056      
TCN1 rs526934 Overdominant CT 0.011 0.022 11 G 27.5% Intronic 
   TT -0.015      
DNMT1 rs2162560 Dominant CT -0.011 0.022 19 A 41.9% Intronic 
   TT -0.025      
AMT rs88973,4 Dominant CT -0.0029 0.022 3 T 26.8% 3' 
   TT 0.033      
DNMT1 rs8101626 Dominant CT 0.00051 0.022 19 G 42.5% Intronic 
   TT -0.025      
SLC19A2 rs19835463 Dominant CT 0.0056 0.023 1 C 37.0% Intronic 
   TT -0.029      
MTR rs1050996 Dominant CT 0.0079 0.023 1 G 41.2% 3' 
   TT 0.023      
TCN2 rs23019573,5 Overdominant CT -0.027 0.023 22 T 41.0% Intronic 
   TT -0.010      
MTHFD1L rs803422 Dominant CT -0.021 0.023 6 T 28.9% Intronic 
   TT 0.016      
DNMT3A rs75785753 Overdominant CT -0.026 0.023 2 A 30.6% Intronic 
   TT -0.022      
BHMT rs5065003 Dominant CT -0.029 0.023 5 T 30.7% Intronic 
   TT -0.015      
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TABLE A3.3 (Continued) 
Gene rs# Genetic Model 
MTHFR 
genotype 
Beta 
coefficient LRT P Chr 
Coded 
allele 
Coded allele 
frequency (%) Type 
BHMT rs7700970 Dominant CT 0.0092 0.024 5 T 29.8% Intronic 
   TT -0.036      
UBE2I rs99260943 Dominant CT 0.0069 0.025 16 C 13.2% Intronic 
   TT 0.0049      
UBE2I rs9099153 Dominant CT 0.0094 0.025 16 T 13.0% Intronic 
   TT -0.00019      
DNMT1 rs22286113 Dominant CT 0.0094 0.025 19 G 49.3% Synonymous 
   TT 0.015      
1 Model adjusted for age and smoking; forward strand allele shown; gene and rs# represent SNP interacting with MTHFR rs1801133; 
interactions among SNPs within the same gene were not considered. 
2False Discovery Rate-adjusted P values reached significance threshold of 0.025 for all tests presented. 
3Sparse data (fewer than 5 individuals per category) for some genotype combinations.   
4SNP maps to more than one gene (rs1650697 also maps to MSH3, rs8897 also maps to NICN1).   
5Lower quality SNP. 
             
             
             
 
 68 
 
 
 
 
 
 
 
 
 
 
TABLE A3.4 
 
NUTRIENT INTERACTIONS WITH THE MOST STATISTICALLY 
SIGNIFICANT ASSOCIATION (P≤0.02) WITH THE PLASMA  
HOMOCYSTEINE (THC) PHENOTYPE1-
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 Folate interactions  
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Gene rs# Nominal P 
Beta 
coefficient Chr
Coded 
allele 
Coded allele 
frequency (%) 
Genetic 
Model Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MTRR rs7730643 1.87E-03 -0.38 5 G 19% Recessive Intronic 
DHFR rs16506974 2.07E-03 -0.13 5 T 25% Overdominant 5' region 
DHFR rs12517451 2.30E-03 -0.12 5 A 25% Overdominant 3' region 
SARDH rs129891 2.55E-03 -0.09 9 A 34% Additive Intronic 
DMGDH rs532964 1.47E-02 -0.10 5 T 46% Dominant 
Coding 
nonsynonymous 
Vitamin B-6 interactions 
GGH rs4617146 1.22E-03 0.09 8 T 19% Additive Intronic 
GLDC rs1929933 1.67E-03 0.16 9 G 31% Recessive Intronic 
FTH1 rs171854134 2.16E-03 0.20 11 C 23% Recessive 3' region 
GNMT rs11752813 4.67E-03 0.09 6 G 46% Overdominant 5' region 
MAT1A rs1819684 9.63E-03 0.11 10 T 7% Dominant Intronic 
SARDH rs756682 1.22E-02 0.08 9 G 36% Dominant Intronic 
SARDH rs2073817 1.29E-02 0.08 9 A 36% Dominant 
Coding 
nonsynonymous 
AMT rs88974 1.34E-02 0.08 3 T 27% Dominant 5' region 
MTHFD1L rs77655215 1.40E-02 -0.08 6 A 47% Overdominant Intronic 
SARDH rs129891 1.70E-02 0.05 9 A 34% Additive Intronic 
MTHFR rs1801133 CT 1.83E-02 -0.033 1 T 35% Dummy 
Coding 
nonsynonymous 
 rs1801133 TT  0.0053      
Vitamin B-12 interactions 
MTHFD1L rs9478162 2.46E-03 0.33 6 A 23% Recessive Intronic 
MTHFD1L rs9478908 2.89E-03 0.32 6 G 25% Recessive Intronic 
DNMT3A rs11678631 6.42E-03 0.17 2 A 49% Recessive Intronic 
GGH rs4617146 7.26E-03 -0.12 8 T 19% Additive Intronic 
BHMT rs16876512 9.46E-03 0.67 5 T 10% Recessive 5' region 
CTH rs663465 9.75E-03 0.15 1 G 42% Dominant 5' region 
CTH rs648743 9.89E-03 0.15 1 C 42% Dominant 5' region 
GNMT rs2296805 1.66E-02 0.19 6 T 41% Recessive Intronic 
ALDH1L1 rs3772424 1.71E-02 -0.13 3 A 20% Dominant Intronic 
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 TABLE A3.4 (Continued) 
 
 70 
Gene rs# Nominal P 
Beta 
coefficient Chr
Coded 
allele 
Coded allele 
frequency (%) 
Genetic 
Model Type 
Vitamin B-12 interactions 
GNMT rs22968044 1.78E-02 0.18 6 G 41% Recessive Intronic 
1Model adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele 
shown; rs# represents SNP involved in interaction.   
2No False Discovery Rate-adjusted P values reached significance threshold of 0.2. 
3No sparse data (fewer than 5 individuals per category) for any genotype categories of these SNPs.   
4SNP maps to more than one gene (rs1650697 also maps to MSH3; rs17185413 also maps to BEST1, rs8897 also maps to NICN1; 
rs2296804 also maps to PEX6).   
5Lower quality SNP. 
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TABLE A3.5 
 
NUTRIENT INTERACTIONS WITH THE MOST STIATISTICALLY 
SIGNIFICANT ASSOCIATION (P≤0.02) WITH THE GLOBAL GENOMIC DNA 
METHYLATION PHENOTYPE (ALU ELEMENTS)1
 72 
 
 Folate interactions  
72 
Gene rs# Nominal P 
Beta 
coefficient Chr 
Coded 
allele 
Coded allele 
frequency (%) Genetic Model Type 
SLC25A32 rs3098243 1.58E-03 0.47 8 C 43% Overdominant Intronic 
SARDH rs25027415 2.78E-03 -0.44 9 A 50% Overdominant Intronic 
ALDH1L1 rs4646760 1.05E-02 -0.68 3 G 35% Recessive Intronic 
SLC46A1 rs177199443 1.08E-02 -2.82 17 G 7% Recessive Intronic 
GART rs8788 1.17E-02 0.38 21 C 26% Overdominant Coding 
nonsynonymous 
GLDC rs4629927 1.57E-02 -0.36 9 G 41% Overdominant Intronic 
DNMT3A rs7578575 1.82E-02 0.35 2 A 31% Overdominant Intronic 
Vitamin B-6 interactions 
AMT rs1464567 5.27E-042 -0.47 3 C 42% Dominant Intronic 
AMT rs1464566 7.97E-042 -0.45 3 G 42% Dominant Intronic 
DNMT3B rs1883729 1.70E-032 0.52 20 A 40% Recessive Intronic 
TCN2 rs5749131 3.19E-03 -0.39 22 A 42% Dominant 5' region 
DNMT3B rs2424922 5.19E-03 0.43 20 C 45% Recessive Coding 
synonymous 
DNMT3B rs6058891 5.19E-03 0.43 20 C 45% Recessive Coding 
synonymous 
DNMT3B rs2424914 5.31E-03 0.43 20 G 45% Recessive Intronic 
BHMT rs10037045 5.58E-03 0.36 5 T 29% Dominant Intronic 
CELF1 rs2242081 6.69E-03 0.27 11 C 46% Additive Intronic 
DNMT3B rs60588695 9.38E-03 0.45 20 T 39% Recessive 5' region 
TCN1 rs519221 1.24E-02 -0.59 11 T 27% Recessive Intronic 
TCN1 rs5575645 1.24E-02 -0.59 11 T 27% Recessive Intronic 
GLDC rs1755617 1.33E-02 0.36 9 T 24% Overdominant Intronic 
TCN1 rs34528912 1.46E-02 0.55 11 T 5% Additive Coding 
nonsynonymous 
AMT rs11922013 1.50E-02 0.25 3 C 30% Additive Intronic 
ALDH1L1 rs1868138 1.79E-02 0.32 3 T 20% Overdominant Intronic 
SLC19A3 rs11694828 1.91E-02 -0.31 2 A 45% Overdominant Intronic 
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 TABLE A3.5 (Continued) 
 
Gene rs# Nominal P 
Beta 
coefficient Chr 
Coded 
allele 
Coded allele 
frequency (%) Genetic Model Type 
Vitamin B-12 interactions 
FPGS rs101065 1.28E-02 0.44 9 G 40% Overdominant 3' region 
FPGS rs4451422 1.44E-02 0.43 9 G 40% Overdominant 3' region 
TYMS rs6995174 1.48E-02 0.75 18 T 32% Recessive 3' region 
AHCYL2 rs1665105 1.54E-02 0.30 7 T 44% Additive 3' region 
 1Model adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele shown; 
rs# represents SNP involved in interaction.     
2False Discovery Rate-adjusted P values reached significance threshold of 0.2.   
3Sparse data (fewer than 5 individuals per category) for some genotype categories of this SNP.   
4SNP maps to more than one gene (rs699517 also maps to ENOSF1).   
5Lower quality SNP. 
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TABLE A3.6  NUTRIENT INTERACTIONS WITH THE MOST STATISTICALLY SIGNIFICANT 
ASSOCIATION (P≤0.02) WITH THE GLOBAL GENOMIC DNA METHYLATION PHENOTYPE (LINE-1 
ELEMENTS)1,3,5 
Folate interactions 
Gene rs# Nominal P 
Beta 
coefficient Chr
Coded 
allele 
Coded allele 
frequency (%) Genetic Model Type 
FOLH1 rs664584 1.53E-02 -0.52 11 A 24% Additive Intronic 
BHMT rs16876512 1.55E-02 -3.55 5 T 10% Recessive 5' region 
MAT1A rs1985908 1.56E-02 0.62 10 C 32% Dominant 3' region 
DMGDH rs28326 1.96E-02 0.58 5 G 18% Additive Intronic 
Vitamin B-6 interactions 
MTHFD1L rs17080689 5.40E-052 -1.10 6 C 11% Overdominant Intronic 
FTH1 rs18000094 3.59E-03 0.65 11 G 34% Overdominant 3' region 
1Model adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele 
shown; rs# represents SNP involved in interaction.   
2False Discovery Rate-adjusted P values reached significance threshold of 0.2.   
3No sparse data (fewer than 5 individuals per category) for any genotype categories of these SNPs.   
4SNP maps to more than one gene (rs1800009 also maps to BEST1).   
5No lower quality SNPs.  
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CHAPTER 4 
 
FOLATE NETWORK GENETIC VARIATION AND CARDIOVASCULAR 
DISEASE RISK: A NETWORK ASSOCIATION STUDY 
 
4.1 Abstract 
 
Sequence variants in genes functioning in folate-mediated one-carbon 
metabolism, particularly the MTHFR rs1801133 677 C→T polymorphism, have been 
associated with cardiovascular disease risk, however, most work has focused on genes 
related to homocysteine. 330 SNPs in 52 genes were prospectively evaluated for their 
association with cardiovascular disease in a U.S. population studied prior to the 
initiation of mandatory folate fortification.  SNPs were selected based on functional 
effects and gene coverage and assayed on the Illumina Goldengate platform. Age- and 
smoking-adjusted genotype—phenotype associations were estimated in regression 
models.  Using a nominal P≤0.005 threshold for statistical significance, 8 SNPs were 
associated with CVD risk in single locus analyses.  Using a more stringent false 
discovery rate threshold, a polymorphism in the GGH gene was associated with 
reduced CVD risk.  A gene x folate interactions was identified (MAT2B) and two gene 
x vitamin B-12 interactions were identified (BHMT and SLC25A32).  Biological 
hypotheses related to SHMT1 were explored and significant gene x gene interactions 
were identified for TYMS x UBE2N, FTH1 x CELF1, and TYMS x MTHFR.  A 
significant association with CVD risk involving variation in MTHFD1L was also 
identified.  Finally, an interaction involving CELF1 x MTR was identified as the most 
statistically significant from among all pair-wise network interactions.  This study 
suggests that variation in genes other than MTHFR and those directly involved in 
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homocysteine metabolism, are associated with CVD risk and supports a role for 
SHMT1 and nuclear folate metabolism, including the thymidylate biosynthesis 
pathway, in relation to CVD.   
 
4.2 Introduction 
 
Heart disease and stroke were responsible for about one-third of U.S. deaths in 
2004 (16, 86), and there is extensive evidence on the contribution of dietary and 
lifestyle factors to risk (60).  Many risk factors for cardiovascular disease (CVD) have 
been identified, including modifiable factors such as high blood cholesterol and lack 
of physical activity and non-modifiable factors such as heredity and male gender, but 
the origins of CVD are complex and the interactive effects of genetic and 
environmental factors, including nutrition, play an important role (26).  
Folate and other B vitamins contribute to biologic processes important to 
health, including DNA synthesis and repair, and the generation of cellular methylation 
potential for a variety of methylation reactions.  Folate status is influenced by dietary 
intake and by variation in genes encoding folate-related enzymes, and altered folate 
status is associated with adverse outcomes, including birth defects, cardiovascular 
disease (CVD), and cancer (32) 
While several candidate genes contributing to folate mediated one-carbon 
metabolism have been thoroughly investigated in relation to CVD risk, most notably 
the MTHFR 677 C→T rs1801133 SNP, other genes in the one carbon metabolic 
pathway, particularly those not directly involved in homocysteine metabolism, are 
understudied in relation to CVD.  A systematic review and meta-analysis was 
conducted in 2008 to evaluate the evidence for the association between genetic 
variation in a set of 52 genes involved in the folate-mediated one-carbon metabolic 
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pathway and cardiovascular disease risk (114).  Overall, folate network genes involved 
in transsulfuration, cytoplasmic metabolism, and vitamin B-12 metabolism have been 
the focus of most work relating to CVD, while folate network genes involved in 
absorption and transport, mitochondrial metabolism, and nuclear folate metabolism are 
less studied in relation to CVD.  For example, serine hydroxymethyltransferase 1 
(soluble), SHMT1, encodes an enzyme that produces 5,10-methylenetetrahydrofolate 
(5,10-methyleneTHF), a key intermediate in the folate metabolic pathway(40), and has 
been shown to govern the competing flow of one-carbon units through thymidylate 
synthesis and methionine cycles (8, 42).  However, despite epidemiologic evidence for 
an interaction between SHMT1 rs1979277 and the MTHFR 677 C→T rs1801133 
variant that is strongly predictive of vascular disease risk (62)(Wernimont et al, 2010, 
in press), only a handful of published studies have evaluated this gene in relation to 
CVD risk (Wernimont et al, 2010, in press).  Another example is 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L), 
which was identified in 2007 by the Wellcome Trust Case Control Consortium 
genome-wide association study of CAD; a significant association was reported for the 
MTHFD1L rs6922269 genetic variant(112). MTHFD1L encodes a monofunctional 
tetrahydrofolate synthase that participates in mitochondrial folate metabolism, an 
aspect of folate metabolism that is far less well-studied than the methylation portion of 
the folate network.   
Thus, enzymes and genes less proximal to homocysteine metabolism may play 
important roles in predicting CVD, yet few studies evaluate a comprehensive set of 
genes in the folate pathway, in spite of an awareness of the importance of multiple 
genetic variants contributing jointly to increased disease risk (34).  An investigation of 
genetic variation within this network of genes is essential to a complete understanding 
of how genetically-driven alterations in folate metabolism influence CVD risk.  
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Determining the role of genetic and nutritional factors in mediating CVD risk is 
ultimately the foundation for developing strategies for CVD prevention (26).  This 
study investigated 330 single nucleotide polymorphisms (SNPs) in 52 genes with a 
role in folate-mediated one-carbon metabolism. The set of genes, SNP markers, and 
nutrients examined in this study were selected to represent the full functional variation 
of the folate-mediated one carbon metabolic pathway and prospectively evaluated for 
their association with cardiovascular disease in a U.S. population studied prior to the 
initiation of mandatory folate fortification. 
 
4.3 Methods 
 
Study Population 
 The Normative Aging Study (NAS) was established by the Veterans’ 
Administration (VA) in 1961, and at that time 2,280 men aged 21-81 years (mean age 
of 42 y at study entry) were enrolled in the study on the basis of health criteria (9, 28). 
The rate of continued participation of NAS men over the follow-up period from 1961 
through 1998 was excellent, with <1% attrition for all causes.  As of June 1998, just 
prior to the end of the follow-up period for the present study, 543 participants (24%) 
were deceased and ~1600 men (70%) were actively participating in follow-up visits 
(mean age of 70 y).  Men in the NAS were primarily non-Hispanic White males 
(>98% of the total NAS population) and the small number of participants in other 
racial/ethnic groups precluded separate analyses.  Thus, this study focused on non-
Hispanic white males using data on 1,131 men successfully genotyped. 
 This study was approved by the following: Brigham and Women’s Hospital 
Human Subjects committee, Veterans’ Administration R&D committee, and the 
Cornell University Committee on Human Subjects.  
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DNA Extraction 
 Genomic DNA from participants was extracted from stored frozen buffy coat 
of 7 ml whole blood using the QIAamp DNA Blood Kit (QIAGEN, Valencia, CA).  
The REPLI-g whole genome amplification kit (QIAGEN) was used to amplify 
genomic DNA when quantity was insufficient for genotyping.  Whole-genome 
amplified samples were quality checked using Taqman genotyping (120) and poor-
performing samples were excluded.  Of 1,304 participant samples submitted for 
genotyping, 54.4% were genomic, 45.5% were whole-genome amplified.   
SNP Selection 
 52 genes that contribute to folate-mediated one-carbon metabolism were 
identified (Table A4.1).  SNP selection encompassed 2 kb on either side of the gene to 
include promoter and/or regulatory region variants.  Four databases were used for SNP 
selection: the National Center for Biotechnology Information (NCBI) dbSNP and 
PubMed databases, (http://www.ncbi.nlm.nih.gov/), the Applied Biosystems 
Incorporated (ABI) SNPBrowser website (http://www.allsnps.com), and the Illumina 
Assay Design Tool (www.illumina.com ).  SNPs identified from literature searches 
and functional variants (non-synonymous coding region SNPs and 
promoter/regulatory region SNPs) were selected preferentially. Whenever possible, 
adjacent SNPs were selected such that the decay of maximum linkage disequilibrium 
between the 2 was no more than 33% (≤0.9 LDU between adjacent SNPs, where 1 
LDU represents the decay of LD between two SNPs by about 37% of its maximum 
value when fitted to the Malecot model (67)) to ensure sufficient SNP density to 
adequately represent the LD characteristics of the gene.  GoldenGate SNP validation 
status was considered at each step, and SNPs with a minor allele frequency (MAF) 
≥5% in European-ancestry populations were selected where possible although 
exceptions were made for SNPs with prior evidence of putative function or when no 
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SNPs with MAF ≥5% were available.  A total of 384 SNPs were selected, including 
SNPs that were intentionally redundant to provide coverage in the event that key SNPs 
of interest failed in the genotyping assay.  To simultaneously evaluate genetic 
variation within the network as a whole, a subset of 52 non-redundant SNPs was 
identified with 1 SNP per gene comprising the most likely functional variant with the 
highest MAF that could be selected for each gene.   
SNP Genotyping 
 384 SNPs were submitted to the Center for Inherited Disease Research at the 
Johns Hopkins University for genotyping via an Illumina GoldenGate custom 
genotyping panel.  Genotype frequencies in controls were compared with those 
expected in Hardy-Weinberg equilibrium (HWE) and tested with a Fisher test using 
Monte Carlo permutation estimates of exact P-values for HWE (10,000 permutations).  
Of the 384 SNPs originally submitted, 54 were ultimately excluded because of assay 
failure (46), monomorphic genotype data (4), minor allele frequency <1% (3), or 
genotype frequencies out of HWE (1), leaving 330 SNPs for analysis (Table A4.2).  
Both blind duplicates and HapMap Centre d'Etude du Polymorphisme Humain 
(CEPH) control samples with known genotypes were included to assess assay quality; 
reproducibility rates were excellent (99.99% for blind duplicates, 99.83% for HapMap 
CEPH controls).  
Covariates 
 Extensive previously collected data on male participants of the Normative 
Aging Study includes physical measurements, lifestyle factors, and blood biomarkers.  
Since the time of enrollment participants have had clinical examinations at 3- to 5-year 
intervals, with a response rate > 90% for mailed questionnaires.  Fasting plasma 
samples were drawn at the VA field site and stored at -80 °C prior to transfer to the 
Jean Mayer USDA Human Nutrition Research Center on Aging, where they were 
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analyzed; the time between blood draw and analysis averaged 1.7 ± 1.2 y as 
previously described (102).  Plasma biomarkers were assayed in an unselected subset 
of stored blood samples.  Measures of plasma folate, vitamin B-6 (as pyridoxal-5'-
phosphate; PLP) and vitamin B-12 are available for the majority of men with genotype 
data.  Methods for these measurements have been previously described and 
coefficients of variation (CV) were excellent, with a value of 4.3% for folate, 5.0% for 
vitamin B-6, and 4.7% for vitamin B-12 (102).  Plasma total homocysteine was 
assayed; methods were previously described, and the assay CV was 4.0% (102).   
Up to three measurements of homocysteine, folate, vitamin B-6, and vitamin B-12 
were available prior to 12/31/98, the end of follow-up, which coincides approximately 
with the start of mandatory folate fortification.  The intraclass correlation coefficients 
for log-transformed homocysteine, folate, vitamin B-6, and vitamin B-12 confirmed 
that a high proportion of the total variance was between-person variability (vs. within 
person), thus, the first available biomarker measure was used in models to best 
represent nutrient status in the pre-mandatory folate fortification era, and to maximize 
case number since we only included cases with nutrients measured prior to disease 
onset. All biomarkers were log-transformed to adjust for skewness and centered for 
best performance in regression models. 
Phenotype Assessment 
Follow-up time for study participants was estimated as the time from study 
baseline to the first occurrence of: a CVD event (angina, fatal and nonfatal MI or other 
coronary heart disease, and fatal and nonfatal stroke) or death from a competing cause.  
For all other men, time of follow-up was time on study through to 12/31/1998, the end 
of follow-up for all study analyses. 
Ascertainment of CVD events within the NAS has been described (62, 111).  
Briefly, the possible occurrence of nonfatal MI and angina was ascertained by 
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participant report, and then confirmed by a cardiologist.  Similarly, the occurrence of a 
nonfatal stroke was ascertained by participant report, and confirmed by a neurologist.  
Fatal myocardial infarction and fatal stroke among men with no prior history of CVD 
were ascertained through death certificates, which were reviewed by a cardiologist to 
assign cause of death using International Classification of Disease (ICD) codes.  CVD 
events comprised the following diagnosis (ICD, version 8) codes: heart disease 
(including angina and myocardial infarction) 410-414.9; and stroke 436.9, 430, 431. 
Ascertainment of fatal CVD events was nearly 100% (89, 111). In all instances, the 
confirming physician was unaware of the participant’s exposure status (genotype).  
From 1964 through 1998, 381 cases of fatal or nonfatal CVD occurred among the 
1,131 men (31,871 person-years of follow-up) with successful Illumina genotyping.   
Statistical Analyses  
 Time to event analysis evaluated the relation of single locus markers to CVD 
risk, estimated as time between entry into the study and end of follow-up, where end 
of follow-up was date of first CVD event for men with the outcome, and either death 
from competing cause or right truncation at 12/31/98 for men with no CVD event. 
Genetic models of inheritance (additive, dominant, recessive, overdominant) were 
tested for each SNP and the model with the most statistically significant association 
with CVD risk in the unadjusted single SNP analysis was chosen as the best model 
going forward; an exception was made for the MTHFR 677 C→T rs1801133 SNP, 
where prior evidence supports a dummy coded model that evaluates the CT and TT 
genotypes separately against the CC reference category (35, 62, 108).  Previous work 
in this cohort demonstrated no population substructure (115), thus no adjustments 
were made.  All regression models were adjusted for age and smoking status, and a 
further model also adjusted for the MTHFR 677 C→T  rs1801133 genotype. The 
interaction of each genotype with folate and vitamins B-6 and B-12 was tested; if 
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specific genetic models of inheritance led to sparse data in interaction models then 
additive coding was used as the default.  Gene-gene interactions were also tested, 
using model-free dummy variable coding in all cases.   
 Regression coefficients with a nominal P≤0.005 were flagged to obtain a 
liberal set of associations for comparison with other studies and consideration for 
further follow up.  Subsequent analyses used the False Discovery Rate (FDR) multiple 
testing correction of Benjamini and Hochberg (10) to adjust P-values, with a q-value 
significance threshold of 0.1, indicating that we expect less than 10% of tests flagged 
by this criterion to be false positives.  For interaction effects statistical significance 
thresholds were less stringent: a nominal P value of P≤0.02 was used, and the FDR q 
value significance threshold was 0.2.  
 To investigate the joint role of nutrition and genetic variation, analyses of the 
SNP—phenotype association considered the possibility that nutrient biomarkers may 
mediate or modify the SNP—phenotype association. To assess mediation by a 
nutrient, models adjusting for the nutrient were compared to unadjusted models. To 
assess effect modification, product terms between the SNP and the nutrient biomarker 
were included in models.  The statistical significance of the interaction was assessed 
by the P value for the interaction term.  To facilitate evaluation of the genotype—
nutrient interaction, a standardized approach was used, as follows: SNP—nutrient 
interactions were evaluated at 3 levels of the centered, log-transformed nutrients: the 
10th percentile (“low nutrient”), the 50th percentile (“median nutrient”), and the 90th 
percentile (“high nutrient”).   
 All statistical analyses were conducted with SAS v. 9.2 (SAS, Cary, NC), 
unless otherwise specified.   
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4.4 Results 
  
 Among 1,131 men with genotype data on 330 SNPs, 381 CVD cases occurred; 
14% were myocardial infarction only, 17% angina only, 4% other coronary heart 
disease only, 8% stroke only; the remaining cases had multiple diagnoses.  A subset of 
735 men had measurements for plasma nutrient biomarkers (folate, vitamins B-6 and 
B-12, and homocysteine). Among study participants the MTHFR 677 C→T rs1801133 
TT genotype frequency was 12.8%, representing over 2200 chromosomes; this 
frequency is higher than a sample of 120 chromosomes from the HapMap CEPH 
population in which the TT frequency was 6.7%, but similar to the TT frequency in a 
sample of 5064 chromosomes from North American coronary heart disease controls in 
a meta-analysis (52) (Table 4.1).  In exploratory regression models, prior to assessing 
the genotype—phenotype associations, baseline age was associated with CVD risk 
(P≤0.0001), as was baseline smoking status and change in smoking status over follow-
up (P≤0.002). When modeled individually, plasma folate (P=0.9) and vitamin B-12 
(P=0.7) had little or no association with CVD, and although vitamin B-6 (P=0.077) 
and homocysteine (P=0.054) had some association in unadjusted models, the 
associations were attenuated in age- and smoking- adjusted models.   
 All models were adjusted for age at study baseline and smoking status (two 
variables, baseline smoking status and change in smoking status over follow-up).  
Further adjusting for diabetes or hypertension (baseline status and change over follow-
up) made little difference overall and identified the same set of most significant SNPs, 
although some minor changes to regression coefficients and P values were noted.  The 
set of most significant SNPs, and the coefficient estimates and standard errors, were 
nearly identical in age- and smoking-adjusted models restricted to the subset of men 
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Table 4.1.  Baseline characteristics of Normative Aging Study 
participants, 1961-1998 
 N=11311  
Age 40.2 (7.8)  
Education – college graduate or higher (%) 28.1  
White (%) 100  
BMI (kg/m2) 25.9 (2.9)  
Obese, BMI ≥ 30 kg/m2 (%) 8.5  
Cigarette smoking (%)   
 Current  30.1  
 Former  37.5  
Never  32.4  
Alcohol intake, ≥2 drinks/day (%) 13.4  
Fasting glucose (mg/dl) 98.2 (10.0)  
Diabetes diagnosis (%) 0.18  
Systolic blood pressure (mm Hg) 122.5 (12.7)  
Diastolic blood pressure (mm Hg) 76.6 (8.6)  
Hypertension diagnosis (%) 2.5  
Total cholesterol (mg/dl) 203.1 (42.8)  
MTHFR 677 C→T (rs1801133) TT genotype (%) 12.8  
Plasma folate (ng/ml)2 10.4 (5.7)  
Plasma PLP (pmol/ml) 84.8 (85.0)  
Plasma B-12 (pg/ml) 458.0 (190.2)   
Plasma homocysteine (nmol/ml) 10.6 (3.7)  
Average follow-up time (years) 28.2 (6.7)  
      
*mean (standard deviation) unless otherwise indicated
1N varies by characteristic as some measurements available on only a subset of data.  
2Plasma measures of folate, vitamin B-6, vitamin B-12, and homocysteine were 
collected prior to the initiation of folate fortification.    
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 with biomarker data (N=735), and further adjusting these models for plasma nutrient 
biomarkers made no difference to the findings. Adjusting for the MTHFR 677 C→T 
(rs1801133) variant had little or no effect on the coefficients for other SNPs.  
Single Locus Marker Associations 
  The top SNP hits for the CVD phenotype were common variants with MAF 
typically  > 13% (Table 4.2).  A nominal significance threshold of P < 0.005 
effectively separated the most significant results (Figure 4.1).   
 Of the 8 SNPs with P≤0.005, 1 SNP, gamma-glutamyl hydrolase (GGH) 
rs12544045, a 5' region marker, was the most significant hit, with a nominal 
P=0.00055 and a False Discovery Rate-adjusted P=0.091 (Table 4.2).  The AG 
genotype was associated with a 32% reduction in CVD risk vs. the combined AA/GG 
reference genotypes (odds ratio (OR) 0.68; 95% confidence interval (CI) 0.5, 0.8).  
The second most significant hit was MTHFS rs7177659; the AC genotype was 
associated with a 29% reduction in CVD risk vs. the combined AA/CC reference 
category (OR 0.71; 95% CI 0.6, 0.9).  The well-known methylenetetrahydrofolate 
reductase (MTHFR) rs1801133 coding nonsynonymous SNP was associated with risk: 
CT (vs. CC) was associated with a 6% increase in CVD risk (OR 1.06; 95% CI 0.8, 
1.3), and TT (vs. CC) was associated with a 71% increase in CVD risk (OR 1.71; 95% 
CI 1.3, 2.3).   
 Of the top 8 SNPs, two SNP—CVD associations (rs6586282 and rs6586281, 
both in the cystathionine-beta-synthase gene, CBS) were substantially mediated by 
nutritional status.  Regression coefficients were reduced by about 36% when adjusted  
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Table 4.2.  Genotypes with the most statistically significant association (P≤0.005) with the CVD phenotype1,3,4,5 
Gene rs# Estimate 
Std 
Error 
Odds 
Ratio Nominal P Chr. 
Coded 
allele 
Coded 
allele 
frequency 
Genetic 
Model SNP Type 
GGH rs12544045 -0.38 0.11 0.68 5.51E-042 8 A 29% Overdominant 5' region 
MTHFS rs7177659 -0.34 0.11 0.71 1.18E-03 15 A 47% Overdominant Intronic 
MTHFR rs1801133 CT 0.06 0.12 1.06 1.48E-036 1 T 35% Dummy 
variable 
Coding 
nonsynonymous  rs1801133 TT 0.54 0.15 1.71     
TCN1 rs17154234 0.49 0.16 1.62 2.40E-03 11 C 5% Overdominant 3' region 
UBE2I rs11248868 0.34 0.11 1.40 3.33E-03 16 G 13% Overdominant Intronic 
CBS rs6586282 -0.32 0.11 0.73 3.35E-03 21 T 18% Additive Intronic 
CBS rs6586281 -0.35 0.12 0.71 3.55E-03 21 A 18% Dominant Intronic 
UBE2I rs909915 0.33 0.11 1.39 4.02E-03 16 T 13% Overdominant Intronic 
1Model adjusted for age and smoking; forward strand allele shown.  
2Adjusted P values reached False Discovery Rate significance threshold of 0.1.   
3No sparse data (fewer than 5 individuals per category) for genotype categories of these SNPs.   
4No SNPs map to more than one gene.   
5No lower quality SNPs. 
6P value for MTHFR rs1801133 SNP only came from Likelihood Ratio Test for model with vs. without CT and TT genotype terms (Chi Sq. 
13.033, 2df) 
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Figure 4.1.  Manhattan plot: Folate-related SNPs as predictors of cardiovascular 
disease risk.  Models adjusted for age and smoking status.  Horizontal lines represent 
nominal P values of 0.05 (lower dashed line), 0.02 (center solid line) and 0.005 
(upper dashed line). Box indicates SNP that reached False Discovery Rate 
significance.  
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for plasma folate, but further adjustment for plasma vitamins B-6, B-12, and 
homocysteine had no effect on the regression coefficients (Table A4.3).  None of the 
associations between the other 6 SNPs and CVD risk was mediated by nutrient 
biomarkers or homocysteine.  For some SNPs, associations were strengthened after 
adding biomarker terms to the model.  The MTHFS rs7177659—CVD association 
increased by 60% after adjusting for plasma nutrients and homocysteine, the TCN1 
rs17154234—CVD association increased 17-19%, and the MTHFR rs1801133 CT 
genotype association increased 163% after adding biomarker terms, while the TT 
genotype association increased 21%.  
 Genetic variation in the folate-mediated one-carbon network as represented by 
a subset of 52 SNPs was predictive of CVD risk (Likelihood Ratio Test for the model 
with vs. without 52 SNPs =760.5; P value 6.19E-126, 53 degrees of freedom).  In the 
simultaneous model, the MTHFR rs1801133 TT genotype was the top hit, and the 
association was increased compared to the single SNP model (simultaneous model OR 
1.96, 95% CI 1.4, 2.7; nominal P= <0.0001).  The top gene hits were similar between 
the single SNP models and the simultaneous model of 52 SNPs, and the rs11545078 
SNP in GGH, the gene containing the most significant hit in the single SNP analysis, 
was the second most significant hit in the simultaneous model.  Overall, regression 
estimates were similar between the two approaches, with one exception: the 
association of markers on the CBS gene with CVD risk was completely attenuated 
after adjusting for other SNPs.   
 Sensitivity analyses considered only those men with complete follow-up data 
(men who did not miss scheduled NAS follow-up visits by more than 1 yr), and 
regression coefficients and standard errors were similar to models including all 
participants. When the outcome was limited to early-onset CVD (age of onset < 55 
years) the associations for some top hits were strengthened, while other associations 
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were attenuated (Table A4.4).  The regression coefficient for the GGH rs12544045 
SNP, the top hit in the original analysis, increased by 215%, and it remained the top 
hit in the early-onset analysis (nominal p value 0.00029, FDR-adjusted p value 0.095).  
The OR associated with GGH rs12544045 (OR 0.3; 95% CI 0.2, 0.6) was consistent 
with a 70% reduction in early-onset CVD risk in men with the AG genotype (vs. 
combined AA/GG genotypes).  Similarly, the association of MTHFS rs7177659 with 
CVD risk increased by 86.3% (OR 0.53; 95% CI 0.6, 0.9; nominal P=0.017).  MTHFR 
rs1801133 associations were consistent in direction with the model for all endpoints, 
but less statistically significant in the early-onset CVD analysis (P=0.34 for early 
onset CVD vs. P=0.0015 for all CVD). Finally, markers in the UBE2I gene, the 
ubiquitin-conjugating enzyme E2I (rs11248868, rs909915, and rs9926094), the 
ferritin, heavy polypeptide 1, FTH1, gene (rs2073588 and rs1801621), and the solute 
carrier family 19 (thiamine transporter), member 2, SLC19A2, gene (rs17518769 and 
rs2038024) were also represented in the set of top 10 hits for early-onset CVD (all 
with nominal P≤0.012).  For two UBE2I SNPs, which were among the top 8 hits in the 
full CVD analysis, the strength of the association with CVD approximately doubled in 
the early-onset CVD analysis. 
Gene-Nutrient Interactions 
 Plasma folate and vitamins B-6 and B-12 are cofactors for enzymes involved 
in the reactions of the one-carbon metabolic network, thus, the nutrients may modify 
the SNP—phenotype association.  In further analyses assessing SNP—nutrient 
interactions (folate, B-6, or B-12), one folate interaction term reached FDR-
significance levels (adjusted P≤0.2) (Table A4.5) for the rs6882306 variant in the 
methionine adenosyltransferase II, beta (MAT2B) gene.  No vitamin B-6 interaction 
terms reached FDR-significance (adjusted P≤0.2), but 2 vitamin B-12 interaction 
terms were significant at FDR thresholds for the rs585800 SNP in betaine-
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homocysteine S-methyltransferase (BHMT) and the rs1061196 SNP in solute carrier 
family 25, member 32 (SLC25A32). 
Gene-Gene Interactions 
 In models investigating interactions between each SNP and MTHFR 677 C→T 
rs1801133, there were 8 interactions with a nominal P≤0.02; however, none reached 
the a priori FDR significance threshold of adjusted P≤0.2 (Table A4.6).  The most 
statistically significant interaction involved the rs2118653 SNP in GLDC, with OR for 
MTHFR TT (vs. CC) of 2.29 (95% CI 1.5, 3.4) within the GLDC rs2118653 GA strata, 
and an OR for MTHFR TT (vs. CC) genotype of 1.86 (95% CI 1, 3.5) within the 
GLDC rs2118653 AA strata.   
 Given the interconnectedness of folate-mediated one-carbon metabolism, gene-
gene interactions within the network are likely to be relevant to CVD risk. Thus, an 
analysis of all pairwise gene-gene interactions within the network was conducted.  For 
this step, dummy variable coding was utilized for all genotypes to avoid making any 
assumptions about the correct genetic model. Of 52,832 unique pairwise interactions 
tested, 58 were associated with CVD risk at P ≤0.001 (Table A4.7).  Using an FDR 
significance threshold of P≤0.2, none of the 58 associations reached the threshold.  
The most statistically significant interaction was between CELF1 (formerly known as 
CUGBP1) rs7933019 and MTR rs16834388 (nominal P=0.00012, FDR-adjusted 
P=0.77).  In men with the CELF1 rs7933019 GG genotype, MTR rs16834388 CT and 
TT genotypes were associated with an increased risk of CVD (by 30% and 73%, 
respectively, vs. MTR rs16834388 CC genotype). In the other genotype classes of 
CELF1 rs7933019 (CG and CC genotypes), the MTR—CVD association was 
reversed, thus genotype was inversely associated with CVD (Table 4.3). 
 92 
 
 
 
                  92 
Table 4.3.  Odds ratios and 95% confidence intervals for network-wide gene-gene interaction most 
significantly associated with cardiovascular disease risk1-4 
Gene Genotype OR 95% CI OR 95% CI OR 95% CI LRT P FDR P 
CELF1 rs7933019:  GG CG CC 0.00012 0.77 
MTR rs16834388 GT vs.GG 1.30 
 
0.9, 1.8 1.03 
 
0.7, 1.4 0.39 
 
0.2, 0.8 
  
 TT vs.GG 1.73 
 
1.1, 2.7 1.00 
 
0.6, 1.7 0.13 
 
0.0, 0.4 
  
 *Odds ratios, 95% confidence intervals  
1Model adjusted for age and smoking; forward strand allele shown.  
2None of interaction estimates above were based on sparse data (fewer than 5 individuals per cell for any cells of the SNP by SNP 
frequency table).   
3No SNPs map to more than one gene. 
4No lower quality SNPs. 
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 Beyond the discovery-based analyses presented above, these data presented the 
opportunity to directly explore hypotheses arising from basic science research and 
prior population-level studies. A reported interaction between the MTHFR and SHMT 
genes (62)(Wernimont et al, 2010, in press) was replicated here, and mediation by 
folate, vitamins B-6 and B-12, and homocysteine was explored.  Adjusting for 
homocysteine strengthened the interaction (Likelihood Ratio Test P=0.010); thus, in 
men with the SHMT rs1979277 TT genotype, men with the MTHFR rs1801133 CT 
genotype had a 2.4-fold increased risk of CVD (vs. rs1801133 CC), and the risk 
increased to 10.4-fold when models were adjusted for homocysteine; little or no 
association of MTHFR genotype was evident in men with the SHMT rs1979277 
CT/CC genotype, and this was not changed in homocysteine-adjusted models. 
Similarly, in men with the SHMT rs1979277 TT genotype, men with the MTHFR 
rs1801133 TT genotype had a 3-fold increased risk of CVD (vs. rs1801133 CC), and 
the risk increased to 15.5-fold when models were adjusted for homocysteine.   
 Previous in vitro studies have demonstrated protein-protein interactions 
between SHMT1 and UBC9 (yeast homolog of human UBE2I), resulting in the 
SUMOylation and nuclear localization of SHMT1, along with the other 2 components 
of thymidylate synthesis: TYMS and DHFR (2, 3, 116);  UBC13 (yeast homolog of 
human UBE2N) has also been shown to be an SHMT1 binding partner, although the 
significance of this interaction is not yet fully understood (116).  Other studies point to 
a role for CELF1 (formerly known as CUGBP1) and FTH1 in interacting with the 
SHMT1 mRNA to influence SHMT1 expression levels (117).  The SHMT1 enzyme 
governs the competing flow of one carbon units to thymidylate biosynthesis or 
remethylation reactions (42), and thus modifications in protein expression levels or 
subcellular location may affect CVD risk by influencing the distribution of one-carbon 
units to competing reactions.  Consistent with this hypothesis, 2 SNPs in UBE2I 
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(rs11248868 and rs909915) were among the most significant SNP hits for CVD 
overall (Table 4.2), and these SNPs, together with SNPs in FTH1 (rs2073588 and 
rs1801621), were also among the most significant SNP hits for early-onset CVD 
(Table A4.4).  The hypothesis was further explored by investigating all pairwise 
interactions among SNPs in the UBE2I, UBE2N, DHFR, TYMS, and SHMT1 genes in 
relation to CVD risk.  Of 451 unique pairwise interactions tested, 8 interactions had a 
nominal P≤0.02 (Table A4.8).  The top hit was for the interaction of UBE2N 
rs7300607 and TYMS rs502396 (Table 4.4); in men with the TYMS rs502396 CC 
genotype, the UBE2N rs7300607 CC genotype (vs. TT) was associated with a 3-fold 
increased risk of CVD.  Second, all pairwise interactions among SNPs in the FTH1, 
CELF1, and SHMT1 genes were investigated in relation to CVD risk. Of 92 unique 
pairwise interactions tested, 16 interactions had a nominal P≤0.02 (Table A4.9). The 
top hit was for the interaction of FTH1 rs17156609 and CELF1 rs7933019 (Table 
4.3); in men with the FTH1 rs17156609 GA genotype, CELF1 rs7933019 CC 
genotype (vs. GG) was associated with a 3-fold increased risk of CVD.  
 A landmark GWAS, the Wellcome Trust Case Control Consortium, previously 
identified an intronic SNP (rs6922269) in the MTHFD1L gene, a mitochondrial folate 
metabolism gene, which was associated with CAD risk (112).  Based on HapMap LD 
plots, this SNP is located in a tightly linked 14 kb block in the MTHFD1L gene.  
Although the intronic rs6922269 SNP, along with the nearby nonsynonymous 
rs9767752 SNP, both failed in genotyping , 6 other SNPs successfully tagged this 
region.  Previous work in the NAS identified joint genotypes involving 2 SNPs within 
that 14 kb region that best captured the association with CVD risk (113) and those 
SNPs 
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Table 4.4.  Odds ratios, 95% confidence intervals for gene-gene interactions most significantly associated with 
cardiovascular disease risk in tests of three hypotheses1-4 
Hypothesis: Gene Genotype OR5 95% CI5 OR 95% CI OR 95% CI LRT P 
Nuclear one-
carbon 
metabolism 
TYMS rs502396:  TT TC CC 0.0034 
UBE2N rs7300607 TC vs.TT 0.77 
 
0.5, 1.2 1.20 
 
0.8, 1.7 3.60 
 
1.7, 7.6 
 
 CC vs.TT 1.29 
 
0.8, 2.1 1.21 
 
0.8, 1.9 3.13 
 
1.4, 7.0 
 
SHMT1 
expression 
FTH1 rs17156609:6  GG GA  0.0074 
CELF1 rs7933019 CG vs.GG 1.08 
 
0.9, 1.3 0.35 
 
0.1, 1.5    
 CC vs.GG 0.92 
 
0.6, 1.4 3.27 
 
1.2, 8.7    
Mitochondrial 
one-carbon 
metabolism 
TYMS rs502396:  TT CT CC 0.010 
MTHFR rs12121543 AC vs.CC 0.93 0.6, 1.4 1.22 
 
0.9, 1.7 0.88 
 
0.5, 1.4  
 
AA vs.CC 0.21 
 
0.1, 0.7 0.67 
 
0.3, 1.4 1.83 
 
0.9, 3.9  
1Model adjusted for age and smoking; forward strand allele shown.  
2Presented P values were not False Discovery Rate-adjusted in this hypothesis-driven analysis.   
3None of interaction estimates above were based on sparse data (fewer than 5 individuals per cell for any cells of the SNP by SNP 
frequency table).   
4No lower quality SNPs.  
5Odds ratios and 95% confidence intervals 
6SNP maps to more than one gene: rs17156609 also maps to bestrophin 1 (BEST1). 
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(rs1474787 and rs803447) were further explored.  Both SNPs were associated with 
CVD in the single SNP analysis, but the nominal P values were not below the 
thresholds set a priori.  Exploring joint genotypes involving these SNPs revealed a 
highly statistically significant association with CVD (Table 4.5); within the 
rs1474787 GA genotype strata, men with the rs803447 TT genotype had a CVD risk 
3.63 times that of men with the rs803447 CC genotype, (interaction P=0.077).  
Adjusting for homocysteine strengthened this interaction; thus, within the rs1474787 
GA genotype strata, men with the rs803447 TT genotype had a CVD risk 6 times that 
of men with the rs803447 CC genotype (interaction P=0.077). 
 Because mitochondrial folate metabolism produces formate, a major source of 
cytoplasmic one-carbon units (32), we hypothesized interactions may exist among 
MTHFD1L, SHMT1 (as a determinant of one-carbon unit distribution among the 
remethylation and thymidylate synthesis pathways (42), and two downstream enzymes 
in each pathway, MTHFR and TYMS.  Of 377 unique pairwise interactions tested, 4 
interactions had a nominal P≤0.02 (Table A4.10). The top hit was for the interaction 
of TYMS rs502396 and MTHFR rs12121543 (Table 4.4); in men with the TYMS 
rs502396 CC genotype, the MTHFR rs12121543 AA genotype (vs. CC) was associated 
with a 2-fold increased risk of CVD.   
  
4.5 Discussion  
  
 We investigated sequence variation in a network of candidate genes involved 
in one-carbon metabolism in relation to CVD risk in a time-to-event analysis. Genes, 
SNPs, and related nutrients were carefully chosen to represent the full functional 
variation of the folate-mediated one carbon metabolism pathway. The analysis 
considered all 330 SNPs in tests for main effects, interactions with the MTHFR 
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Table 4.5.  Odds ratios and 95% confidence intervals for MTHFD1L 14 kb region genotypes most 
significantly associated with cardiovascular disease risk1-4 
Gene Genotype OR* 95% CI* OR 95% CI OR 95% CI LRT P 
Unadjusted 
MTHFD1L rs1474787:  GG GA AA 0.077 
MTHFD1L rs8034474 CT vs.CC 1.15 0.8, 1.7 1.24 0.8, 1.8 1.012 
 
0.1, 7.5 
 
 TT vs.CC 1.15 0.8, 1.7 3.63 1.8, 7.5   
  
  
 
Homocysteine Adjusted 
MTHFD1L rs1474787:  GG GA AA 0.077 
MTHFD1L rs8034474 CT vs.CC 1.32 0.8, 2.1 1.62 
 
1.0, 2.7 1.212 
 
0.2, 9.2  
 TT vs.CC 1.37 
 
0.8, 2.3 6.14 
 
2.5, 15.3   
  
  
 
*Odds ratios, 95% confidence intervals 
1Model adjusted for age and smoking; forward strand allele shown.  
2Sparse data (fewer than 5 individuals) in this cell of the SNP by SNP frequency table.   
3No SNPs map to more than one gene. 
4Lower quality SNP. 
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rs1801133 SNP, and a simultaneous evaluation of network variation.  The interaction 
of each SNP with plasma measures of folate, vitamins B-6 and B-12 was also 
considered.  FDR-significant main effects were identified, as well as FDR significant 
SNP—folate and SNP—vitamin B-12 interactions and nominally significant gene-
gene interactions were identified in a more thorough investigation of 3 hypotheses 
about the network.   
 The study identified several novel results. Genetic variation in genes related to 
folate absorption and transport, such as the gamma-glutamyl hydrolase gene (GGH), 
were more significantly predictive of CVD risk than any other genetic polymorphism 
in the folate-mediated one-carbon network including MTHFR rs1801133, and effect 
sizes were doubled in analyses of early-onset CVD.  Genes in this category of folate 
metabolism are not well-studied in relation to CVD risk.  The simultaneous evaluation 
of genetic variation in 52 genes of folate-mediated one-carbon metabolism showed 
stronger associations with CVD risk than the MTHFR rs1801133 polymorphism 
considered alone, confirming the importance of multiple genes within the network.  
An in-depth evaluation of nuclear folate metabolism revealed significant epistasis 
predictive of CVD risk, and genes that regulate SHMT1 expression interact to 
influence risk of CVD. The findings underscore the importance of mitochondrial 
metabolism  to the folate pathway association with CVD risk and epistasis predictive 
of CVD risk exists between the thymidylate synthesis and remethylation pathways. 
Finally, gene-nutrient interactions, beyond the well-known MTHFR rs1801133-folate 
interaction, are strongly associated with CVD risk, including MAT2B and folate, 
BHMT and vitamin B-12, and SLC25A32 and vitamin B-12. 
 In studying the association of single locus markers with CVD risk, genes in 
absorption and transport, purine metabolism, the methylation/homocysteine pathway, 
nuclear metabolism, and B-12 metabolism were represented in the top hits.  Other than 
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SNPs in the CBS gene, there was little evidence that plasma folate or vitamins B-6 or 
B-12 or homocysteine mediated the association of SNPs with CVD risk; in fact, 
regression coefficients for several SNPs, including the MTHFR rs1801133 variant, as 
well as SNPs in the MTHFS and TCN1 genes, strengthened after models were adjusted 
for plasma folate, B-6, B-12, and homocysteine (Table A4.3).  When restricted to 
early onset cases only (onset age <55 yrs), main effects for SNPs in the GGH, 
MTHFS, and UBE2I genes strengthened, consistent with a true effect of these genes on 
risk.    
Single Locus Marker Associations 
 GGH.   An FDR-significant association was identified between the intronic 
rs12544045 SNP in GGH and CVD risk. The AG genotype group had a 32% lower 
risk of CVD compared to the AA/GG genotype group. The GGH gene encodes an 
enzyme that functions to hydrolyze polyglutamate residues from intracellular folate to 
facilitate folate export (46).  The SNP is located in the 5’ regulatory region of the 
gene; cell culture studies identified several other polymorphisms in the 5’ region of 
this gene associated with increased promoter activity (19), and one of these SNPs, 
GGH -124T→G, was associated with a dose-dependent increase in DNA uracil 
content in humans (30).  Since the SNP may affect cellular folate export and therefore 
measures of folate status, a reasonable assumption is that the SNP—CVD association 
might be mediated by plasma folate; however, in analyses adjusted for plasma folate, 
the coefficient for GGH rs12544045 decreased only slightly.  Given our current 
understanding of the role of GGH in contributing to cellular folate export, there are 
several possible explanations for this finding.  First, the marker of folate status 
available, plasma folate, may not represent the full extent of mediation of the 
association of GGH rs12544045 with CVD, either because it does not reflect folate 
status in the compartment relevant to CVD risk, or it does not reflect folate status 
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during the window of time relevant for CVD development, or our understanding of the 
role of GGH in contributing to CVD risk is incomplete. 
 MTHFR.  There was a nominally significant association between the MTHFR 
677 C→T rs1801133 SNP and CVD risk; the rs1801133 CT (vs. CC) genotype was 
associated with a 6% increase in CVD risk (OR 1.06; 95% CI 0.8, 1.3), and the 
rs1801133 TT (vs. CC) genotype was associated with a 71% increase (OR 1.71; 95% 
CI 1.3, 2.3).  The MTHFR gene encodes an enzyme that catalyzes the conversion of 
5,10-methyleneTHF to 5-methylTHF, which supplies a one-carbon unit for 
methylation reactions including the remethylation of homocysteine to methionine, as 
well as the generation of S-adenosylmethionine (AdoMet), the universal methyl donor 
(32) and is well-studied in relation to CVD risk (15, 27, 52, 58, 108).  The findings in 
the present study are consistent with these prior reports. 
Gene-Nutrient Interactions 
 The MTHFR rs1801133 polymorphism results in the production of a thermally 
labile enzyme with reduced activity (35); the effect of the SNP varies by folate status 
(47, 52). A gene-nutrient interaction between MTHFR 677 C→T rs1801133 and folate 
was not statistically significant in these data (P= 0.90) perhaps due to the relatively 
high folate status among the men in this cohort study (mean plasma folate: 10.4 ng/ml, 
significantly higher than the prefortification serum folate mean of 5.8 ng/ml in non-
Hispanic Whites reported by NHANES III (1988-1994), albeit lower than the post-
fortification mean of 14.8 ng/ml (80).  SNP—nutrient interactions may be blunted in 
this range of folate status. When the dataset was restricted to men with folate levels 
below the 25th percentile (6.20 ng/ml, 187 men/59 CVD events), the interaction was 
more evident, and marginally statistically significant. The observed effect sizes were 
consistent with the magnitude and direction of the well-known MTHFR 677-folate 
interaction (15, 27, 52, 58, 108).   
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 The association of variants in folate-related genes with CVD risk, including 
MTHFR 677 C→T rs1801133, is hypothesized to be mediated by homocysteine, 
which is sensitive to B vitamin status, including folate, vitamin B-12 and to a lesser 
extent, vitamin B-6(52) (45); thus, gene-nutrient interactions may exist such that the 
association of a given polymorphism with CVD risk may be modified by nutrient 
status.  In this study, there were no FDR-significant interactions between studied SNPs 
and vitamin B-6.  However, FDR-significant interactions were identified for plasma 
folate (methionine adenosyltransferase II, beta, MAT2B, rs6882306, intronic) and 
vitamin B-12 (betaine-homocysteine S-methyltransferase, BHMT, rs585800, 3’ region; 
and, solute carrier family 25, member 32, SLC25A32, rs1061196, 3’ region).  The lack 
of additional highly significant gene-nutrient interactions may reflect limited power 
for gene-nutrient interactions, or the lack of men with low B vitamin status, even 
within this pre-fortification cohort of U.S. men. 
 MAT2B encodes the regulatory subunit of the methionine adenosyltransferase 
(MAT) enzyme that catalyzes the synthesis of S-adenosylmethionine from methionine 
and ATP (Entrez Gene).  S-adenosylmethionine (or AdoMet) is the universal methyl 
donor for numerous intracellular methylation reactions.  At high folate levels (17.27 
ng folate/ml) men with the MAT2B rs6882306 CC genotype had 91% lower CVD risk 
(vs. combined CT/TT); at median folate levels (9.62 ng folate/ml) men with the 
MAT2B rs6882306 CC genotype had 42% lower CVD risk (vs. combined CT/TT); at 
low folate levels (4.38 ng folate/ml) men with the MAT2B rs6882306 CC genotype 
had a CVD risk that was 6.93 times that of the CT/TT reference group.  The rs6882306 
SNP is an intronic SNP that may tag functional variation elsewhere in the gene; 
HapMap LD plots are incomplete, but suggest high linkage.  While no previous papers 
report an interaction between MAT2B polymorphisms and folate, a recent study 
identified variants in a closely related gene, methionine adenosyltransferase I, alpha 
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(MAT1A), that decreased risk of hypertension and DNA damage and increased risk of 
stroke, independently of the MTHFR 677 rs1801133 polymorphism (55); MAT1A 
interactions with folate were predictive of homocysteine (low folate and the variant 
predicted high homocysteine), and consistent with the direction of effect seen for the 
MAT2B-folate interaction in relation to CVD risk.    
 The BHMT gene encodes a cytosolic enzyme that catalyzes the transfer of a 
methyl group from betaine to homocysteine, yielding dimethylglycine and methonine 
(Entrez Gene).  This pathway provides an alternate route for the remethylation of 
homocysteine to methionine compared to the vitamin B-12-dependent methionine 
synthase pathway and may account for up to half of the homocysteine remethylation 
capacity of the cell in some tissues (59).  The rs585800 SNP is a 3’ region 
polymorphism and thus may have a regulatory function; at high B-12 levels (678.89 
pg B-12/ml), CVD risk for the BHMT rs585800 TA genotype class was 36% lower 
compared to the AA/TT reference group.  At median B-12 levels (418.62 pg B-12/ml), 
CVD risk for the BHMT rs585800 TA genotype class was 19% higher compared to 
AA/TT, and at low B-12 levels (259.29 pg B-12/ml), CVD risk for the BHMT 
rs585800 TA genotype class was 2.19 times higher compared to the AA/TT reference 
group.  While the BHMT enzyme is not known to bind vitamin B-12, previous work 
has identified regions of homology with bacterial vitamin B-12-dependent methionine 
synthases (38). In rats, hepatic BHMT activity was not sensitive to vitamin B-12 
deficiency(31), however, epidemiologic work in humans suggests that enhancing 
methionine-synthase dependent remethylation of homocysteine down regulates BHMT 
reactions (44).  
 The SLC25A32 gene encodes a folate transporter that shuttles folate from the 
cytoplasm into the mitochondria (Entrez Gene).  The rs1061196 polymorphism is a 3’ 
region variant and thus may have a regulatory function.  At low B-12 levels (259.29 
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pg/ml), CVD risk in men with the SLC25A32 rs1061196 AG genotype was 55% lower 
compared to the AA/AG reference group; at median B-12 levels (418.62 pg/ml) CVD 
risk in men with the SLC25A32 rs1061196 AG genotype was 17% lower compared to 
AA/AG; at high B-12 levels (678.89 pg/ml) CVD risk in men with the SLC25A32 
rs1061196 AG genotype was 1.56 times higher than the AA/AG reference group.  No 
prior reports link SLC25A32 to biochemical or disease phenotypes, and a biological 
basis for the link to vitamin B-12 metabolism could not be identified.   
Gene-Gene Interactions 
 No FDR-significant interactions were identified between studied SNPs and 
MTHFR 677 C→T rs1801133.  Furthermore, of all pairwise interactions within the 
network, no interactions surpassed the FDR significance threshold of P≤0.2. 
 In exploring hypotheses derived from prior findings, we focused on the 
SHMT1 intersection in the folate network. Previous work (62) (Wernimont et al, 2010, 
in press) identified a gene-gene interaction between the MTHFR rs1801133 and the 
rs1979277 variant in the serine hydroxymethyltransferase 1 (soluble) gene, SHMT1, in 
which the association of the MTHFR rs1801133 CT and TT genotypes was much 
stronger among individuals who also carried the SHMT1 rs1979277 TT genotype 
(62)(Wernimont et al, 2010, in press).  The interaction was replicated here in an age- 
and smoking-adjusted model, and suggests that appropriate modeling of the MTHFR 
rs1801133 SNP is critical to detecting the gene-gene interaction, which exists only 
within a specific population subgroup. 
 Finally, pleiotropic effects were examined across outcomes.  Previous work in 
the Normative Aging Study identified sets of SNPs most significantly associated with 
biomarkers of CVD risk, including plasma homocysteine and global genomic DNA 
methylation (Wernimont, in preparation).  Of the 8 nominally significant hits for the 
CVD analysis, only a single pleiotropic SNP hit was identified, CBS rs6586282, which 
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was also among the most significant hits for the plasma homocysteine phenotype 
(nominal P value for CVD was 3.3 E-03, nominal P value for homocysteine was 4.06 
x E-03).  However, this SNP was not among the most significant hits for LINE-1 or 
ALU methylation; in fact, there were no SNP hits shared among the most significant 
hits for CVD and either the LINE-1 or ALU methylation phenotypes.  The 
overdominant genetic model was the most statistically significant model in the 
homocysteine analysis, and the CBS rs6586282 CT (vs. combined CC/TT) genotype 
was associated with a 5.8% reduction in plasma homocysteine.  Consistent with this, 
the T allele was associated with a reduction in CVD risk of 29%, in an additive model 
(selected as the best code for CVD analysis).  The CBS rs6586282 polymorphism was 
the only SNP in the CVD analysis mediated by nutrition, which is consistent with the 
association of this polymorphism with both homocysteine and CVD.  While the CBS 
rs6586282 SNP was the only SNP hit replicated across any of the 4 phenotypes 
studied, there were genes that had associations with multiple phenotypes; GGH was 
nominally significant for plasma homocysteine and FDR-significant for CVD, and 
MTHFR was nominally significant for CVD and LINE-1 methylation.   
 
4.6 Conclusion 
  
Strengths of the present study include a complete investigation of genetic 
variation in the folate metabolic network.  Furthermore, the analysis was conducted 
within a large cohort with CVD outcome data collected prior to the introduction of 
mandatory folate-fortification in the U.S.; thus, the study population is well-suited to 
investigate the network of folate-related genes in relation to CVD risk.  SNP selection 
for the genotyping assay reflected coverage of genes based on function, linkage, and 
physical coverage, which led to markers that captured functional variants in addition 
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to tagging variation elsewhere in the gene. In a systematic approach to the data 
analysis, we identified the best genetic models for each SNP, tested single SNPs, a 
reduced set of non-redundant SNPs, the interaction of each SNP with MTHFR 677 
rs1801133, and the interaction of each SNP with folate, vitamin B-6 and vitamin B-12.  
Findings were corrected for multiple comparisons and findings based on the FDR 
threshold were discussed in more detail.  Hypotheses based on basic science findings 
were explored.  Weaknesses of the study include the fact that, despite restricting data 
to the pre-folate fortification time period, the level of folate nutrition within the 
population was relatively high compared to other measures of pre-fortification folate 
status in the U.S., which may have attenuated associations, particularly gene-nutrient 
interactions, that would have been present in a population with more variation in B-
vitamin status.  
 This study suggests that variation in genes other than MTHFR and those 
directly involved in homocysteine metabolism, are associated with CVD risk.  For 
example, a gene involved in folate absorption and transport, GGH, was more 
significantly associated with CVD than any of the other 51 genes evaluated, including 
MTHFR and CBS. This study also supports a role for mitochondrial metabolism in 
predicting CVD risk, and although a previously identified polymorphism in 
MTHFD1L (112) could not be studied directly, nearby variants showed strong 
associations with CVD risk.  The epidemiologic findings presented here replicated 
molecular biology studies of interactions among the SHMT1, UBE2I, UBE2N, DHFR, 
and TYMS proteins resulting in the cell cycle-dependent nuclear localization of the 
thymidylate biosynthesis pathway, and further established that epistatic interaction 
among genes encoding these proteins is predictive of CVD risk.  Polymorphisms in 
genes such as FTH1 and CELF1, whose products have been shown to influence 
expression of SHMT1, a key regulator of the distribution of one-carbon units, were 
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evaluated and epistatic interactions among these genes were found to predict CVD 
risk.  These findings support a role for SHMT1 and nuclear folate metabolism, 
including the thymidylate biosynthesis pathway, in relation to CVD.  This 
investigation of genetic variation within the folate network, including absorption and 
transport, mitochondrial, and nuclear metabolism, alters our current understanding of 
the relation between the folate-mediated one-carbon network and CVD. To date, the 
focus has been on the role of homocysteine, but the findings in this study suggest 
important contributions to risk through other aspects of folate metabolism.  These 
findings may help explain the results of randomized controlled trials focused on CVD 
risk reduction through homocysteine lowering, which have experienced limited 
success (70, 71).  A thorough understanding of the role of folate network genetic and 
nutritional variation in relation to CVD is important, particularly in the context of the 
numerous unfortified populations around the world.   
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE A4.1 
 
 
THE 52 GENES IN THE FOLATE-MEDIATED ONE-CARBON PATHWAY 
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Gene 
Symbol Gene Name 
Entrez 
GeneID 
AHCY Adenosylhomocysteinase 191 
AHCYL1 Adenosylhomocysteinase-like 1 10768 
AHCYL2 Adenosylhomocysteinase-like 2, KIAA0828 23382 
ALDH1L1 Aldehyde dehydrogenase 1 family, member L1 10840 
AMT Aminomethyltransferase 275 
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
471 
BHMT Betaine-homocysteine S-methyltransferase 635 
CBS Cystathionine-beta-synthase 875 
CTH Cystathionase (cystathionine gamma-lyase) 1491 
CELF1 CUGBP, Elav-like family member 1 10658 
DHFR Dihydrofolate reductase 1719 
DMGDH Dimethylglycine dehydrogenase 29958 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 1786 
DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha 1788 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 1789 
FOLH1 Folate hydrolase (prostate-specific membrane antigen) 1 2346 
FOLR1 Folate receptor 1 (adult) 2348 
FOLR2 Folate receptor 2 (fetal) 2350 
FOLR3 Folate receptor 3 (gamma) 2352 
FPGS Folylpolyglutamate synthase 2356 
FTCD Formiminotransferase cyclodeaminase 10841 
FTH1 Ferritin, heavy polypeptide 1 2495 
GART Phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
2618 
GCSH Glycine cleavage system protein H (aminomethyl carrier) 2653 
GGH Gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
8836 
GLDC Glycine dehydrogenase (decarboxylating) 2731 
GNMT Glycine N-methyltransferase 27232 
HSPA8 Heat shock 70kDa protein 8 3312 
MARS Methionyl-tRNA synthetase 4141 
MAT1A Methionine adenosyltransferase I, alpha 4143 
MAT2A Methionine adenosyltransferase II, alpha 4144 
MAT2B Methionine adenosyltransferase II, beta 27430 
MTHFD1 Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1, methenyltetrahydrofolate cyclohydrolase, 
formyltetrahydrofolate synthetase 
4522 
MTHFD1L Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 
25902 
MTHFD2 Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate cyclohydrolase 
10797 
MTHFR Methylenetetrahydrofolate reductase (NAD(P)H) 4524 
MTHFS 5,10-methenyltetrahydrofolate synthetase (5-
formyltetrahydrofolate cyclo-ligase) 
10588 
MTR 5-methyltetrahydrofolate-homocysteine methyltransferase 4548 
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TABLE A4.1 (Continued) 
Gene Symbol Gene Name 
Entrez 
GeneID 
MTRR 5-methyltetrahydrofolate-homocysteine methyltransferase 
reductase 
4552 
SARDH Sarcosine dehydrogenase 1757 
SHMT1 Serine hydroxymethyltransferase 1 (soluble) 6470 
SHMT2 Serine hydroxymethyltransferase 2 (mitochondrial) 6472 
SLC19A1  Solute carrier family 19 (folate transporter), member 1 6573 
SLC19A2 Solute carrier family 19 (thiamine transporter), member 2 10560 
SLC19A3 Solute carrier family 19, member 3 80704 
SLC25A32 Solute carrier family 25, member 32 81034 
SLC46A1 Solute carrier family 46 (folate transporter), member 1 113235 
TCN1 Transcobalamin I (vitamin B-12 binding protein, R binder 
family) 
6947 
TCN2 Transcobalamin II 6948 
TYMS Thymidylate synthetase 7298 
UBE2I Ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) 7329 
UBE2N Ubiquitin-conjugating enzyme E2N (UBC13 homolog, 
yeast) 
7334 
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TABLE A4.2 
 
330 FOLATE-RELATED SNPS ASSAYED IN MEN IN THE NORMATIVE 
AGING STUDY1-5 
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Gene SNP Name Gene SNP Name Gene SNP Name 
AHCY rs819133 BHMT rs558133 DMGDH rs1805073 
AHCY rs819159 BHMT rs585800 DMGDH rs532964 
AHCY rs819155 CBS rs706209 DMGDH rs2253262 
AHCY rs13043752 CBS rs2124458 DMGDH rs644191 
AHCY rs819148 CBS rs760124 DNMT1 rs8101626 
AHCY rs1205366 CBS rs6586281 DNMT1 rs11880388 
AHCY AHCYC34T CBS rs6586282 DNMT1 rs2228611 
AHCY rs819146 CBS rs11203172 DNMT1  rs22286121 
AHCYL1 rs333079 CBS rs234704 DNMT1 rs2162560 
AHCYL1 rs3768480 CBS rs1801181 DNMT3A rs11695471 
AHCYL1 rs2298116 CBS rs2014564 DNMT3A rs6546045 
AHCYL1 rs720917 CBS rs1789953 DNMT3A rs7578575 
AHCYL1 rs186724 CBS rs12329764 DNMT3A rs6733868 
AHCYL2 rs6467233 CBS rs234705 DNMT3A rs11678631 
AHCYL2 rs4731569 CBS rs234706 DNMT3A rs1550117 
AHCYL2 rs7788327 CBS rs234709 DNMT3B rs6058869 
AHCYL2 rs6467244 CBS rs234711 DNMT3B rs1883729 
AHCYL2 rs1665105 CBS rs11701048 DNMT3B rs2424914 
ALDH1L1 rs4646760 CBS rs1788484 DNMT3B rs6058891 
ALDH1L1 rs4646750 CTH rs648743 DNMT3B rs2424922 
ALDH1L1 rs4646745 CTH rs663465 DNMT3B rs6058896 
ALDH1L1 rs3772424 CTH rs681475 FOLH1 rs16906158 
ALDH1L1 rs3772414 CTH rs535112 FOLH1 rs202673 
ALDH1L1 rs2305230 CTH rs663649 FOLH1 rs664584 
ALDH1L1 rs11715574 CTH rs1021737 FOLH1 rs202676 
ALDH1L1 rs1868138 CUGBP1 rs7102372 FOLR1 rs2071010 
ALDH1L1 rs1823213 CUGBP1 rs2242081 FOLR1 rs9282688 
AMT rs11922013 CUGBP1 rs7933019 FOLR2 rs514933 
AMT rs1464567 CUGBP1 rs4752843 FOLR2 rs2298444 
AMT rs1464566 DHFR rs12517451 FOLR3 rs7926875 
AMT rs8897 DHFR rs1677666 FOLR3 rs11235449 
ATIC rs7585489 DHFR rs1650723 FPGS rs10106 
ATIC rs2372536 DHFR rs2560424 FPGS rs41319447 
ATIC rs3821353 DHFR rs1643659 FPGS rs4451422 
ATIC rs1997059 DHFR rs1643650 FTCD rs16978930 
ATIC rs4672768 DHFR rs836822 FTCD rs2277820 
BHMT rs16876512 DHFR rs1650697 FTH1 rs1800009 
BHMT rs7700970 DHFR rs380691 FTH1 rs17185413 
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TABLE A4.2 (Continued) 
Gene SNP Name Gene SNP Name Gene SNP Name 
BHMT rs506500 DHFR rs1382540 FTH1 rs1801621 
BHMT rs567754 DMGDH rs28326 FTH1 rs17156609 
BHMT rs10037045 DMGDH rs1805074 FTH1 rs2073588 
GART rs8971 MAT1A rs1819684 MTHFD1L rs538017 
GART rs1804385 MAT1A rs17677908 MTHFD1L rs9478162 
GART rs87882 MAT2A rs1446667 MTHFD1L rs9478908 
GART rs2027592 MAT2A rs2028900 MTHFD1L rs7770982 
GART rs4817580 MAT2A rs1078004 MTHFD1L rs17080689 
GCSH rs8177940 MAT2A rs2043675 MTHFD1L rs1076746 
GCSH rs8177876 MAT2B rs10515861 MTHFD1L rs509474 
GCSH rs4889233 MAT2B rs6882306 MTHFD1L rs7746991 
GCSH rs11866124 MAT2B rs4869087 MTHFD1L rs6910267 
GCSH rs1563072 MAT2B rs17061795 MTHFD1L rs17354394 
GGH rs11995525 MAT2B rs7733775 MTHFD1L rs1047665 
GGH rs11545078 MTHFD1 rs1076991 MTHFD2 rs7340453 
GGH rs4617146 MTHFD1 rs8003379 MTHFD2 rs1667627 
GGH rs3780126 MTHFD1 rs1950902 MTHFR rs1537516 
GGH rs12544045 MTHFD1 rs17751556 MTHFR rs4846049 
GLDC rs7848919 MTHFD1 rs3783728 MTHFR rs13306556 
GLDC rs3902970 MTHFD1 rs11627525 MTHFR        rs1801131 
GLDC rs1929933 MTHFD1 rs8003567 MTHFR rs12121543 
GLDC rs4237166 MTHFD1 rs8012229 MTHFR rs1994798 
GLDC rs10975681 MTHFD1 rs2281603 MTHFR rs6541003 
GLDC rs4629927 MTHFD1L rs7765521 MTHFR rs1801133 
GLDC rs7049056 MTHFD1L rs11754661 MTHFR rs17421462 
GLDC rs1821892 MTHFD1L rs4869953 MTHFR rs17367629 
GLDC rs2118653 MTHFD1L rs17349743 MTHFR rs3737965 
GLDC rs1755617 MTHFD1L rs803422 MTHFS rs8923 
GNMT rs11752813 MTHFD1L rs997429 MTHFS rs7177659 
GNMT rs2296805 MTHFD1L rs2295084 MTHFS rs6495450 
GNMT rs2296804 MTHFD1L rs803456 MTHFS rs2733106 
GNMT rs736158 MTHFD1L rs803455 MTHFS rs2586167 
GNMT rs1051218 MTHFD1L rs803454 MTR rs16834388 
HSPA8 rs4936770 MTHFD1L rs12201472 MTR rs3754255 
HSPA8 rs1461496 MTHFD1L rs4869954 MTR rs10925260 
HSPA8 rs11218941 MTHFD1L rs6902664 MTR rs1805087 
HSPA8 rs1136141 MTHFD1L rs1474787 MTR rs2275566 
MARS rs899653 MTHFD1L rs4869955 MTR  rs22292763 
MARS rs496245 MTHFD1L rs742832 MTR rs11314494 
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TABLE A4.2 (Continued) 
Gene SNP Name Gene SNP Name Gene SNP Name 
MARS rs1678537 MTHFD1L rs803447 MTR rs1050996 
MAT1A rs1985908 MTHFD1L rs803446 MTRR rs2966952 
MAT1A rs2993763 MTHFD1L rs803466 MTRR rs1801394 
MAT1A rs10788546 MTHFD1L rs1738574 MTRR rs7730643 
MAT1A rs1143694 MTHFD1L rs524732 MTRR rs161869 
MTRR rs1532268 SLC19A1 rs1051266 TCN2 rs5749132 
MTRR rs3776465 SLC19A1 rs11315965 TCN2 rs9606756 
MTRR rs162036 SLC19A1 rs4819130 TCN2 rs740233 
MTRR rs2303081 SLC19A2 rs6656822 TCN2 rs757874 
MTRR rs10380 SLC19A2 rs1983546 TCN2 rs4820021 
MTRR rs1802059 SLC19A2 rs17518769 TCN2 rs9621049 
MTRR rs8659 SLC19A2 rs2038024 TCN2 rs4820886 
SARDH rs129886 SLC19A3 rs13025803 TCN2 rs4820887 
SARDH rs129932 SLC19A3 rs11694828 TCN2 rs2301957 
SARDH rs129891 SLC19A3 rs13007334 TCN2 rs2301958 
SARDH rs756682 SLC19A3 rs17438244 TCN2 rs4820889 
SARDH rs2073817 SLC25A32 rs1061196 TCN2 rs10418 
SARDH rs2502741 SLC25A32 rs3098260 TYMS rs2853533 
SARDH rs4979632 SLC25A32 rs17803441 TYMS rs502396 
SARDH rs2073815 SLC25A32 rs3098243 TYMS rs2612095 
SHMT1 rs12952556 SLC25A32 rs3134297 TYMS rs2853543 
SHMT1 rs1979276 SLC46A1 rs2239908 TYMS rs16948305 
SHMT1 rs1979277 SLC46A1 rs2239907 TYMS rs699517 
SHMT1 rs2273028 SLC46A1 rs17719944 TYMS rs2790 
SHMT1 rs17806489 TCN1 rs17154234 UBE2I rs9926094 
SHMT1 rs4924750 TCN1 rs34324219 UBE2I rs909915 
SHMT1 rs2461838 TCN1 rs519221 UBE2I rs8052688 
SHMT1 rs643333 TCN1 rs557564 UBE2I rs11248868 
SHMT2 rs28365862 TCN1 rs2000613 UBE2N rs4020454 
SHMT2 rs7301155 TCN1 rs34528912 UBE2N rs7311222 
SLC19A1 rs1051298 TCN1 rs526934 UBE2N rs7309933 
SLC19A1 rs12482346 TCN2 rs5749131 UBE2N rs7300607 
SLC19A1 rs2297291 TCN2 rs5753231 UBE2N rs1483003 
1Formerly known as rs8111085;  2Formerly known as rs9984077; 3Formerly known as 
rs16834521; 4Formerly known as rs10737812; 5Formerly known as rs3177999. 
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TABLE A4.3  MEDIATION OF MAIN EFFECT ASSOCIATIONS WITH CVD RISK BY PLASMA BIOMARKERS1-3  
  Model 1 Model 2 Model 3 Model 4 
Gene rs# Estimate P Estimate P 
% 
change Estimate P 
% 
change Estimate P 
% 
change 
GGH rs12544045 -0.38 0.0006 -0.36 0.013 -6% -0.37 0.0103 -3% -0.38 0.0093 -2% 
MTHFS rs7177659 -0.34 0.0012 -0.55 <.0001 59% -0.54 0.0001 57% -0.55 <.0001 62% 
MTHFR rs1801133 CT 0.06 0.6 0.14 0.35 134% 0.15 0.33 144% 0.16 0.29 163% 
 rs1801133 TT 0.54 0.0003 0.62 0.0013 15% 0.66 0.0007 22% 0.65 0.0008 21% 
TCN1 rs17154234 0.49 0.0024 0.57 0.005 17% 0.57 0.0048 18% 0.58 0.0045 19% 
UBE2I rs11248868 0.34 0.0033 0.32 0.029 -4% 0.34 0.023 1% 0.34 0.024 0% 
CBS rs6586282 -0.32 0.0033 -0.2 0.14 -36% -0.2 0.14 -36% -0.2 0.14 -37% 
CBS rs6586281 -0.35 0.0035 -0.22 0.14 -36% -0.22 0.15 -36% -0.22 0.15 -37% 
UBE2I rs909915 0.33 0.004 0.3 0.047 -10% 0.31 0.037 -5% 0.31 0.039 -6% 
1Model 1 adjusted for age and smoking only; Model 2 adjusted for age, smoking, and folate; Model 3 adjusted for age, smoking, folate, vitamin B-6, and 
vitamin B-12; Model 4 adjusted for age, smoking, folate, vitamin B-6, vitamin B-12, and homocysteine. 
2Nominal P values shown. 
3% change reflects change in regression estimate from Model 1. 
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TABLE A4.4  GENOTYPES WITH THE MOST STATISTICALLY SIGNIFICANT ASSOCIATION (P≤0.005) 
WITH THE EARLY-ONSET CVD PHENOTYPE1,3,5 
Gene rs# Estimate 
Std 
Error OR 
Nominal 
P Chr. 
Coded 
allele 
Coded 
allele 
frequency Genetic Model SNP Type 
GGH rs12544045 -1.21 0.33 0.30 2.89E-042 8 A 29% Overdominant 5' region 
UBE2I rs11248868 0.79 0.27 2.20 3.49E-03 16 G 13% Overdominant Intronic 
FTH1 rs2073588 2.12 0.73 8.31 3.63E-03 11 G 5% Recessive 5' region 
UBE2I rs909915 0.76 0.27 2.14 4.49E-03 16 T 13% Overdominant Intronic 
FTH1 rs18016213,4 2.88 1.02 17.87 4.71E-03 11 C 3% Recessive 3' region 
1Model adjusted for age and smoking; forward strand allele shown.  
2Adjusted P values reached False Discovery Rate significance threshold of 0.1.   
3Sparse data (fewer than 5 individuals per category) for genotype categories of this SNP.   
4SNP maps to more than one gene: FTH1 rs1801621 also maps to bestrophin 1 (BEST1). 
5No lower quality SNPs. 
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TABLE A4.5  NUTRIENT INTERACTIONS WITH THE MOST STATISTICALLY SIGNIFICANT 
ASSOCIATION (P≤0.02) WITH CARDIOVASCULAR DISEASE RISK1,2,4,5 
Folate interactions 
Gene rs# Estimate 
Std 
Error 
Nominal 
P Chr 
Coded 
allele 
Coded allele 
frequency (%) Genetic Model Type 
MAT2B rs6882306 -3.16 0.91 5.04E-042 5 C 16% Recessive Intronic 
SLC19A2 rs175187693 -7.23 2.70 7.40E-03 1 A 9% Recessive Intronic 
Vitamin B-6 interactions 
BHMT rs585800 -0.56 0.20 4.69E-03 5 T 27% Overdominant 3' region 
DNMT3A rs11695471 -0.56 0.20 4.94E-03 2 A 32% Dominant Intronic 
BHMT rs506500 -0.50 0.20 1.09E-02 5 T 31% Overdominant Intronic 
SLC19A2 rs175187693 -5.13 2.07 1.33E-02 1 A 9% Recessive Intronic 
BHMT rs558133 -0.48 0.20 1.48E-02 5 G 32% Overdominant Intronic 
SLC19A2 rs6656822 0.50 0.21 1.62E-02 1 T 26% Overdominant Intronic 
Vitamin B-12 interactions 
BHMT rs585800 -1.28 0.37 5.39E-042 5 T 27% Overdominant 3' region 
SLC25A32 rs1061196 1.30 0.39 9.01E-042 8 A 23% Overdominant 3' region 
BHMT rs558133 -1.09 0.36 2.42E-03 5 G 32% Overdominant Intronic 
BHMT rs506500 -1.07 0.36 2.76E-03 5 T 31% Overdominant Intronic 
AMT rs14645664 1.11 0.40 5.08E-03 3 G 42% Dominant Intronic 
MTHFD1L rs997429 1.03 0.39 8.23E-03 6 A 18% Dominant Intronic 
MTR rs16834388 -0.91 0.36 1.09E-02 1 T 37% Dominant 5' region 
FOLR1 rs2071010 1.12 0.45 1.35E-02 11 A 5% Overdominant Intronic 
GART rs8788 
0.89 0.38 
1.75E-02 21 C 26% Overdominant Coding 
nonsynonymous 
AMT rs14645674 0.62 0.26 1.85E-02 3 C 42% Additive Intronic 
1Model adjusted for age and smoking; forward strand allele shown.  
2Adjusted P values reached False Discovery Rate significance threshold of 0.2.   
3Sparse data (fewer than 5 individuals per category) for some genotype categories of this SNP.   
4SNP maps to more than one gene: rs1464566 also maps to nicolin 1(NICN1).  
5No lower quality SNPs. 
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TABLE A4.6 
 
ALL MTHFR 677 C→T (rs1801133) PAIRWISE INTERACTIONS WITH 
LIKELIHOOD RATIO TEST P≤0.021,2
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 
SNP 
Type 2 Estimate LRT 
LRT 
df 
LRT 
P 
FDR 
P 
MTHFR rs1801133 T/T Nonsynonymous 0.65 12.30 2 
0.002
1 0.35 
MTHFR rs1801133 C/T Nonsynonymous 0.13 
FPGS rs41319447 C/T 3' 0.61 
MTHFR rs1801133 T/T Nonsynonymous FPGS rs41319447 C/T 3' -13.08 
MTHFR rs1801133 C/T Nonsynonymous FPGS rs41319447 C/T 3' -1.01         
MTHFR rs1801133 T/T Nonsynonymous 0.42 16.71 4 
0.002
2 0.35 
MTHFR rs1801133 C/T Nonsynonymous 0.04 
TYMS rs2853533 C/C Intronic 0.40 
TYMS rs2853533 G/C Intronic -0.10 
MTHFR rs1801133 T/T Nonsynonymous TYMS rs2853533 C/C Intronic -12.81 
MTHFR rs1801133 C/T Nonsynonymous TYMS rs2853533 C/C Intronic 0.37 
MTHFR rs1801133 T/T Nonsynonymous TYMS rs2853533 G/C Intronic 0.78 
MTHFR rs1801133 C/T Nonsynonymous TYMS rs2853533 G/C Intronic 0.10         
MTHFR rs1801133 T/T Nonsynonymous 0.05 15.06 4 
0.004
6 0.49 
MTHFR rs1801133 C/T Nonsynonymous -0.20 
GLDC rs2118653 A/A Intronic -0.44 
GLDC rs2118653 G/A Intronic -0.21 
MTHFR rs1801133 T/T Nonsynonymous GLDC rs2118653 A/A Intronic 0.57 
MTHFR rs1801133 C/T Nonsynonymous GLDC rs2118653 A/A Intronic 0.90 
MTHFR rs1801133 T/T Nonsynonymous GLDC rs2118653 G/A Intronic 0.78 
MTHFR rs1801133 C/T Nonsynonymous GLDC rs2118653 G/A Intronic 0.13         
MTHFR rs1801133 T/T Nonsynonymous 0.98 13.92 4 
0.007
6 0.60 
MTHFR rs1801133 C/T Nonsynonymous 0.10 
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 TABLE A4.6 (Continued) 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 
SNP 
Type 2 Estimate LRT 
LRT 
df 
LRT 
P 
FDR 
P 
SLC46A1 rs2239908 G/G 3' 0.33 
SLC46A1 rs2239908 A/G 3' 0.11 
MTHFR rs1801133 T/T Nonsynonymous SLC46A1 rs2239908 G/G 3' -1.74 
MTHFR rs1801133 C/T Nonsynonymous SLC46A1 rs2239908 G/G 3' -0.38 
MTHFR rs1801133 T/T Nonsynonymous SLC46A1 rs2239908 A/G 3' -0.38 
MTHFR rs1801133 C/T Nonsynonymous SLC46A1 rs2239908 A/G 3' 0.10         
MTHFR rs1801133 T/T Nonsynonymous 0.91 12.87 4 0.012 0.66 
MTHFR rs1801133 C/T Nonsynonymous 0.06 
SLC46A1 rs2239907 T/T 3' 0.26 
SLC46A1 rs2239907 C/T 3' 0.06 
MTHFR rs1801133 T/T Nonsynonymous SLC46A1 rs2239907 T/T 3' -1.65 
MTHFR rs1801133 C/T Nonsynonymous SLC46A1 rs2239907 T/T 3' -0.29 
MTHFR rs1801133 T/T Nonsynonymous SLC46A1 rs2239907 C/T 3' -0.26 
MTHFR rs1801133 C/T Nonsynonymous SLC46A1 rs2239907 C/T 3' 0.13         
MTHFR rs1801133 T/T Nonsynonymous 0.52 12.67 4 0.013 0.66 
MTHFR rs1801133 C/T Nonsynonymous 0.19 
SARDH rs756682 G/G Intronic 0.32 
SARDH rs756682 A/G Intronic -0.02 
MTHFR rs1801133 T/T Nonsynonymous SARDH rs756682 G/G Intronic -0.18 
MTHFR rs1801133 C/T Nonsynonymous SARDH rs756682 G/G Intronic -1.35 
MTHFR rs1801133 T/T Nonsynonymous SARDH rs756682 A/G Intronic 0.13 
MTHFR rs1801133 C/T Nonsynonymous SARDH rs756682 A/G Intronic 0.03         
MTHFR rs1801133 T/T Nonsynonymous 0.36 12.42 4 0.015 0.66 
MTHFR rs1801133 C/T Nonsynonymous 0.22 
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 TABLE A4.6 (Continued)  
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 
SNP 
Type 2 Estimate LRT 
LRT 
df 
LRT 
P 
FDR 
P 
FOLR3 rs11235449 A/A 3' -0.11 
FOLR3 rs11235449 G/A 3' -0.24 
MTHFR rs1801133 T/T Nonsynonymous FOLR3 rs11235449 A/A 3' 0.73 
MTHFR rs1801133 C/T Nonsynonymous FOLR3 rs11235449 A/A 3' -0.68 
MTHFR rs1801133 T/T Nonsynonymous FOLR3 rs11235449 G/A 3' 0.13 
MTHFR rs1801133 C/T Nonsynonymous FOLR3 rs11235449 G/A 3' -0.07         
MTHFR rs1801133 T/T Nonsynonymous 0.97 11.73 4 0.019 0.68 
MTHFR rs1801133 C/T Nonsynonymous 0.54 
MTHFD1L rs7765521 A/A Intronic 0.10 
MTHFD1L rs7765521 G/A Intronic 0.41 
MTHFR rs1801133 T/T Nonsynonymous MTHFD1L rs7765521 A/A Intronic -0.10 
MTHFR rs1801133 C/T Nonsynonymous MTHFD1L rs7765521 A/A Intronic -0.63 
MTHFR rs1801133 T/T Nonsynonymous MTHFD1L rs7765521 G/A Intronic -0.87 
MTHFR rs1801133 C/T Nonsynonymous MTHFD1L rs7765521 G/A Intronic -0.68 
 1Interactions among SNPs within the same gene were not considered. 
2No FDR-adjusted Likelihood Ratio Test P values reached significance threshold of P≤0.02. 
3Genotype of SNPs 1 and 2, respectively. 
 
 
 
 121 
 
 
 
 
 
 
 
 
 
 
 
TABLE A4.7 
 
ALL PAIRWISE SNP INTERACTIONS WITH LIKELIHOOD  
RATIO P≤0.0011,2
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
CELF1 rs4752843 C/C Intronic -0.34 25.42 4 0.000041 0.68 
CELF1 rs4752843 A/C Intronic -0.33 
SLC19A3 rs11694828 A/A Intronic -0.37 
SLC19A3 rs11694828 G/A Intronic -0.08 
CELF1 rs4752843 C/C Intronic SLC19A3 rs11694828 A/A Intronic -11.38 
CELF1 rs4752843 A/C Intronic SLC19A3 rs11694828 A/A Intronic 0.95 
CELF1 rs4752843 C/C Intronic SLC19A3 rs11694828 G/A Intronic 1.97 
CELF1 rs4752843 A/C Intronic SLC19A3 rs11694828 G/A Intronic -0.02         
CELF1 rs4752843 C/C Intronic -0.31 25.01 4 0.000050 0.68 
CELF1 rs4752843 A/C Intronic -0.31 
SLC19A3 rs13025803 T/T Intronic -0.37 
SLC19A3 rs13025803 C/T Intronic -0.03 
CELF1 rs4752843 C/C Intronic SLC19A3 rs13025803 T/T Intronic -11.39 
CELF1 rs4752843 A/C Intronic SLC19A3 rs13025803 T/T Intronic 0.94 
CELF1 rs4752843 C/C Intronic SLC19A3 rs13025803 C/T Intronic 1.92 
CELF1 rs4752843 A/C Intronic SLC19A3 rs13025803 C/T Intronic -0.06         
AHCYL1 rs186724 A/A Intronic -13.53 24.96 4 0.000051 0.68 
AHCYL1 rs186724 G/A Intronic -0.27 
FPGS rs10106 G/G 3' -0.08 
FPGS rs10106 A/G 3' -0.38 
AHCYL1 rs186724 A/A Intronic FPGS rs10106 G/G 3' 12.52 
AHCYL1 rs186724 G/A Intronic FPGS rs10106 G/G 3' -0.23 
AHCYL1 rs186724 A/A Intronic FPGS rs10106 A/G 3' 13.96 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
AHCYL1 rs186724 G/A Intronic FPGS rs10106 A/G 3' 0.33         
FOLR1 rs9282688 T/T 5' -10.79 19.75 2 0.000051 0.68 
FOLR1 rs9282688 C/T 5' 0.02 
ALDH1L1 rs3772424 A/A Intronic -0.27 
ALDH1L1 rs3772424 G/A Intronic -0.11 
FOLR1 rs9282688 T/T 5' ALDH1L1 rs3772424 A/A Intronic 0.00 
FOLR1 rs9282688 C/T 5' ALDH1L1 rs3772424 A/A Intronic 4.37 
FOLR1 rs9282688 T/T 5' ALDH1L1 rs3772424 G/A Intronic 0.00 
FOLR1 rs9282688 C/T 5' ALDH1L1 rs3772424 G/A Intronic -0.51         
CELF1 rs7933019 C/C Intronic 1.02 23.07 4 0.00012 0.77 
CELF1 rs7933019 G/C Intronic 0.25 
MTR rs16834388 T/T 5' 0.55 
MTR rs16834388 G/T 5' 0.27 
CELF1 rs7933019 C/C Intronic MTR rs16834388 T/T 5' -2.60 
CELF1 rs7933019 G/C Intronic MTR rs16834388 T/T 5' -0.55 
CELF1 rs7933019 C/C Intronic MTR rs16834388 G/T 5' -1.20 
CELF1 rs7933019 G/C Intronic MTR rs16834388 G/T 5' -0.23         
MTHFD1L rs803456 C/C Intronic 0.37 22.24 4 0.00018 0.77 
MTHFD1L rs803456 T/C Intronic -0.34 
DHFR rs380691 C/C 5' -0.85 
DHFR rs380691 T/C 5' -0.28 
MTHFD1L rs803456 C/C Intronic DHFR rs380691 C/C 5' -0.43 
MTHFD1L rs803456 T/C Intronic DHFR rs380691 C/C 5' 1.21 
MTHFD1L rs803456 C/C Intronic DHFR rs380691 T/C 5' -0.30 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
MTHFD1L rs803456 T/C Intronic DHFR rs380691 T/C 5' 0.68         
CELF1 rs7933019 C/C Intronic 0.99 22.07 4 0.00019 0.77 
CELF1 rs7933019 G/C Intronic 0.25 
MTR rs2229276 G/G Synonymous 0.50 
MTR rs2229276 A/G Synonymous 0.24 
CELF1 rs7933019 C/C Intronic MTR rs2229276 G/G Synonymous -2.54 
CELF1 rs7933019 G/C Intronic MTR rs2229276 G/G Synonymous -0.58 
CELF1 rs7933019 C/C Intronic MTR rs2229276 A/G Synonymous -1.18 
CELF1 rs7933019 G/C Intronic MTR rs2229276 A/G Synonymous -0.24         
CELF1 rs7102372 T/T Intronic -0.45 19.05 3 0.00027 0.77 
CELF1 rs7102372 C/T Intronic -0.24 
FTCD rs16978930 G/G Intronic -0.94 
FTCD rs16978930 A/G Intronic -0.13 
CELF1 rs7102372 T/T Intronic FTCD rs16978930 G/G Intronic 0.00 
CELF1 rs7102372 C/T Intronic FTCD rs16978930 G/G Intronic 3.62 
CELF1 rs7102372 T/T Intronic FTCD rs16978930 A/G Intronic 0.36 
CELF1 rs7102372 C/T Intronic FTCD rs16978930 A/G Intronic 0.94         
AHCY rs819148 G/G Intronic 0.34 20.89 4 0.00033 0.77 
AHCY rs819148 A/G Intronic -0.51 
FTH1 rs1800009 G/G 3' -0.57 
FTH1 rs1800009 A/G 3' -0.11 
AHCY rs819148 G/G Intronic FTH1 rs1800009 G/G 3' -11.02 
AHCY rs819148 A/G Intronic FTH1 rs1800009 G/G 3' 1.63 
AHCY rs819148 G/G Intronic FTH1 rs1800009 A/G 3' -0.05 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
AHCY rs819148 A/G Intronic FTH1 rs1800009 A/G 3' 0.68         
MTHFD1L rs803447 T/T Intronic 0.38 20.81 4 0.00034 0.77 
MTHFD1L rs803447 C/T Intronic 0.33 
TYMS rs16948305 T/T Intronic 0.47 
TYMS rs16948305 C/T Intronic 0.44 
MTHFD1L rs803447 T/T Intronic TYMS rs16948305 T/T Intronic 1.11 
MTHFD1L rs803447 C/T Intronic TYMS rs16948305 T/T Intronic -13.66 
MTHFD1L rs803447 T/T Intronic TYMS rs16948305 C/T Intronic -0.56 
MTHFD1L rs803447 C/T Intronic TYMS rs16948305 C/T Intronic -0.62         
DNMT3A rs1550117 A/A 5' -12.47 20.74 4 0.00036 0.77 
DNMT3A rs1550117 G/A 5' -0.47 
MTHFR rs12121543 A/A Intronic -0.56 
MTHFR rs12121543 C/A Intronic -0.12 
DNMT3A rs1550117 A/A 5' MTHFR rs12121543 A/A Intronic 15.26 
DNMT3A rs1550117 G/A 5' MTHFR rs12121543 A/A Intronic 0.96 
DNMT3A rs1550117 A/A 5' MTHFR rs12121543 C/A Intronic 12.64 
DNMT3A rs1550117 G/A 5' MTHFR rs12121543 C/A Intronic 1.15         
MTHFD1 rs17751556 C/C Intronic -11.22 17.93 3 0.00045 0.77 
MTHFD1 rs17751556 T/C Intronic 0.03 
GLDC rs10975681 C/C Intronic 0.19 
GLDC rs10975681 T/C Intronic -0.05 
MTHFD1 rs17751556 C/C Intronic GLDC rs10975681 C/C Intronic 0.00 
MTHFD1 rs17751556 T/C Intronic GLDC rs10975681 C/C Intronic -1.82 
MTHFD1 rs17751556 C/C Intronic GLDC rs10975681 T/C Intronic 12.60 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
MTHFD1 rs17751556 T/C Intronic GLDC rs10975681 T/C Intronic 0.49         
AHCY rs819146 G/G 5' 0.37 20.13 4 0.00047 0.77 
AHCY rs819146 T/G 5' -0.47 
FTH1 rs1800009 G/G 3' -0.58 
FTH1 rs1800009 A/G 3' -0.11 
AHCY rs819146 G/G 5' FTH1 rs1800009 G/G 3' -11.04 
AHCY rs819146 T/G 5' FTH1 rs1800009 G/G 3' 1.58 
AHCY rs819146 G/G 5' FTH1 rs1800009 A/G 3' -0.09 
AHCY rs819146 T/G 5' FTH1 rs1800009 A/G 3' 0.64         
CELF1 rs7933019 C/C Intronic 1.00 20.07 4 0.00048 0.77 
CELF1 rs7933019 G/C Intronic 0.27 
MTR rs3754255 T/T Intronic 0.39 
MTR rs3754255 C/T Intronic 0.16 
CELF1 rs7933019 C/C Intronic MTR rs3754255 T/T Intronic -2.29 
CELF1 rs7933019 G/C Intronic MTR rs3754255 T/T Intronic -0.64 
CELF1 rs7933019 C/C Intronic MTR rs3754255 C/T Intronic -1.14 
CELF1 rs7933019 G/C Intronic MTR rs3754255 C/T Intronic -0.23         
AHCY rs819133 T/T Intronic 0.47 20.06 4 0.00049 0.77 
AHCY rs819133 G/T Intronic -0.44 
FTH1 rs1800009 G/G 3' -0.57 
FTH1 rs1800009 A/G 3' -0.11 
AHCY rs819133 T/T Intronic FTH1 rs1800009 G/G 3' -11.15 
AHCY rs819133 G/T Intronic FTH1 rs1800009 G/G 3' 1.56 
AHCY rs819133 T/T Intronic FTH1 rs1800009 A/G 3' -0.19 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
AHCY rs819133 G/T Intronic FTH1 rs1800009 A/G 3' 0.65         
CELF1 rs2242081 C/C Intronic 0.68 20.05 4 0.00049 0.77 
CELF1 rs2242081 T/C Intronic -0.06 
MTR rs16834388 T/T 5' 0.35 
MTR rs16834388 G/T 5' 0.39 
CELF1 rs2242081 C/C Intronic MTR rs16834388 T/T 5' -1.63 
CELF1 rs2242081 T/C Intronic MTR rs16834388 T/T 5' -0.01 
CELF1 rs2242081 C/C Intronic MTR rs16834388 G/T 5' -1.01 
CELF1 rs2242081 T/C Intronic MTR rs16834388 G/T 5' -0.23         
AHCY rs819159 A/A Intronic 0.47 20.03 4 0.00049 0.77 
AHCY rs819159 T/A Intronic -0.45 
FTH1 rs1800009 G/G 3' -0.57 
FTH1 rs1800009 A/G 3' -0.11 
AHCY rs819159 A/A Intronic FTH1 rs1800009 G/G 3' -11.14 
AHCY rs819159 T/A Intronic FTH1 rs1800009 G/G 3' 1.57 
AHCY rs819159 A/A Intronic FTH1 rs1800009 A/G 3' -0.18 
AHCY rs819159 T/A Intronic FTH1 rs1800009 A/G 3' 0.63         
GLDC rs4237166 C/C Intronic 0.32 20.02 4 0.00049 0.77 
GLDC rs4237166 G/C Intronic 0.22 
SLC25A32 rs1061196 A/A 3' 0.72 
SLC25A32 rs1061196 G/A 3' 0.57 
GLDC rs4237166 C/C Intronic SLC25A32 rs1061196 A/A 3' -2.43 
GLDC rs4237166 G/C Intronic SLC25A32 rs1061196 A/A 3' -0.49 
GLDC rs4237166 C/C Intronic SLC25A32 rs1061196 G/A 3' -1.08 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
GLDC rs4237166 G/C Intronic SLC25A32 rs1061196 G/A 3' -0.73         
MTHFD1L rs524732 T/T Intronic 0.11 19.90 4 0.00052 0.77 
MTHFD1L rs524732 C/T Intronic -0.31 
AMT rs11922013 C/C Intronic -0.90 
AMT rs11922013 G/C Intronic -0.01 
MTHFD1L rs524732 T/T Intronic AMT rs11922013 C/C Intronic -9.78 
MTHFD1L rs524732 C/T Intronic AMT rs11922013 C/C Intronic 1.82 
MTHFD1L rs524732 T/T Intronic AMT rs11922013 G/C Intronic -0.26 
MTHFD1L rs524732 C/T Intronic AMT rs11922013 G/C Intronic 0.22         
FTCD rs2277820 T/T Intronic -0.40 19.90 4 0.00052 0.77 
FTCD rs2277820 C/T Intronic -0.14 
GGH rs11995525 A/A Intronic -0.49 
GGH rs11995525 G/A Intronic -0.36 
FTCD rs2277820 T/T Intronic GGH rs11995525 A/A Intronic -11.42 
FTCD rs2277820 C/T Intronic GGH rs11995525 A/A Intronic 1.46 
FTCD rs2277820 T/T Intronic GGH rs11995525 G/A Intronic 0.66 
FTCD rs2277820 C/T Intronic GGH rs11995525 G/A Intronic 0.38         
GNMT rs11752813 G/G 5' 0.43 19.89 4 0.00053 0.77 
GNMT rs11752813 C/G 5' 0.26 
GLDC rs10975681 C/C Intronic 0.79 
GLDC rs10975681 T/C Intronic 0.37 
GNMT rs11752813 G/G 5' GLDC rs10975681 C/C Intronic -0.79 
GNMT rs11752813 C/G 5' GLDC rs10975681 C/C Intronic -1.17 
GNMT rs11752813 G/G 5' GLDC rs10975681 T/C Intronic -1.19 
 129 
 
 TABLE A4.7 (Continued) 
 129
Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
GNMT rs11752813 C/G 5' GLDC rs10975681 T/C Intronic -0.19         
TCN2 rs4820886 G/G Intronic -12.17 19.84 4 0.00054 0.77 
TCN2 rs4820886 T/G Intronic 0.58 
DNMT3A rs11678631 A/A Intronic -0.03 
DNMT3A rs11678631 T/A Intronic 0.13 
TCN2 rs4820886 G/G Intronic DNMT3A rs11678631 A/A Intronic 14.04 
TCN2 rs4820886 T/G Intronic DNMT3A rs11678631 A/A Intronic -0.61 
TCN2 rs4820886 G/G Intronic DNMT3A rs11678631 T/A Intronic 12.27 
TCN2 rs4820886 T/G Intronic DNMT3A rs11678631 T/A Intronic -0.64         
CBS rs6586281 A/A Intronic -1.88 19.79 4 0.00055 0.77 
CBS rs6586281 G/A Intronic -0.58 
SLC19A3 rs17438244 C/C 5' -1.74 
SLC19A3 rs17438244 A/C 5' -0.03 
CBS rs6586281 A/A Intronic SLC19A3 rs17438244 C/C 5' -7.32 
CBS rs6586281 G/A Intronic SLC19A3 rs17438244 C/C 5' 2.76 
CBS rs6586281 A/A Intronic SLC19A3 rs17438244 A/C 5' 2.05 
CBS rs6586281 G/A Intronic SLC19A3 rs17438244 A/C 5' 0.48         
FOLH1 rs16906158 C/C Intronic 0.64 19.64 4 0.00059 0.77 
FOLH1 rs16906158 T/C Intronic 0.29 
GGH rs11995525 A/A Intronic 0.41 
GGH rs11995525 G/A Intronic -0.04 
FOLH1 rs16906158 C/C Intronic GGH rs11995525 A/A Intronic -12.20 
FOLH1 rs16906158 T/C Intronic GGH rs11995525 A/A Intronic -1.72 
FOLH1 rs16906158 C/C Intronic GGH rs11995525 G/A Intronic 0.80 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
FOLH1 rs16906158 T/C Intronic GGH rs11995525 G/A Intronic -0.90         
MTHFS rs8923 G/G Nonsynonymous 3.24 17.30 3 0.00061 0.77 
MTHFS rs8923 A/G Nonsynonymous -0.68 
GNMT rs2296805 T/T Intronic -0.21 
GNMT rs2296805 G/T Intronic 0.09 
MTHFS rs8923 G/G Nonsynonymous GNMT rs2296805 T/T Intronic 0.00 
MTHFS rs8923 A/G Nonsynonymous GNMT rs2296805 T/T Intronic 1.46 
MTHFS rs8923 G/G Nonsynonymous GNMT rs2296805 G/T Intronic -4.66 
MTHFS rs8923 A/G Nonsynonymous GNMT rs2296805 G/T Intronic 0.54         
SLC25A32 rs3098243 C/C Intronic 0.15 19.40 4 0.00066 0.77 
SLC25A32 rs3098243 T/C Intronic -0.10 
MTHFD1L rs17349743 C/C Intronic 0.84 
MTHFD1L rs17349743 T/C Intronic -0.27 
SLC25A32 rs3098243 C/C Intronic MTHFD1L rs17349743 C/C Intronic -1.08 
SLC25A32 rs3098243 T/C Intronic MTHFD1L rs17349743 C/C Intronic -0.64 
SLC25A32 rs3098243 C/C Intronic MTHFD1L rs17349743 T/C Intronic -0.03 
SLC25A32 rs3098243 T/C Intronic MTHFD1L rs17349743 T/C Intronic 0.68         
MTHFD1L rs803466 G/G Intronic 0.06 19.37 4 0.00066 0.77 
MTHFD1L rs803466 A/G Intronic -0.11 
CELF1 rs7933019 C/C Intronic 0.34 
CELF1 rs7933019 G/C Intronic -0.24 
MTHFD1L rs803466 G/G Intronic CELF1 rs7933019 C/C Intronic -0.25 
MTHFD1L rs803466 A/G Intronic CELF1 rs7933019 C/C Intronic -0.92 
MTHFD1L rs803466 G/G Intronic CELF1 rs7933019 G/C Intronic -0.04 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
MTHFD1L rs803466 A/G Intronic CELF1 rs7933019 G/C Intronic 0.67         
MTHFR rs1801131 C/C Nonsynonymous -0.42 19.32 4 0.00068 0.77 
MTHFR rs1801131 A/C Nonsynonymous -0.23 
DNMT3A rs1550117 A/A 5' -11.61 
DNMT3A rs1550117 G/A 5' -0.61 
MTHFR rs1801131 C/C Nonsynonymous DNMT3A rs1550117 A/A 5' 13.32 
MTHFR rs1801131 A/C Nonsynonymous DNMT3A rs1550117 A/A 5' 11.60 
MTHFR rs1801131 C/C Nonsynonymous DNMT3A rs1550117 G/A 5' 0.93 
MTHFR rs1801131 A/C Nonsynonymous DNMT3A rs1550117 G/A 5' 1.20         
MTHFS rs8923 G/G Nonsynonymous 3.22 17.06 3 0.00069 0.77 
MTHFS rs8923 A/G Nonsynonymous -0.68 
GNMT rs2296804 G/G Intronic -0.19 
GNMT rs2296804 C/G Intronic 0.08 
MTHFS rs8923 G/G Nonsynonymous GNMT rs2296804 G/G Intronic 0.00 
MTHFS rs8923 A/G Nonsynonymous GNMT rs2296804 G/G Intronic 1.44 
MTHFS rs8923 G/G Nonsynonymous GNMT rs2296804 C/G Intronic -4.63 
MTHFS rs8923 A/G Nonsynonymous GNMT rs2296804 C/G Intronic 0.54         
FTH1 rs1800009 G/G 3' -0.59 19.28 4 0.00069 0.77 
FTH1 rs1800009 A/G 3' -0.11 
AHCY rs1205366 T/T Intronic 0.38 
AHCY rs1205366 C/T Intronic -0.46 
FTH1 rs1800009 G/G 3' AHCY rs1205366 T/T Intronic -9.72 
FTH1 rs1800009 A/G 3' AHCY rs1205366 T/T Intronic -0.38 
FTH1 rs1800009 G/G 3' AHCY rs1205366 C/T Intronic 1.60 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
FTH1 rs1800009 A/G 3' AHCY rs1205366 C/T Intronic 0.65         
BHMT rs16876512 T/T 5' -0.42 19.24 4 0.00070 0.77 
BHMT rs16876512 C/T 5' -0.50 
MAT1A rs1143694 T/T Synonymous 0.23 
MAT1A rs1143694 C/T Synonymous -0.19 
BHMT rs16876512 T/T 5' MAT1A rs1143694 T/T Synonymous -10.78 
BHMT rs16876512 C/T 5' MAT1A rs1143694 T/T Synonymous -0.91 
BHMT rs16876512 T/T 5' MAT1A rs1143694 C/T Synonymous 1.14 
BHMT rs16876512 C/T 5' MAT1A rs1143694 C/T Synonymous 0.88         
CBS rs2014564 A/A Intronic 0.02 19.24 4 0.00071 0.77 
CBS rs2014564 G/A Intronic -0.01 
HSPA8 rs1136141 T/T 5' 1.55 
HSPA8 rs1136141 C/T 5' -0.26 
CBS rs2014564 A/A Intronic HSPA8 rs1136141 T/T 5' -0.76 
CBS rs2014564 G/A Intronic HSPA8 rs1136141 T/T 5' -2.31 
CBS rs2014564 A/A Intronic HSPA8 rs1136141 C/T 5' 0.94 
CBS rs2014564 G/A Intronic HSPA8 rs1136141 C/T 5' 0.42         
GNMT rs11752813 G/G 5' 0.37 19.20 4 0.00072 0.77 
GNMT rs11752813 C/G 5' 0.48 
BHMT rs10037045 T/T Intronic 0.99 
BHMT rs10037045 A/T Intronic 0.44 
GNMT rs11752813 G/G 5' BHMT rs10037045 T/T Intronic -1.01 
GNMT rs11752813 C/G 5' BHMT rs10037045 T/T Intronic -1.90 
GNMT rs11752813 G/G 5' BHMT rs10037045 A/T Intronic -0.90 
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G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
GNMT rs11752813 C/G 5' BHMT rs10037045 A/T Intronic -0.60         
SARDH rs129891 A/A Intronic 0.19 19.10 4 0.00075 0.77 
SARDH rs129891 G/A Intronic 0.31 
GNMT rs11752813 G/G 5' -0.13 
GNMT rs11752813 C/G 5' 0.47 
SARDH rs129891 A/A Intronic GNMT rs11752813 G/G 5' -0.31 
SARDH rs129891 G/A Intronic GNMT rs11752813 G/G 5' 0.16 
SARDH rs129891 A/A Intronic GNMT rs11752813 C/G 5' -0.22 
SARDH rs129891 G/A Intronic GNMT rs11752813 C/G 5' -0.87         
TCN1 rs34528912 C/T Nonsynonymous -0.85 14.33 2 0.00077 0.77 
FOLR2 rs2298444 G/G Intronic 0.32 
FOLR2 rs2298444 A/G Intronic 0.00 
TCN1 rs34528912 C/T Nonsynonymous FOLR2 rs2298444 G/G Intronic -10.62 
TCN1 rs34528912 C/T Nonsynonymous FOLR2 rs2298444 A/G Intronic 1.43         
CBS rs6586281 A/A Intronic -13.25 19.02 4 0.00078 0.77 
CBS rs6586281 G/A Intronic -0.24 
MTRR rs1801394 A/A Nonsynonymous -0.10 
MTRR rs1801394 G/A Nonsynonymous 0.12 
CBS rs6586281 A/A Intronic MTRR rs1801394 A/A Nonsynonymous 15.79 
CBS rs6586281 G/A Intronic MTRR rs1801394 A/A Nonsynonymous -0.13 
CBS rs6586281 A/A Intronic MTRR rs1801394 G/A Nonsynonymous 12.59 
CBS rs6586281 G/A Intronic MTRR rs1801394 G/A Nonsynonymous -0.10         
MTHFR rs3737965 C/T 5' 0.19 11.29 1 0.00078 0.77 
DNMT1 rs2228612 C/C Nonsynonymous -13.20 
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13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
DNMT1 rs2228612 T/C Nonsynonymous 0.24 
MTHFR rs3737965 C/T 5' DNMT1 rs2228612 C/C Nonsynonymous 0.00 
MTHFR rs3737965 C/T 5' DNMT1 rs2228612 T/C Nonsynonymous -13.36         
GLDC rs2118653 A/A Intronic 0.40 19.01 4 0.00078 0.77 
GLDC rs2118653 G/A Intronic 0.02 
ALDH1L1 rs1868138 T/T Intronic 0.16 
ALDH1L1 rs1868138 A/T Intronic 0.42 
GLDC rs2118653 A/A Intronic ALDH1L1 rs1868138 T/T Intronic -1.75 
GLDC rs2118653 G/A Intronic ALDH1L1 rs1868138 T/T Intronic 0.95 
GLDC rs2118653 A/A Intronic ALDH1L1 rs1868138 A/T Intronic -0.88 
GLDC rs2118653 G/A Intronic ALDH1L1 rs1868138 A/T Intronic -0.35         
MTHFD1 rs17751556 C/C Intronic 0.93 16.75 3 0.00080 0.77 
MTHFD1 rs17751556 T/C Intronic -0.13 
MAT1A rs17677908 G/G 5' 0.19 
MAT1A rs17677908 A/G 5' -0.18 
MTHFD1 rs17751556 C/C Intronic MAT1A rs17677908 G/G 5' 0.00 
MTHFD1 rs17751556 T/C Intronic MAT1A rs17677908 G/G 5' -11.25 
MTHFD1 rs17751556 C/C Intronic MAT1A rs17677908 A/G 5' -12.29 
MTHFD1 rs17751556 T/C Intronic MAT1A rs17677908 A/G 5' 1.07         
GNMT rs2296804 G/G Intronic 0.10 18.92 4 0.00081 0.77 
GNMT rs2296804 C/G Intronic 0.04 
FTH1 rs2073588 G/G 3' 4.39 
FTH1 rs2073588 T/G 3' -0.52 
GNMT rs2296804 G/G Intronic FTH1 rs2073588 G/G 3' -14.28 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
GNMT rs2296804 C/G Intronic FTH1 rs2073588 G/G 3' -3.63 
GNMT rs2296804 G/G Intronic FTH1 rs2073588 T/G 3' -0.79 
GNMT rs2296804 C/G Intronic FTH1 rs2073588 T/G 3' 1.04         
DNMT3A rs6733868 C/C Intronic -0.18 18.91 4 0.00082 0.77 
DNMT3A rs6733868 G/C Intronic 0.07 
MTHFD1 rs2281603 G/G Intronic 1.51 
MTHFD1 rs2281603 A/G Intronic -0.13 
DNMT3A rs6733868 C/C Intronic MTHFD1 rs2281603 G/G Intronic -0.49 
DNMT3A rs6733868 G/C Intronic MTHFD1 rs2281603 G/G Intronic -1.87 
DNMT3A rs6733868 C/C Intronic MTHFD1 rs2281603 A/G Intronic 0.23 
DNMT3A rs6733868 G/C Intronic MTHFD1 rs2281603 A/G Intronic 0.16         
CBS rs6586282 T/T Intronic -1.86 18.84 4 0.00084 0.77 
CBS rs6586282 C/T Intronic -0.56 
SLC19A3 rs17438244 C/C 5' -1.74 
SLC19A3 rs17438244 A/C 5' -0.03 
CBS rs6586282 T/T Intronic SLC19A3 rs17438244 C/C 5' -7.34 
CBS rs6586282 C/T Intronic SLC19A3 rs17438244 C/C 5' 2.75 
CBS rs6586282 T/T Intronic SLC19A3 rs17438244 A/C 5' 1.84 
CBS rs6586282 C/T Intronic SLC19A3 rs17438244 A/C 5' 0.51         
MTHFR rs6541003 G/G Intronic -0.77 18.83 4 0.00085 0.77 
MTHFR rs6541003 A/G Intronic -0.31 
SLC46A1 rs2239908 G/G 3' -1.03 
SLC46A1 rs2239908 A/G 3' -0.07 
MTHFR rs6541003 G/G Intronic SLC46A1 rs2239908 G/G 3' 1.92 
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G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
MTHFR rs6541003 A/G Intronic SLC46A1 rs2239908 G/G 3' 1.13 
MTHFR rs6541003 G/G Intronic SLC46A1 rs2239908 A/G 3' 0.36 
MTHFR rs6541003 A/G Intronic SLC46A1 rs2239908 A/G 3' 0.20         
CELF1 rs7933019 C/C Intronic -0.16 16.61 3 0.00085 0.77 
CELF1 rs7933019 G/C Intronic 0.05 
ALDH1L1 rs4646750 G/G Nonsynonymous -12.26 
ALDH1L1 rs4646750 A/G Nonsynonymous -0.22 
CELF1 rs7933019 C/C Intronic ALDH1L1 rs4646750 G/G Nonsynonymous 0.00 
CELF1 rs7933019 G/C Intronic ALDH1L1 rs4646750 G/G Nonsynonymous 13.87 
CELF1 rs7933019 C/C Intronic ALDH1L1 rs4646750 A/G Nonsynonymous 1.50 
CELF1 rs7933019 G/C Intronic ALDH1L1 rs4646750 A/G Nonsynonymous 0.02         
FOLR2 rs514933 G/G Intronic -0.45 18.79 4 0.00087 0.77 
FOLR2 rs514933 A/G Intronic 0.10 
DNMT3A rs1550117 A/A 5' -11.46 
DNMT3A rs1550117 G/A 5' 0.48 
FOLR2 rs514933 G/G Intronic DNMT3A rs1550117 A/A 5' 0.24 
FOLR2 rs514933 A/G Intronic DNMT3A rs1550117 A/A 5' 11.68 
FOLR2 rs514933 G/G Intronic DNMT3A rs1550117 G/A 5' -0.08 
FOLR2 rs514933 A/G Intronic DNMT3A rs1550117 G/A 5' -1.33         
SLC25A32 rs3098243 C/C Intronic -0.32 18.67 4 0.00091 0.77 
SLC25A32 rs3098243 T/C Intronic -0.45 
CBS rs1788484 T/T 5' -0.29 
CBS rs1788484 C/T 5' -0.66 
SLC25A32 rs3098243 C/C Intronic CBS rs1788484 T/T 5' 0.61 
 137 
 
 TABLE A4.7 (Continued) 
 137
Gene 1 SNP 1 
G’type 
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23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
SLC25A32 rs3098243 T/C Intronic CBS rs1788484 T/T 5' 0.68 
SLC25A32 rs3098243 C/C Intronic CBS rs1788484 C/T 5' 0.50 
SLC25A32 rs3098243 T/C Intronic CBS rs1788484 C/T 5' 1.07         
FOLH1 rs202673 G/G Intronic 0.39 18.65 4 0.00092 0.77 
FOLH1 rs202673 A/G Intronic -0.36 
MAT1A rs1143694 T/T Synonymous 0.19 
MAT1A rs1143694 C/T Synonymous -0.19 
FOLH1 rs202673 G/G Intronic MAT1A rs1143694 T/T Synonymous 0.93 
FOLH1 rs202673 A/G Intronic MAT1A rs1143694 T/T Synonymous -0.93 
FOLH1 rs202673 G/G Intronic MAT1A rs1143694 C/T Synonymous -1.20 
FOLH1 rs202673 A/G Intronic MAT1A rs1143694 C/T Synonymous 0.74         
CTH rs663649 T/T Intronic 0.35 18.61 4 0.00094 0.77 
CTH rs663649 G/T Intronic -0.12 
SLC25A32 rs1061196 A/A 3' 0.07 
SLC25A32 rs1061196 G/A 3' 0.03 
CTH rs663649 T/T Intronic SLC25A32 rs1061196 A/A 3' 0.88 
CTH rs663649 G/T Intronic SLC25A32 rs1061196 A/A 3' -0.41 
CTH rs663649 T/T Intronic SLC25A32 rs1061196 G/A 3' -1.35 
CTH rs663649 G/T Intronic SLC25A32 rs1061196 G/A 3' 0.28         
MTHFD1L rs803456 C/C Intronic 0.55 18.60 4 0.00094 0.77 
MTHFD1L rs803456 T/C Intronic 0.37 
MTHFD1 rs1950902 T/T Nonsynonymous 1.77 
MTHFD1 rs1950902 C/T Nonsynonymous 0.32 
MTHFD1L rs803456 C/C Intronic MTHFD1 rs1950902 T/T Nonsynonymous -3.33 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
MTHFD1L rs803456 T/C Intronic MTHFD1 rs1950902 T/T Nonsynonymous -1.97 
MTHFD1L rs803456 C/C Intronic MTHFD1 rs1950902 C/T Nonsynonymous -0.71 
MTHFD1L rs803456 T/C Intronic MTHFD1 rs1950902 C/T Nonsynonymous -0.75         
MAT2B rs7733775 A/A Intronic -0.18 18.60 4 0.00094 0.77 
MAT2B rs7733775 G/A Intronic -0.30 
SHMT1 rs12952556 C/C 3' -1.17 
SHMT1 rs12952556 T/C 3' -0.13 
MAT2B rs7733775 A/A Intronic SHMT1 rs12952556 C/C 3' 0.47 
MAT2B rs7733775 G/A Intronic SHMT1 rs12952556 C/C 3' 1.79 
MAT2B rs7733775 A/A Intronic SHMT1 rs12952556 T/C 3' 0.37 
MAT2B rs7733775 G/A Intronic SHMT1 rs12952556 T/C 3' 0.39         
AHCY rs819155 G/G Intronic 0.47 18.57 4 0.00095 0.77 
AHCY rs819155 A/G Intronic -0.42 
FTH1 rs1800009 G/G 3' -0.58 
FTH1 rs1800009 A/G 3' -0.11 
AHCY rs819155 G/G Intronic FTH1 rs1800009 G/G 3' -9.81 
AHCY rs819155 A/G Intronic FTH1 rs1800009 G/G 3' 1.56 
AHCY rs819155 G/G Intronic FTH1 rs1800009 A/G 3' -0.46 
AHCY rs819155 A/G Intronic FTH1 rs1800009 A/G 3' 0.63         
SLC19A3 rs13007334 C/C Intronic 0.28 18.55 4 0.00096 0.77 
SLC19A3 rs13007334 T/C Intronic -0.19 
BHMT rs10037045 T/T Intronic -1.10 
BHMT rs10037045 A/T Intronic 0.06 
SLC19A3 rs13007334 C/C Intronic BHMT rs10037045 T/T Intronic 0.12 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
SLC19A3 rs13007334 T/C Intronic BHMT rs10037045 T/T Intronic 1.71 
SLC19A3 rs13007334 C/C Intronic BHMT rs10037045 A/T Intronic -0.63 
SLC19A3 rs13007334 T/C Intronic BHMT rs10037045 A/T Intronic 0.05         
MTHFD1L rs9478908 G/G Intronic -0.16 16.32 3 0.00098 0.77 
MTHFD1L rs9478908 A/G Intronic 0.08 
MTHFD1 rs17751556 C/C Intronic 1.88 
MTHFD1 rs17751556 T/C Intronic 0.35 
MTHFD1L rs9478908 G/G Intronic MTHFD1 rs17751556 C/C Intronic 0.00 
MTHFD1L rs9478908 A/G Intronic MTHFD1 rs17751556 C/C Intronic -13.73 
MTHFD1L rs9478908 G/G Intronic MTHFD1 rs17751556 T/C Intronic -1.04 
MTHFD1L rs9478908 A/G Intronic MTHFD1 rs17751556 T/C Intronic -0.43         
MTHFD1L rs9478162 A/A Intronic -0.08 16.27 3 0.0010 0.77 
MTHFD1L rs9478162 G/A Intronic 0.06 
MTHFD1 rs17751556 C/C Intronic 1.86 
MTHFD1 rs17751556 T/C Intronic 0.33 
MTHFD1L rs9478162 A/A Intronic MTHFD1 rs17751556 C/C Intronic 0.00 
MTHFD1L rs9478162 G/A Intronic MTHFD1 rs17751556 C/C Intronic -13.70 
MTHFD1L rs9478162 A/A Intronic MTHFD1 rs17751556 T/C Intronic -1.11 
MTHFD1L rs9478162 G/A Intronic MTHFD1 rs17751556 T/C Intronic -0.46         
SLC19A2 rs17518769 A/A Intronic 2.10 16.26 3 0.0010 0.77 
SLC19A2 rs17518769 G/A Intronic 0.25 
DHFR rs1650697 T/T 5' 0.30 
DHFR rs1650697 C/T 5' 0.28 
SLC19A2 rs17518769 A/A Intronic DHFR rs1650697 T/T 5' -13.62 
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Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
SLC19A2 rs17518769 G/A Intronic DHFR rs1650697 T/T 5' 0.23 
SLC19A2 rs17518769 A/A Intronic DHFR rs1650697 C/T 5' 0.00 
SLC19A2 rs17518769 G/A Intronic DHFR rs1650697 C/T 5' -0.80         
MTRR rs161869 T/T Intronic -0.51 18.45 4 0.0010 0.77 
MTRR rs161869 C/T Intronic -0.43 
SARDH rs129932 A/A Synonymous -1.05 
SARDH rs129932 G/A Synonymous -0.26 
MTRR rs161869 T/T Intronic SARDH rs129932 A/A Synonymous 1.52 
MTRR rs161869 C/T Intronic SARDH rs129932 A/A Synonymous 1.39 
MTRR rs161869 T/T Intronic SARDH rs129932 G/A Synonymous 0.15 
MTRR rs161869 C/T Intronic SARDH rs129932 G/A Synonymous 0.43         
TCN2 rs9606756 G/G Nonsynonymous 0.30 18.41 4 0.0010 0.77 
TCN2 rs9606756 A/G Nonsynonymous -0.07 
MTHFD1L rs17349743 C/C Intronic 0.21 
MTHFD1L rs17349743 T/C Intronic 0.03 
TCN2 rs9606756 G/G Nonsynonymous MTHFD1L rs17349743 C/C Intronic -11.64 
TCN2 rs9606756 A/G Nonsynonymous MTHFD1L rs17349743 C/C Intronic 1.12 
TCN2 rs9606756 G/G Nonsynonymous MTHFD1L rs17349743 T/C Intronic 1.24 
TCN2 rs9606756 A/G Nonsynonymous MTHFD1L rs17349743 T/C Intronic -0.01         
MAT2B rs7733775 A/A Intronic -0.19 18.40 4 0.0010 0.77 
MAT2B rs7733775 G/A Intronic -0.29 
SHMT1 rs1979277 A/A Nonsynonymous -1.17 
SHMT1 rs1979277 G/A Nonsynonymous -0.13 
MAT2B rs7733775 A/A Intronic SHMT1 rs1979277 A/A Nonsynonymous 0.48 
 141 
 
 TABLE A4.7 (Continued) 
141
Gene 1 SNP 1 
G’type 
13 SNP Type 1 Gene 2 SNP 2 
G’type 
23 SNP Type 2 Est.4 LRT 
LRT 
df LRT P 
FDR 
P 
MAT2B rs7733775 G/A Intronic SHMT1 rs1979277 A/A Nonsynonymous 1.78 
MAT2B rs7733775 A/A Intronic SHMT1 rs1979277 G/A Nonsynonymous 0.39 
MAT2B rs7733775 G/A Intronic SHMT1 rs1979277 G/A Nonsynonymous 0.36         
MTHFS rs2586167 T/T 5' 0.15 18.38 4 0.0010 0.77 
MTHFS rs2586167 C/T 5' 0.05 
SLC19A3 rs17438244 C/C 5' 0.27 
SLC19A3 rs17438244 A/C 5' 0.15 
MTHFS rs2586167 T/T 5' SLC19A3 rs17438244 C/C 5' -13.56 
MTHFS rs2586167 C/T 5' SLC19A3 rs17438244 C/C 5' -13.31 
MTHFS rs2586167 T/T 5' SLC19A3 rs17438244 A/C 5' -0.54 
MTHFS rs2586167 C/T 5' SLC19A3 rs17438244 A/C 5' 0.03 
1Interactions among SNPs within the same gene were not considered. 
2No FDR-adjusted Likelihood Ratio Test P values reached significance threshold of P≤0.2. 
3Genotype of SNPs 1 and 2, respectively. 
4Regression estimate. 
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TABLE A4.8 
 
ALL SHMT1, TS, DHFR, UBE2I, AND UBE2N PAIRWISE INTERACTIONS WITH 
LIKELIHOOD RATIO TEST P≤0.021 
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
UBE2N rs7300607 C/C Intronic 0.25 15.74 4 0.0034 
UBE2N rs7300607 T/C Intronic -0.26 
TYMS rs502396 C/C Intronic -1.28 
TYMS rs502396 T/C Intronic -0.38 
UBE2N rs7300607 C/C Intronic TYMS rs502396 C/C Intronic 0.89 
UBE2N rs7300607 T/C Intronic TYMS rs502396 C/C Intronic 1.54 
UBE2N rs7300607 C/C Intronic TYMS rs502396 T/C Intronic -0.07 
UBE2N rs7300607 T/C Intronic TYMS rs502396 T/C Intronic 0.44       
TYMS rs502396 C/C Intronic -1.28 15.46 4 0.0038 
TYMS rs502396 T/C Intronic -0.39 
UBE2N rs1483003 G/G Intronic 0.22 
UBE2N rs1483003 A/G Intronic -0.24 
TYMS rs502396 C/C Intronic UBE2N rs1483003 G/G Intronic 0.94 
TYMS rs502396 T/C Intronic UBE2N rs1483003 G/G Intronic -0.05 
TYMS rs502396 C/C Intronic UBE2N rs1483003 A/G Intronic 1.54 
TYMS rs502396 T/C Intronic UBE2N rs1483003 A/G Intronic 0.42       
UBE2N rs7300607 C/C Intronic 0.24 14.35 4 0.0063 
UBE2N rs7300607 T/C Intronic -0.19 
TYMS rs2612095 C/C Intronic -1.19 
TYMS rs2612095 T/C Intronic -0.18 
UBE2N rs7300607 C/C Intronic TYMS rs2612095 C/C Intronic 1.13 
UBE2N rs7300607 T/C Intronic TYMS rs2612095 C/C Intronic 1.49 
UBE2N rs7300607 C/C Intronic TYMS rs2612095 T/C Intronic -0.12 
 UBE2N rs7300607 T/C Intronic TYMS rs2612095 T/C Intronic 0.36       
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
UBE2N rs7300607 C/C Intronic 0.29 14.17 4 0.007 
UBE2N rs7300607 T/C Intronic -0.17 
TYMS rs2853543 G/G Intronic -1.16 
TYMS rs2853543 C/G Intronic -0.17 
UBE2N rs7300607 C/C Intronic TYMS rs2853543 G/G Intronic 1.10 
UBE2N rs7300607 T/C Intronic TYMS rs2853543 G/G Intronic 1.42 
UBE2N rs7300607 C/C Intronic TYMS rs2853543 C/G Intronic -0.20 
UBE2N rs7300607 T/C Intronic TYMS rs2853543 C/G Intronic 0.36       
TYMS rs2853543 G/G Intronic -1.16 13.89 4 0.008 
TYMS rs2853543 C/G Intronic -0.17 
UBE2N rs1483003 G/G Intronic 0.26 
UBE2N rs1483003 A/G Intronic -0.15 
TYMS rs2853543 G/G Intronic UBE2N rs1483003 G/G Intronic 1.15 
TYMS rs2853543 C/G Intronic UBE2N rs1483003 G/G Intronic -0.17 
TYMS rs2853543 G/G Intronic UBE2N rs1483003 A/G Intronic 1.41 
TYMS rs2853543 C/G Intronic UBE2N rs1483003 A/G Intronic 0.34       
TYMS rs2612095 C/C Intronic -1.19 13.73 4 0.008 
TYMS rs2612095 T/C Intronic -0.18 
UBE2N rs1483003 G/G Intronic 0.19 
UBE2N rs1483003 A/G Intronic -0.17 
TYMS rs2612095 C/C Intronic UBE2N rs1483003 G/G Intronic 1.20 
TYMS rs2612095 T/C Intronic UBE2N rs1483003 G/G Intronic -0.07 
TYMS rs2612095 C/C Intronic UBE2N rs1483003 A/G Intronic 1.47 
 TYMS rs2612095 T/C Intronic UBE2N rs1483003 A/G Intronic 0.33       
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
DHFR rs380691 C/C 5' -0.78 12.75 4 0.013 
DHFR rs380691 T/C 5' -0.37 
SHMT1 rs2273028 T/T Intronic -0.04 
SHMT1 rs2273028 C/T Intronic -0.27 
DHFR rs380691 C/C 5' SHMT1 rs2273028 T/T Intronic 0.11 
DHFR rs380691 T/C 5' SHMT1 rs2273028 T/T Intronic 0.08 
DHFR rs380691 C/C 5' SHMT1 rs2273028 C/T Intronic 1.05 
DHFR rs380691 T/C 5' SHMT1 rs2273028 C/T Intronic 0.69       
DHFR rs380691 C/C 5' -0.79 11.76 4 0.019 
DHFR rs380691 T/C 5' -0.34 
SHMT1 rs1979276 A/A 3' -0.11 
SHMT1 rs1979276 G/A 3' -0.29 
DHFR rs380691 C/C 5' SHMT1 rs1979276 A/A 3' 0.11 
DHFR rs380691 T/C 5' SHMT1 rs1979276 A/A 3' 0.12 
DHFR rs380691 C/C 5' SHMT1 rs1979276 G/A 3' 1.07 
DHFR rs380691 T/C 5' SHMT1 rs1979276 G/A 3' 0.63 
 1Interactions among SNPs within the same gene were not considered. 
2Genotype of SNPs 1 and 2, respectively. 
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TABLE A4.9 
 
ALL SHMT1, FTH1, AND CELF1 PAIRWISE INTERACTIONS WITH 
LIKELIHOOD RATIO TEST P≤0.021 
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
SHMT1 rs1979276 A/A 3' 0.47 15.33 4 0.0041 
SHMT1 rs1979276 G/A 3' 0.29 
FTH1 rs1800009 G/G 3' 0.15 
FTH1 rs1800009 A/G 3' 0.28 
SHMT1 rs1979276 A/A 3' FTH1 rs1800009 G/G 3' -13.49 
SHMT1 rs1979276 G/A 3' FTH1 rs1800009 G/G 3' -0.22 
SHMT1 rs1979276 A/A 3' FTH1 rs1800009 A/G 3' -0.92 
SHMT1 rs1979276 G/A 3' FTH1 rs1800009 A/G 3' -0.37       
SHMT1 rs2273028 T/T Intronic 0.51 15.08 4 0.0045 
SHMT1 rs2273028 C/T Intronic 0.33 
FTH1 rs1800009 G/G 3' 0.18 
FTH1 rs1800009 A/G 3' 0.28 
SHMT1 rs2273028 T/T Intronic FTH1 rs1800009 G/G 3' -13.54 
SHMT1 rs2273028 C/T Intronic FTH1 rs1800009 G/G 3' -0.27 
SHMT1 rs2273028 T/T Intronic FTH1 rs1800009 A/G 3' -0.84 
SHMT1 rs2273028 C/T Intronic FTH1 rs1800009 A/G 3' -0.38       
SHMT1 rs2273028 T/T Intronic 0.32 14.77 4 0.0052 
SHMT1 rs2273028 C/T Intronic 0.32 
FTH1 rs17185413 C/C 3' 0.51 
FTH1 rs17185413 T/C 3' 0.25 
SHMT1 rs2273028 T/T Intronic FTH1 rs17185413 C/C 3' -12.82 
SHMT1 rs2273028 C/T Intronic FTH1 rs17185413 C/C 3' -1.88 
SHMT1 rs2273028 T/T Intronic FTH1 rs17185413 T/C 3' -0.68 
SHMT1 rs2273028 C/T Intronic FTH1 rs17185413 T/C 3' -0.29       
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
SHMT1 rs1979276 A/A 3' 0.27 14.75 4 0.0053 
SHMT1 rs1979276 G/A 3' 0.26 
FTH1 rs17185413 C/C 3' 0.48 
FTH1 rs17185413 T/C 3' 0.23 
SHMT1 rs1979276 A/A 3' FTH1 rs17185413 C/C 3' -12.78 
SHMT1 rs1979276 G/A 3' FTH1 rs17185413 C/C 3' -1.82 
SHMT1 rs1979276 A/A 3' FTH1 rs17185413 T/C 3' -0.79 
SHMT1 rs1979276 G/A 3' FTH1 rs17185413 T/C 3' -0.23       
CELF1 rs7933019 C/C Intronic -0.08 9.83 2 0.0074 
CELF1 rs7933019 G/C Intronic 0.08 
FTH1 rs17156609 G/A 3' -0.12 
CELF1 rs7933019 C/C Intronic FTH1 rs17156609 G/A 3' 1.26 
CELF1 rs7933019 G/C Intronic FTH1 rs17156609 G/A 3' -1.14       
SHMT1 rs2461838 T/T Intronic 0.13 13.44 4 0.0093 
SHMT1 rs2461838 C/T Intronic 0.09 
FTH1 rs17185413 C/C 3' 0.30 
FTH1 rs17185413 T/C 3' 0.10 
SHMT1 rs2461838 T/T Intronic FTH1 rs17185413 C/C 3' -11.47 
SHMT1 rs2461838 C/T Intronic FTH1 rs17185413 C/C 3' -2.20 
SHMT1 rs2461838 T/T Intronic FTH1 rs17185413 T/C 3' -0.72 
SHMT1 rs2461838 C/T Intronic FTH1 rs17185413 T/C 3' 0.02       
CELF1 rs7102372 T/T Intronic 0.13 11.19 3 0.011 
CELF1 rs7102372 C/T Intronic -0.10 
SHMT1 rs17806489 A/A Intronic -1.10 
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
SHMT1 rs17806489 G/A Intronic 0.22 
CELF1 rs7102372 T/T Intronic SHMT1 rs17806489 A/A Intronic 0.00 
CELF1 rs7102372 C/T Intronic SHMT1 rs17806489 A/A Intronic 2.57 
CELF1 rs7102372 T/T Intronic SHMT1 rs17806489 G/A Intronic -12.58 
CELF1 rs7102372 C/T Intronic SHMT1 rs17806489 G/A Intronic 0.18       
FTH1 rs1800009 G/G 3' 0.15 12.59 4 0.013 
FTH1 rs1800009 A/G 3' 0.26 
SHMT1 rs12952556 C/C 3' 0.40 
SHMT1 rs12952556 T/C 3' 0.32 
FTH1 rs1800009 G/G 3' SHMT1 rs12952556 C/C 3' -13.38 
FTH1 rs1800009 A/G 3' SHMT1 rs12952556 C/C 3' -0.75 
FTH1 rs1800009 G/G 3' SHMT1 rs12952556 T/C 3' -0.25 
FTH1 rs1800009 A/G 3' SHMT1 rs12952556 T/C 3' -0.38       
SHMT1 rs1979277 A/A Nonsynonymous 0.19 12.43 4 0.014 
SHMT1 rs1979277 G/A Nonsynonymous 0.24 
FTH1 rs17185413 C/C 3' 0.45 
FTH1 rs17185413 T/C 3' 0.16 
SHMT1 rs1979277 A/A Nonsynonymous FTH1 rs17185413 C/C 3' -11.61 
SHMT1 rs1979277 G/A Nonsynonymous FTH1 rs17185413 C/C 3' -1.88 
SHMT1 rs1979277 A/A Nonsynonymous FTH1 rs17185413 T/C 3' -0.54 
SHMT1 rs1979277 G/A Nonsynonymous FTH1 rs17185413 T/C 3' -0.14       
SHMT1 rs2273028 T/T Intronic 0.06 8.22 2 0.016 
SHMT1 rs2273028 C/T Intronic 0.08 
FTH1 rs17156609 G/A 3' -0.38 
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
SHMT1 rs2273028 T/T Intronic FTH1 rs17156609 G/A 3' -11.87 
SHMT1 rs2273028 C/T Intronic FTH1 rs17156609 G/A 3' 0.74       
SHMT1 rs1979277 A/A Nonsynonymous 0.39 12.09 4 0.017 
SHMT1 rs1979277 G/A Nonsynonymous 0.29 
FTH1 rs1800009 G/G 3' 0.14 
FTH1 rs1800009 A/G 3' 0.24 
SHMT1 rs1979277 A/A Nonsynonymous FTH1 rs1800009 G/G 3' -13.37 
SHMT1 rs1979277 G/A Nonsynonymous FTH1 rs1800009 G/G 3' -0.26 
SHMT1 rs1979277 A/A Nonsynonymous FTH1 rs1800009 A/G 3' -0.73 
SHMT1 rs1979277 G/A Nonsynonymous FTH1 rs1800009 A/G 3' -0.35       
SHMT1 rs2273028 T/T Intronic 0.05 10.16 3 0.017 
SHMT1 rs2273028 C/T Intronic 0.13 
FTH1 rs1801621 C/C 3' -11.91 
FTH1 rs1801621 T/C 3' 0.22 
SHMT1 rs2273028 T/T Intronic FTH1 rs1801621 C/C 3' 0.00 
SHMT1 rs2273028 C/T Intronic FTH1 rs1801621 C/C 3' 16.19 
SHMT1 rs2273028 T/T Intronic FTH1 rs1801621 T/C 3' -12.07 
SHMT1 rs2273028 C/T Intronic FTH1 rs1801621 T/C 3' -0.25       
SHMT1 rs1979277 A/A Nonsynonymous 0.00 10.00 3 0.019 
SHMT1 rs1979277 G/A Nonsynonymous 0.11 
FTH1 rs1801621 C/C 3' -11.93 
FTH1 rs1801621 T/C 3' 0.20 
SHMT1 rs1979277 A/A Nonsynonymous FTH1 rs1801621 C/C 3' 0.00 
SHMT1 rs1979277 G/A Nonsynonymous FTH1 rs1801621 C/C 3' 16.21 
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
SHMT1 rs1979277 A/A Nonsynonymous FTH1 rs1801621 T/C 3' -12.01 
SHMT1 rs1979277 G/A Nonsynonymous FTH1 rs1801621 T/C 3' -0.22       
FTH1 rs1801621 C/C 3' -11.93 10.00 3 0.019 
FTH1 rs1801621 T/C 3' 0.21 
SHMT1 rs12952556 C/C 3' 0.00 
SHMT1 rs12952556 T/C 3' 0.11 
FTH1 rs1801621 C/C 3' SHMT1 rs12952556 C/C 3' 0.00 
FTH1 rs1801621 T/C 3' SHMT1 rs12952556 C/C 3' -12.01 
FTH1 rs1801621 C/C 3' SHMT1 rs12952556 T/C 3' 16.20 
FTH1 rs1801621 T/C 3' SHMT1 rs12952556 T/C 3' -0.23       
SHMT1 rs1979276 A/A 3' -0.02 9.97 3 0.019 
SHMT1 rs1979276 G/A 3' 0.09 
FTH1 rs1801621 C/C 3' -11.94 
FTH1 rs1801621 T/C 3' 0.20 
SHMT1 rs1979276 A/A 3' FTH1 rs1801621 C/C 3' 0.00 
SHMT1 rs1979276 G/A 3' FTH1 rs1801621 C/C 3' 16.22 
SHMT1 rs1979276 A/A 3' FTH1 rs1801621 T/C 3' -12.00 
SHMT1 rs1979276 G/A 3' FTH1 rs1801621 T/C 3' -0.21       
FTH1 rs17185413 C/C 3' 0.46 11.79 4 0.019 
FTH1 rs17185413 T/C 3' 0.17 
SHMT1 rs12952556 C/C 3' 0.20 
SHMT1 rs12952556 T/C 3' 0.25 
FTH1 rs17185413 C/C 3' SHMT1 rs12952556 C/C 3' -11.61 
FTH1 rs17185413 T/C 3' SHMT1 rs12952556 C/C 3' -0.55 
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 
G’type 
22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
FTH1 rs17185413 C/C 3' SHMT1 rs12952556 T/C 3' -1.81 
FTH1 rs17185413 T/C 3' SHMT1 rs12952556 T/C 3' -0.16       
 1Interactions among SNPs within the same gene were not considered. 
2Genotype of SNPs 1 and 2, respectively. 
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TABLE A4.10 
 
ALL MTHFD1L, MTHFR, TS, AND SHMT1 PAIRWISE INTERACTIONS WITH 
LIKELIHOOD RATIO TEST P≤0.021 
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Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 G’type 22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
MTHFD1L rs803447 T/T Intronic 0.38 20.81 4 0.00035 
MTHFD1L rs803447 C/T Intronic 0.33 
TYMS rs16948305 T/T Intronic 0.47 
TYMS rs16948305 C/T Intronic 0.44 
MTHFD1L rs803447 T/T Intronic TYMS rs16948305 T/T Intronic 1.11 
MTHFD1L rs803447 C/T Intronic TYMS rs16948305 T/T Intronic -13.66 
MTHFD1L rs803447 T/T Intronic TYMS rs16948305 C/T Intronic -0.56 
MTHFD1L rs803447 C/T Intronic TYMS rs16948305 C/T Intronic -0.62       
TYMS rs2853533 C/C Intronic 0.40 16.71 4 0.0022 
TYMS rs2853533 G/C Intronic -0.10 
MTHFR rs1801133 T/T Nonsynonymous 0.42 
MTHFR rs1801133 C/T Nonsynonymous 0.04 
TYMS rs2853533 C/C Intronic MTHFR rs1801133 T/T Nonsynonymous -12.81 
TYMS rs2853533 G/C Intronic MTHFR rs1801133 T/T Nonsynonymous 0.78 
TYMS rs2853533 C/C Intronic MTHFR rs1801133 C/T Nonsynonymous 0.37 
TYMS rs2853533 G/C Intronic MTHFR rs1801133 C/T Nonsynonymous 0.10       
TYMS rs502396 C/C Intronic -0.30 13.20 4 0.010 
TYMS rs502396 T/C Intronic -0.31 
MTHFR rs12121543 A/A Intronic -1.55 
MTHFR rs12121543 C/A Intronic -0.07 
TYMS rs502396 C/C Intronic MTHFR rs12121543 A/A Intronic 2.16 
TYMS rs502396 T/C Intronic MTHFR rs12121543 A/A Intronic 1.16 
TYMS rs502396 C/C Intronic MTHFR rs12121543 C/A Intronic -0.06 
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 TABLE A4.10 (Continued) 
                                                                   155
Gene 1 SNP 1 
G’type 
12 SNP Type 1 Gene 2 SNP 2 G’type 22 SNP Type 2 Estimate LRT 
LRT 
df LRT P 
TYMS rs502396 T/C Intronic MTHFR rs12121543 C/A Intronic 0.27       
MTHFR rs6541003 G/G Intronic -0.21 11.70 4 0.020 
MTHFR rs6541003 A/G Intronic -0.13 
SHMT1 rs17806489 A/A Intronic -12.04 
SHMT1 rs17806489 G/A Intronic 0.09 
MTHFR rs6541003 G/G Intronic SHMT1 rs17806489 A/A Intronic 16.71 
MTHFR rs6541003 A/G Intronic SHMT1 rs17806489 A/A Intronic 11.49 
MTHFR rs6541003 G/G Intronic SHMT1 rs17806489 G/A Intronic -0.18 
MTHFR rs6541003 A/G Intronic SHMT1 rs17806489 G/A Intronic 0.26       
1Interactions among SNPs within the same gene were not considered. 
2Genotype of SNPs 1 and 2, respectively. 
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CHAPTER 5 
 
CONCLUSION 
 
The unifying theme of these three research projects was to understand the 
associations between genetic variation in the folate-mediated one-carbon network and 
cardiovascular disease risk.  At the time these projects were undertaken, much of 
gene-disease association research was focused on single genetic variants or small 
groups of variants and few studies included an evaluation of gene or nutrient 
interactions; at the same time, the first discovery-oriented genome-wide association 
studies involving statistical tests of hundreds of thousands of genetic variants in 
relation to disease status were being published. Important questions in the field of 
folate metabolism and cardiovascular risk surrounded the role of B-vitamin 
supplementation for CVD prevention through homocysteine-lowering (14, 65, 101).  
Several recent meta-analyses had built consensus for the relation of the MTHFR 
rs1801133 genetic variant and CVD risk (15, 27, 52, 58, 108), while the bulk of the 
research on another important folate-related gene, SHMT1, focused on cancer 
outcomes with little evidence for associations with CVD.  Few studies had 
investigated gene-gene interactions in the network; however, a recent publication 
studying the SHMT1 1420 C→T rs1979277 variant in relation to CVD had identified a 
novel interaction with MTHFR 677 C→T rs1801133 such that CVD risk was 
increased  in subgroups of individuals carrying both the SHMT1 1979277 TT and 
MTHFR rs1801133 CT or TT genotypes (62). 
Against this backdrop, and with the knowledge that folate related genes 
function as part of a highly interconnected biochemical network, we set out to 
investigate the role of genetic variation within the folate-mediated one-carbon network 
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and CVD risk.  The research goals were multifold: 1) to summarize the current 
evidence base for the association between genetic variants in folate-mediated one-
carbon metabolism and cardiovascular disease risk; 2) to investigate the hypothesis 
that the SHMT1 rs1979277 and MTHFR rs1801133 genotypes interact to increase 
heart disease risk in the Health Professionals Follow-Up Study (HPFS) and the 
Nurses’ Health Study (NHS); 3) to evaluate the association between genetic variation 
in the folate-mediated one-carbon network and methylation-related phenotypes in the 
Normative Aging Study, including main effects, gene-gene interactions, and gene-
nutrient interactions; and 4) to evaluate the association between genetic variation in 
the folate-mediated one-carbon network and CVD risk in the Normative Aging Study, 
including main effects, gene-gene interactions, and gene-nutrient interactions. 
A systematic review and meta-analysis was conducted in 2008 to evaluate the 
evidence base for the association between genetic variation in a set of 52 genes 
involved in the folate-mediated one-carbon metabolic pathway and cardiovascular 
disease risk (114).  This work revealed that folate network genes involved in 
transsulfuration, cytoplasmic metabolism, and vitamin B12 metabolism have been the 
focus of most work relating to CVD, while folate network genes involved in 
absorption and transport, mitochondrial metabolism, and nuclear folate metabolism, 
have few publications relating to CVD, with many genes lacking any evidence 
whatsoever.  Further, only variants in genes related to homocysteine metabolism 
(CBS, MTR, MTRR, and TCN2) had been sufficiently well-studied to allow meta-
analysis, and the association with CVD differed by gene and outcome. 
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Polymorphisms in Serine Hydroxymethyltransferase 1 and 
Methylenetetrahydrofolate Reductase Interact to Increase Cardiovascular Risk in 
Humans 
 
The first analysis of this dissertation was a candidate gene association study 
conducted to investigate the hypothesis that the SHMT1 rs1979277 and MTHFR 
rs1801133 genotypes interact to increase heart disease risk in the paired cohorts of the 
Health Professionals Follow-Up Study (HPFS) and the Nurses’ Health Study (NHS).  
Since the association between these genotypes and CVD risk may be mediated by 
homocysteine and/or modified by B vitamins, these questions were also investigated.  
The published literature investigating the role of the SHMT1 rs1979277 1420 C→T 
genotype in chronic disease risk focuses mainly on cancer risk, and evidence for 
genotype associations with cardiovascular disease (CVD) is limited to 3 studies, 
underscoring the need for further population-level studies of SHMT1 and CVD.   
The NHS findings were consistent with associations previously reported in the 
Normative Aging Study (NAS): risk associated with the MTHFR rs1801133 T allele 
was stronger in women with the SHMT1 rs1979277 TT genotype.  The absence of 
double homozygote cases in the NHS precluded estimating the association of MTHFR 
rs1801133 TT genotype with CHD risk in women with the SHMT1 rs1979277 TT 
genotype.  The lack of double homozygote cases may indicate the selective loss of 
such individuals from the cohort, but this scenario is highly unlikely given observed 
association sizes.  An alternative and more likely explanation is that observed 
genotype frequencies are a chance phenomenon.  The findings in the HPFS, however, 
were inconsistent with summary estimates from prior meta-analyses regarding the 
association of the MTHFR rs1801133 genotype on CVD risk. In the HPFS, the 
MTHFR rs1801133 T allele was associated with a decreased risk of CVD, thus 
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opposite in direction to findings from prior meta-analyses (52, 58, 108). The HPFS 
findings are also inconsistent with the past report (62) and the NHS findings reported 
herein with regard to the gene-gene interaction between MTHFR rs1801133 and 
SHMT1 rs1979277.  
This study addressed an important gap in the literature by investigating the 
relation of the SHMT1 rs1979277 TT genotype to heart disease.   The study was based 
on a biologically plausible hypothesis, linked to basic science findings, and, coupled 
with the results of the systematic review and meta-analysis, highlights the need for a 
more complete evaluation of genetic variation within the folate metabolic network and 
cardiovascular disease risk, particularly in pre-fortification or unfortified populations, 
including gene-gene epistasis and gene-nutrient interactions.   
 
Folate Network Genetic Variation, Plasma Homocysteine, and Global Genomic 
Methylation Content 
 
Most previous work investigating variation in genes contributing to folate-
mediated one-carbon metabolism in relation to homocysteine and genomic 
methylation phenotypes focused on a small number of candidate genes. Given the 
interconnectedness of the one-carbon pathway, less proximal enzymes and genes may 
be important, yet few studies have attempted to evaluate a comprehensive set of 
folate-related genes.  Having completed an investigation of the role of polymorphisms 
in two key folate network genes in relation to CVD risk, we wished to explore a more 
complete set of genes and polymorphisms within the folate network, to better 
understand how genetic variation within this interconnected pathway was associated 
with CVD risk.   
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 Therefore, we next investigated sequence variation in a network of candidate 
genes involved in one-carbon metabolism in relation to plasma total homocysteine and 
two measures of global genomic DNA methylation (Alu and LINE-1 elements). 
Genes, SNPs, and related nutrients were carefully chosen to represent the full 
functional variation of the folate-mediated one carbon metabolism pathway. The 
analysis considered all 330 SNPs in tests for main effects, interactions between each 
SNP and the MTHFR rs1801133 SNP, and interactions between each SNP and plasma 
measures of folate, vitamins B-6 and B-12. FDR-significant main effects were 
identified for the plasma total homocysteine phenotype, and FDR significant SNP—B-
6 interactions were identified for Alu and LINE-1 element methylation phenotypes. 
 Polymorphisms in the SLC19A1, FTCD, and SLC19A3 genes were most 
predictive of plasma homocysteine levels, suggesting the importance of pathways that 
function to generate one-carbon units.  Together, the variability in homocysteine 
explained by the model containing the set of the 3 most significant nonredundant SNP 
hits was 3.6%, a small proportion of the estimated >50% heritability in homocysteine, 
based on twin studies (76, 92), but similar to the variability explained by two other 
determinants of homocysteine, age and smoking (84), which together explained 3.5%.  
In this study, there were FDR-significant interactions between studied SNPs and 
MTHFR 677 C→T rs1801133 in relation to the homocysteine outcome, but no FDR-
significant interactions between studied SNPs and plasma folate, vitamin B-6, or 
vitamin B-12 for the plasma homocysteine phenotype, a finding which may reflect the 
relative high folate status of this pre-fortification population or limited power for 
gene-nutrient interactions. 
 Variation in the GNMT was associated with Alu element methylation levels at 
nominal significance levels.   The biological rationale for this association is strong, as 
the GNMT gene encodes a methyltransferase that regulates cellular methylation 
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potential by catalyzing the conversion of S-adenosylmethionine (AdoMet) and glycine 
to S-adenosylhomocysteine (AdoHcy) and sarcosine.  When AdoMet is low, the 
MTHFR enzyme produces 5-methyl-THF, which in turn binds to GNMT and prevents 
AdoMet catabolism.  When AdoMet is high, AdoMet inhibits the production of 5-
methyl-THF by MTHFR, thus activating GNMT, which catabolizes the excess 
AdoMet to yield AdoHcy (32).  In the current study, there was little or no mediation of 
the GNMT rs1051218—Alu phenotype association by plasma folate, vitamin B-6 or 
vitamin B-12, but methylation status was assessed after the initiation of mandatory 
folate fortification in the U.S. and that limits consideration of mediation.  The 
variability in Alu element global genomic DNA methylation explained by the 
rs1051218 SNP was 2.2%.  Heritability estimates for DNA methylation are highly 
variable, ranging from 0 to 94% (12, 50), and the variability explained by the 
rs1051218 SNP was greater than the variation explained by age and smoking, which 
accounted for about 2% of variation in Alu element methylation in our models.  There 
were no SNP—MTHFR 677 rs1801133 interactions associated with Alu element 
methylation at FDR significance levels.  Similarly, none of the SNP—folate or SNP—
vitamin B-12 interaction terms reached FDR significance in predicting Alu element 
methylation.  However, three FDR-significant SNP—vitamin B-6 interactions were 
identified, including two intronic SNPs in the AMT gene (rs1464567 and rs1464566) 
and one intronic SNP in the DNMT3B gene (rs1883729).  
 There were no FDR-significant associations observed for the LINE-1 
methylation phenotype.  Similarly, no SNPs had statistically significant interactions 
with MTHFR 677 rs1801133, and there were no FDR-significant interactions between 
SNPs and folate or vitamin B-12. Because the LINE-1 phenotype was measured after 
the introduction of mandatory folate fortification in the U.S. findings may be limited 
by this timing.  An interaction of plasma B-6 with 1 SNP in the MTHFD1L gene was 
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significant at the FDR threshold.  While the MTHFD1L gene is not vitamin B-6-
dependent, it functions as part of mitochondrial folate metabolism, downstream from 
the vitamin B-6-dependent glycine cleavage system (23). Intronic variation in 
MTHFD1L was associated with CVD in a large-scale genome-wide association study 
(112). 
This analysis demonstrated that genes involved in absorption and transport of 
nutrients related to folate-mediated one-carbon metabolism had the most significant 
associations with the homocysteine phenotype; consistent with this finding, about 30-
40% of the association was mediated through plasma folate and vitamin B-6 and B-12 
levels.  Mitochondrial metabolism, methylation/ homocysteine pathways, cytoplasmic 
metabolism, nuclear metabolism, and B-12 metabolism were also represented in the 
top hits.  For the Alu-element methylation phenotype, the top hits were in genes 
playing a role in mitochondrial metabolism, nuclear metabolism, and 
methylation/homocysteine metabolism.  For the global genomic methylation LINE-1 
phenotype, the top SNP was in a gene in the methylation/homocysteine pathway of 
one-carbon metabolism.  There was no evidence that plasma folate or vitamins B-6 or 
B-12 mediated the association of SNPs with the methylation phenotypes. 
 This study suggests that beyond the well-described MTHFR rs1801133 SNP, 
other SNPs make important contributions to homocysteine and global genomic DNA 
methylation phenotypes, and some associations are sensitive to nutritional status of B 
vitamins. Future work should continue to include a broad evaluation of one-carbon 
network genetic and nutritional variation in unfortified or pre-fortification populations 
and extend these findings for CVD biomarkers to investigate CVD phenotypes 
directly.    
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Folate Network Genetic Variation and Cardiovascular Disease (CVD) Risk: A 
Network Association Study 
 
The previous 2 studies established that associations of folate network genetic 
variants with CVD risk extends beyond the MTHFR 677 C→T rs1801133 
polymorphism, that polymorphisms in genes related to the generation of one-carbon 
units were predictive of methylation-related CVD biomarkers, and that gene-gene 
interactions predictive of CVD risk exist within the network.  Therefore, goal of the 
final analysis was to study genetic variation in the folate metabolic network as a whole 
in relation to CVD risk, including gene-gene and gene-nutrient interactions.  
 We investigated sequence variation in a network of candidate genes involved 
in one-carbon metabolism in relation to CVD risk in a time-to-event analysis. Genes, 
SNPs, and related nutrients were carefully chosen to represent the full functional 
variation of the folate-mediated one carbon metabolism pathway. The analysis 
considered all 330 SNPs in tests for main effects, interactions with the MTHFR 
rs1801133 SNP, and a simultaneous evaluation of network variation.  The interaction 
of each SNP with plasma measures of folate, vitamins B-6 and B-12 was also 
considered.  FDR-significant main effects were identified, as well as FDR significant 
SNP—folate and SNP—vitamin B-12 interactions and nominally significant gene-
gene interactions were identified in a more thorough investigation of 3 hypotheses 
about the network.   
  Variation in the GGH gene was associated with CVD risk at FDR-significance 
levels.  The GGH gene encodes an enzyme that functions to hydrolyze polyglutamate 
residues from intracellular folate to facilitate folate export (46); however, the 
association was not substantially mediated by plasma folate.  The previously described 
association between the MTHFR rs1801133 polymorphism and CVD risk was 
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observed in this cohort and findings, including the rs1801133-folate interaction, were 
consistent with previous reports; however, the relatively high folate status among the 
men in this cohort study (mean plasma folate: 10.4 ng/ml, significantly higher than the 
prefortification serum folate mean of 5.8 ng/ml in non-Hispanic Whites reported by 
NHANES III (1988-1994), albeit lower than the post-fortification mean of 14.8 ng/ml 
(80) may have blunted the strength of this interaction.  No FDR-significant 
interactions between studied SNPs and vitamin B-6, were observed; however, FDR-
significant interactions were identified for plasma folate and a polymorphism in the 
MAT2B gene, and vitamin B-12 and polymorphisms in the BHMT and SLC25A32 
genes. The lack of additional highly significant gene-nutrient interactions may reflect 
limited power for gene-nutrient interactions, or the lack of men with low B vitamin 
status, even within this pre-fortification cohort of U.S. men.   
 No FDR-significant interactions were identified between studied SNPs and 
MTHFR 677 C→T rs1801133.  Furthermore, of all pairwise interactions within the 
network, no interactions surpassed the FDR significance threshold of P≤0.2.  A 
previously described gene-gene interaction involving SHMT1 and MTHFR was 
replicated in these data; the association was strengthened considerably in models 
adjusted for homocysteine, and attenuated in models adjusted for folate and vitamin B-
12.  Finally, pleiotropic effects were examined across outcomes.  Of the 8 nominally 
significant hits for the CVD analysis, only a single pleiotropic SNP hit was identified, 
CBS rs6586282, which was also among the most significant hits for the plasma 
homocysteine phenotype.  Genes that had associations with multiple phenotypes 
included GGH and MTHFR. 
 In a systematic approach to the data analysis, we identified the best genetic 
models for each SNP, tested single SNPs, a reduced set of non-redundant SNPs, the 
interaction of each SNP with MTHFR 677 rs1801133, and the interaction of each SNP 
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with folate, vitamin B-6 and vitamin B-12.  Findings were corrected for multiple 
comparisons and findings based on the FDR threshold were discussed in more detail.  
Hypotheses based on basic science findings were explored.   
 This study suggests that variation in genes other than MTHFR and those 
directly involved in homocysteine metabolism, are associated with CVD risk.  For 
example, a gene involved in folate absorption and transport, GGH, was more 
significantly associated with CVD than any of the other 51 genes evaluated, including 
MTHFR and CBS. This study also supports a role for mitochondrial metabolism in 
predicting CVD risk, and although a previously identified polymorphism in 
MTHFD1L (112) could not be studied directly, nearby variants showed strong 
associations with CVD risk.  The epidemiologic findings presented here replicated 
molecular biology studies of interactions among the SHMT1, UBE2I, UBE2N, DHFR, 
and TYMS proteins resulting in the cell cycle-dependent nuclear localization of the 
thymidylate biosynthesis pathway, and further established that epistatic interaction 
among genes encoding these proteins is predictive of CVD risk.   
Strengths of this work include a complete investigation of genetic variation in 
the folate metabolic network.  Furthermore, the analysis was conducted within a large 
cohort with CVD outcome data collected prior to the introduction of mandatory folate-
fortification in the U.S.; thus, the study population is well-suited to investigate the 
network of folate-related genes in relation to CVD risk.  SNP selection for the 
genotyping assay reflected coverage of genes based on function, linkage, and physical 
coverage, which led to markers that captured functional variants in addition to tagging 
variation elsewhere in the gene. In a systematic approach to the data analysis, we 
identified the best genetic models for each SNP, tested single SNPs, a reduced set of 
non-redundant SNPs, the interaction of each SNP with MTHFR 677 rs1801133, and 
the interaction of each SNP with folate, vitamin B-6 and vitamin B-12.  Findings were 
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corrected for multiple comparisons and findings based on the FDR threshold were 
discussed in more detail.  Hypotheses based on basic science findings were explored.  
Weaknesses of the study include the fact that, despite restricting data to the pre-folate 
fortification time period, the level of folate nutrition within the population was 
relatively high compared to other measures of pre-fortification folate status in the 
U.S., which may have attenuated associations, particularly gene-nutrient interactions, 
that would have been present in a population with more variation in B-vitamin status.  
 These findings support a role for SHMT1 and nuclear folate metabolism, 
including the thymidylate biosynthesis pathway, in relation to CVD.  This 
investigation of genetic variation within the folate network, including absorption and 
transport, mitochondrial, and nuclear metabolism, alters our current understanding of 
the relation between the folate-mediated one-carbon network and CVD. To date, the 
focus has been on the role of homocysteine, but the findings in this study suggest 
important contributions to risk through other aspects of folate metabolism.  These 
findings may help explain the results of randomized controlled trials focused on CVD 
risk reduction through homocysteine lowering, which have experienced limited 
success (70, 71).  A thorough understanding of the role of folate network genetic and 
nutritional variation in relation to CVD is important, particularly in the context of the 
numerous unfortified populations around the world.   
 
Significance of this work  
 
This dissertation was designed to address the role of genetic variation in the 
folate-mediated one-carbon metabolic network as a whole in relation to CVD risk, and 
has shown that evaluations of networks of candidate genes and related nutrients can 
contribute to our understanding of chronic disease risk in ways that are not possible 
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through more limited evaluations of genes or nutrients involved in biochemical 
pathways.   
The work presented in this dissertation represents several novel findings.   The 
most significant hits for the homocysteine and methylation outcomes reflected genes 
involved in the generation of one-carbon units, including SLC19A1, FTCD, and a gene 
known to regulate levels of AdoMet, GNMT.  A genetic variant in gamma-glutamyl 
hydrolase (GGH), was more significantly predictive of CVD risk than any other one-
carbon network polymorphism studied, and the effect size for the GGH variant 
doubled in analyses of early-onset CVD.  Genes in this category of folate metabolism 
are not well-studied in relation to CVD risk.  An in-depth evaluation of nuclear folate 
metabolism revealed significant epistasis predictive of CVD risk, and genes that 
regulate SHMT1 expression interact to influence risk of CVD. The findings underscore 
the importance of mitochondrial metabolism in the folate pathway–CVD association, 
and epistasis predictive of CVD risk exists between the thymidylate synthesis and 
remethylation pathways.  Overall, genetic variants beyond the well-known MTHFR 
rs1801133 polymorphism, are strongly associated with CVD risk as well as the 
homocysteine and global genomic DNA methylation phenotypes, epistatic interactions 
predictive of CVD risk exist within the network, and some associations are sensitive to 
nutritional status of B vitamins.  
 
Future directions 
 
The work presented here represents an important contribution to our 
understanding of genetic variation within a network of genes and CVD risk, and 
suggests several possible directions for future work.  First, future studies should 
consider utilizing the approach outlined here to evaluate genetic variation in the folate-
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mediated one-carbon network in relation to phenotypes other than CVD.  Previous 
work has identified important associations between genetic and nutritional variation in 
the folate-mediated one-carbon network and phenotypes including cancer, birth 
defects, and cognitive outcomes; it would be informative to investigate whether the 
same set of most significant SNPs, gene-gene, and gene-nutrient interactions identified 
for CVD also predict other disease outcomes when a more complete set of genetic 
variation is considered.  Furthermore, where known gene-gene interactions exist, 
future evaluations of gene-disease association should explore these interactions in lieu 
of main effects for the relevant polymorphisms.    
To help capture missing heritability and increase the proportion of variation 
explained by models, future work may wish to extend considerations of genetic 
variation beyond SNPs to include copy number variants, rare variants, haplotypes, and 
higher order gene-gene and gene-nutrient interactions.  There are a number of copy 
number variants within the genes of the folate-mediated one-carbon network, such as 
those in the CBS and TYMS genes, that have been previously associated with disease 
phenotypes, and although every effort was made to capture this variation through LD, 
these should be included in future evaluations of network genetic variation as they 
may not be completely captured by SNPs (24).  Future genetic association studies 
using large sample sizes could consider sequencing folate network genes to capture 
rare variants that may have strong associations with disease but are not well-
represented in these data.  This approach would allow complete typing of both rare 
and common variants, and explicitly capture haplotypes.  Future work should also 
attempt to characterize the functional consequences of genetic variation in the 
MTHFD1L gene, particularly the 14 kb block identified in the Wellcome Trust study, 
with regard to cardiovascular disease risk.  Where sufficient power exists, future 
studies may wish to investigate higher order gene-gene and gene-nutrient interactions 
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than could be studied here.   Finally, these findings should be replicated in other 
cohorts, particularly unfortified populations with large ranges in B vitamin status; 
European populations may be a good choice.   
Understanding the functional consequences of the genetic variants highlighted 
in this work is an important next step, and work to characterize these consequences in 
terms of their impact on protein structure and enzyme kinetics will be important to 
provide a mechanism for the epidemiologic associations identified here.  For example, 
genes involved in absorption and transport, nuclear, and mitochondrial metabolism 
would be good targets for further functional characterization, as would genes involved 
in epistatic interactions.  In addition, functional characterization of genetic variation in 
genes such as SLC19A3, which have not been well-studied thus far, would be 
informative; this gene belongs to the family of folate transporters but is not known to 
directly transport folate, vitamin B-6, or vitamin B-12 yet was among the most 
significant SNP hits for the homocysteine phenotype and the association was mediated 
by folate, B-6 and B-12.  For studies investigating genetic variants in relation to 
cellular methylation potential, indicators of methylation potential more sensitive than 
homocysteine and global genomic DNA methylation, such as AdoHcy (51, 107), and 
gene-specific DNA methylation and expression levels, may yield even stronger 
associations with network variants and facilitate our understanding of the mechanism 
for the associations observed here.   
Ultimately, more complete information on the associations between networks 
of genetic variants and disease risk will enable more appropriate nutrition 
interventions for disease prevention.  However, additional work is needed to translate 
findings from gene-disease association studies into practice.  Currently, most gene-
disease association hits have not been sufficiently well-characterized to be clinically 
useful(68, 69).  Therefore, the clinical applications of findings resulting from such 
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studies should be explored, including an evaluation of CVD risk prediction based on a 
knowledge of genetic variation in the folate network.  Ultimately, the benefit of 
genetic testing for CVD risk prediction will need to be weighed against the costs 
associated with implementing testing and resulting interventions(54); however, better 
understanding the ways in which genetic variation and nutrient status interact to 
influence risk of CVD may enable the development of more effective strategies for 
preventing this common and costly disease.   
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